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Revascularization in Diabetes Study
VALIDATE Bivalirudin versus Heparin in ST-Segment
and Non–ST-Segment Elevation Myocardial
Infarction in Patients on Modern Antiplatelet
Therapy
VKA Vitamin K antagonist
1 Preamble
Clinical practice guidelines summarize and evaluate all available evi-
dence at the time of the writing process on a particular issue with the
aim of assisting physicians in selecting the best management strategies
for an individual patient with a given condition, taking into account
the impact on outcome as well as the risk–benefit ratio of particular
diagnostic or therapeutic means. Clinical practice guidelines are no
substitutes for textbooks, but complement them, and cover the
European Society of Cardiology (ESC) Core Curriculum topics. As
such they should help physicians to make decisions in their daily prac-
tice. However, final decisions should be individualized by responsible
physicians and the patient.
A great number of clinical practice guidelines have been issued in
recent years both by the ESC as well as by other societies and organi-
zations. Because of the impact on clinical practice, quality criteria for
the development of guidelines have been established in order to
make all decisions transparent to the user. The recommendations for
formulating and issuing ESC and joint society guidelines can be found
on the ESC website (https://www.escardio.org/Guidelines/Clinical-
Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines).
These Guidelines represent the official position of the ESC and the
European Association for Cardio-Thoracic Surgery (EACTS) on this
given topic and will be regularly updated.
Members of this Task Force were selected by the ESC and EACTS
to represent professionals involved with the medical care of patients
with this pathology. Selected experts in the field undertook a com-
prehensive review of the published evidence for diagnosis, manage-
ment (including treatment) and/or prevention of a given condition
according to the ESC Committee for Practice Guidelines (CPG) and
EACTS policy. A critical evaluation of diagnostic and therapeutic pro-
cedures was performed including assessment of the risk–benefit
ratio. Estimates of expected health outcomes for larger populations
were included, where data exist. The level of evidence and the
strength of recommendation of particular treatment options were
weighed and graded according to predefined scales, as outlined in
Tables 1 and 2.
The experts of the writing and reviewing panels completed decla-
rations of interest forms on what might be perceived as real or
potential sources of conflicts of interest. These forms were compiled
into one file and can be found on the ESC and EACTS websites
http://www.escardio.org/guidelines and http://www.eacts.org). Any
changes in declarations of interest that arise during the writing period
must be notified to the ESC and EACTS and updated. The Task
Force received its entire financial support from the ESC and EACTS
without any involvement from the healthcare industry.
The CPG-ESC and EACTS supervised and coordinated the prepa-
ration of these new Guidelines produced by the joint Task Force.
These entities are also responsible for the endorsement process of
these Guidelines. The ESC/EACTS Guidelines underwent extensive
review by a wide panel of relevant external experts. After appropri-
ate revisions it was approved by all the experts involved in the Task
Force. The finalized document was approved by the ESC CPG and
EACTS for joint publication in the European Heart Journal and the
European Journal of Cardio-Thoracic Surgery.
The task of developing clinical practice guidelines covers not only
the integration of the most recent research, but also the creation of
educational tools and implementation programmes for the recom-
mendations. To implement the guidelines, condensed pocket guide-
lines, summary slides, booklets with essential messages, and an
electronic version for digital applications (smartphones, etc.) are pro-



















































always refer to the full text version, which is freely available on the
ESC and EACTS websites. The National Societies of the ESC are
encouraged to endorse, translate, and implement the ESC
Guidelines. Implementation programmes are needed because it has
been shown that the outcome of disease may be favourably influ-
enced by the thorough application of clinical recommendations.
Surveys and registries are needed to verify that real-life daily prac-
tice is in keeping with what is recommended in the guidelines, thus
completing the loop between clinical research, writing of guidelines,
and implementing them in clinical practice.
The guidelines do not, however, override the individual responsi-
bility of healthcare professionals to make appropriate decisions in the
circumstances of the individual patients, in consultation with that
patient, and where appropriate and necessary the patient’s guardian
or carer. It is also the health professional’s responsibility to verify the
rules and regulations applicable to drugs and devices at the time of
prescription.
2 Introduction
These Guidelines represent the third time that the ESC and EACTS
have brought together cardiologists and cardiac surgeons in a joint
Task Force to review the ever-increasing body of evidence, with the
mission of drafting balanced, patient-centred practice Guidelines on
myocardial revascularization. Summaries of the key changes in com-
parison with the previous Guidelines are provided in Figures 1 and 2.
There is considerable overlap of the current document with other
Guidelines, specifically those on stable coronary artery disease, non-
ST-elevation myocardial infarction, ST-elevation myocardial infarc-
tion, heart failure, valvular heart disease and the Focused Update on
Dual Antiplatelet Therapy. Unless supported by new evidence, we
followed the recommendations of these Guidelines where pertinent
to our Guidelines, and refer the reader to the respective sections in
those documents for detailed discussion. We reserve more in-depth
discussion for topics that are specific to issues pertaining to myocar-
dial revascularization that are not covered in other Guidelines. To
keep the current document concise and reader-friendly, we also
moved some of the detailed descriptions of study results to the
online Supplementary Data.










Definition Suggested wording to use
Class I Evidence and/or general agreement 




Class II Conflicting evidence and/or a 
divergence of opinion about the 
usefulness/efficacy of the given 
treatment or procedure.
Class IIa Weight of evidence/opinion is in favour 
of usefulness/efficacy.
Should be considered
Class IIb Usefulness/efficacy is less well 
established by evidence/opinion. 
May be considered
Class III Evidence or general agreement that 
the given treatment or procedure is 
not useful/effective, and in some cases
may be harmful. 
Is not recommended
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2.1 What is new in the 2018 Guidelines?
Calculation of the Syntax Score, if left 
main or multivessel revascularization 
is considered
Radial access as standard approach 
for coronary angiography and PCI
DES for any PCI
Systematic re-evaluation of patients 
after myocardial revascularization
Stabilised NSTE-ACS patients:
revascularization strategy according 
to principles for SCAD
Use of the radial artery grafts over 
saphenous vein grafts in patients with 
high-degree stenosis
Myocardial revascularization in 
patients with CAD, heart failure, and 
LVEF ≤35%
CABG preferred
PCI as alternative to CABG
Completeness of revascularization 
prioritized, when considering CABG 
vs PCI 
NOAC preferred over VKA in patients 
with non-valvular AF requiring 
anticoagulation and antiplatelet 
treatment
No-touch vein technique, if open vein 
harvesting for CABG
Annual operator volume for left main 
PCI of at least 25 cases per year
Pre- and post-hydration with isotonic
saline in patients with moderate or
severe CKD if the expected contrast
volume is >100 mL
Routine non-invasive imaging
surveillance in high-risk patients
6 months after revascularization
Double-kissing crush technique 
preferred over provisional T-stenting 
in true left main bifurcations.
Cangrelor in P2Y12-inhibitor naïve 
patients undergoing PCI
GP IIb/IIIa inhibitors for PCI in P2Y12-
inhibitor naïve patients with ACS 
undergoing PCI
Dabigatran 150-mg dose preferred 
over 110-mg dose when combined with 
single antiplatelet therapy after PCI
De-escalation of P2Y12 inhibitor guided 
by platelet function testing in ACS 
patients
Routine revascularization of non-IRA 
lesions in myocardial infarction with 
cardiogenic shock
Current generation BRS for clinical use 
outside clinical studies
Class I Class IIa
Class IIb Class III
ACS = acute coronary syndromes; AF = atrial fibrillation; BRS = bioresorbable scaffolds; CABG = coronary artery bypass grafting; CAD = coronary artery disease;
CKD = chronic kidney disease; DES = drug-eluting stents; FFR = fractional flow reserve; GP = glycoprotein; IRA = infarct-related artery; LVEF = left ventricular
ejection fraction; NOAC = non-vitamin K oral anticoagulants; NSTEMI = non-ST-elevation; PCI = percutaneous coronary intervention; SCAD = stable coronary 








The figure does not show changes 
compared with the 2014 version of 
the Myocardial Revascularization 
Guidelines that were due to updates for 
consistency with other ESC Guidelines 
published since 2014.
Figure 1 New recommendations.
Class I Class IIa
Class IIb Class III
CABG = coronary artery bypass grafting; MVD = multivessel coronary artery disease; NSTE-ACS = non-ST-elevation acute coronary syndromes; OCT = optical 
coherence tomography; PCI = percutaneous coronary interventions; STEMI = ST-elevation myocardial infarction, 









For PCI of bifurcation lesions, stent implantation in 
the main vessel only, followed by provisional balloon 
angioplasty with or without stenting of  the side branch
Immediate coronary angiography and revascularization,
if appropriate,  in survivors of out-of-hospital cardiac arrest 
and an ECG consistent with STEMI
Assess all patients for the risk of
contrast-induced nephropathy
OCT for stent optimization
The figure does not show changes compared with the 2014 
version of the Myocardial Revascularization Guidelines 
that were due to updates for consistency with other ESC 
Guidelines published since 2014.
DOWNGRADES
Distal protection devices for PCI of SVG lesions
Bivalirudin for PCI in NSTE-ACS
Bivalirudin for PCI in STEMI
PCI for MVD with diabetes and  SYNTAX score <23
Platelet function testing to guide antiplatelet therapy 
interruption in  patients undergoing cardiac surgery
EuroSCORE II to assess in-hospital mortality after CABG
















































3 Diagnostic tools to guide
myocardial revascularization
The use of diagnostic imaging and functional testing modalities to
detect patients with coronary artery disease (CAD) is discussed in
detail in the clinical practice Guidelines for patients with SCAD.1
Further diagnostic assessment of patients with obstructive CAD is
critical in order to identify patients and select specific lesions that are
likely to benefit from myocardial revascularization, in addition to opti-
mal medical therapy.
3.1 Non-invasive diagnostic tools
3.1.1 Assessment of myocardial ischaemia
Non-invasive diagnostic assessment of patients with CAD being con-
sidered for myocardial revascularization comprises the assessment of
ischaemia and the evaluation of viability in patients with regional wall
motion abnormalities or reduced ejection fraction (EF).
Functional testing to assess ischaemia is critical for the assessment
of stable patients with CAD. Documentation of ischaemia using func-
tional testing before elective invasive procedures for CAD is the pre-
ferred approach. It may also have a role in the assessment of some
patients presenting with acute coronary syndrome (ACS). Because of
the low sensitivity of exercise electrocardiogram (ECG) testing in the
assessment of patients with symptoms of angina, non-invasive imaging
is recommended as the first-line test.1 Detection of a large area of
myocardial ischaemia by functional imaging is associated with
impaired prognosis of patients and identifies patients who should
undergo revascularization (see section 5).
In patients undergoing coronary computed tomography (CT),
both CT-derived fractional flow reserve (CT-FFR) and CT perfusion
represent possible approaches to evaluate lesion-specific ischaemia.
Although the evidence for both is limited at present, there are con-
siderably more data from clinical investigations of CT-FFR. A number
of trials have shown that correlation between CT-derived FFR
and invasive FFR is high.2,3 The non-randomized PLATFORM
(Prospective LongitudinAl Trial of FFRct: Outcome and Resource
Impacts) study showed that in patients referred for invasive angiogra-
phy due to chest pain (predominantly atypical angina) and intermedi-
ate pre-test probability of CAD, assessment with CT and CT-FFR
reduced the number of patients with subsequently normal invasive
coronary angiograms compared with standard care.4 Currently, clini-
cal trial data with CT-FFR are insufficient to make a recommendation
for its use in clinical practice.
3.1.2 Assessment of myocardial viability in patients with
heart failure and coronary artery disease
In patients with regional wall motion abnormalities or ventricular dys-
function, heart failure (HF) can be caused by stunned or hibernating
myocardium and may be reversed by revascularization. Assessment
of myocardial viability may be done in order to select patients that
are more likely to benefit from myocardial revascularization and can
be achieved with several imaging modalities: myocardial contrast
echocardiography, single-photon emission CT (SPECT), and late
gadolinium enhancement cardiac magnetic resonance (LGE-CMR) all
assess cellular integrity; positron emission tomography (PET)
assesses cellular metabolism; and dobutamine techniques assess
contractile reserve.1,5 Assessment of ischaemia provides incremental
benefit over viability in mild to moderate CAD, but with extensive
CAD viability assessment may be sufficient.6 Patients with advanced
HF and viable myocardium should first undergo revascularization
with coronary artery bypass grafting (CABG) or percutaneous coro-
nary intervention (PCI) before being considered for mechanical circu-
latory support (MCS) or heart transplantation.7,8
The PARR-2 (PET and Recovery following Revascularization) trial
included patients with severe left ventricular (LV) dysfunction being
considered for revascularization or HF/transplantation workups, and
randomized them to management assisted by fluorodeoxyglucose
PET (FDG-PET) or standard care.6 The primary outcome of cardiac
death, myocardial infarction (MI), or recurrent hospital stay for car-
diac cause at 1 year was not improved in the group managed by
FDG-PET [relative risk (RR) 0.82, 95% confidence interval (CI)
0.59–1.14, P = 0.16], though the rate of compliance with the treat-
ment recommended by FDG-PET was variable.
The viability substudy of the STICH (Surgical Treatment for
Ischemic Heart Failure) trial found viable myocardium in 487/601
patients (81%) and none in 114 (19%).9 There was a significant associ-
ation between myocardial viability and outcome by univariate analy-
sis, but not on multivariable analysis. The lack of correlation between
myocardial viability and benefit from revascularization indicates that
this strategy should not be the only test when selecting the optimal
therapy.
3.2 Invasive diagnostic tools
3.2.1 Pressure-derived fractional flow reserve
3.2.1.1 Use of fractional flow reserve in patients with intermediate-grade
coronary stenosis including left main stenosis
Coronary pressure-derived FFR is the current standard of care for
the functional assessment of lesion severity in patients with
intermediate-grade stenosis (typically around 40 – 90% stenosis)
without evidence of ischaemia in non-invasive testing, or in those
with multivessel disease.
Recommendations for non-invasive imaging in patients
with coronary artery disease and heart failure with
reduced ejection fraction
Recommendations Classa Levelb
Non-invasive stress imaging (CMR, stress
echocardiography, SPECT, or PET) may be
considered for the assessment of myocar-
dial ischaemia and viability in patients with
HF and CAD (considered suitable for coro-
nary revascularization) before the decision
on revascularization.9–11
IIb B
CAD = coronary artery disease; CMR = cardiac magnetic resonance; HF = heart



































































































Multiple studies have shown that PCI can be safely deferred if FFR
is >0.75.12–15 The DEFER trial enrolled 325 patients scheduled for
PCI of an intermediate stenosis.15 If FFR was >_0.75, patients were
randomly assigned to deferral (defer group; n = 91) or performance
(perform group; n = 90) of PCI. The composite rate of cardiac death
and acute MI (AMI) in the defer and perform groups was 3.3 vs. 7.9%
(P = 0.21).
However, most contemporary studies use an FFR cut-off of 0.80.
A recent large-scale observational study supports the use of FFR
>0.80 rather than 0.75 as a cut-off.16 Indeed, the two largest studies
in this field, DEFINE-FLAIR (Define Functional Lesion Assessment of
Intermediate Stenosis to Guide Revascularization DES drug-eluting
stent)17 and iFR-SWEDEHEART (Swedish Web-system for
Enhancement and Development of Evidence-based care in Heart dis-
ease Evaluated According to Recommended Therapies),18 used the
0.80 cut-off for lesion selection by FFR, with favourable event rates at
1 year. Thus, 0.80 is the accepted FFR threshold for defining haemo-
dynamically relevant lesions.
Haemodynamic relevance, as defined by FFR <_0.80, correlates
poorly with diameter stenosis by visual assessment. In the FAME
(Fractional Flow Reserve versus Angiography for Multivessel
Evaluation) trial, only 35% of the 50–70% stenoses were haemody-
namically relevant and, of the 71–90% stenoses, 20% were not. Only
an estimated diameter stenosis >90% predicted haemodynamic rele-
vance with high accuracy (96% correct classification). A number of
studies have shown that utilization of an FFR-based assessment strat-
egy at the time of angiography results in reclassification of the revas-
cularization strategy (PCI, bypass surgery, or medical therapy) in a
high proportion of patients with intermediate-grade lesions (>40% of
patients are reclassified).19–22 In addition, separate and pooled analy-
ses of the patients included in those studies have shown that the end
results of ‘FFR-based reclassification’ in patients investigated at the
time of diagnostic angiography is neutral overall for the number of
patients indicated for revascularization.23
A patient-level and study-level meta-analysis of 9173 lesions dem-
onstrated that with lesions with FFR <0.75, revascularization reduced
the 1 year risk of major adverse cardiac events (MACE), including a
reduction in the composite risk of death and MI.24 Thus, the FFR
threshold of 0.75 is used to define more severe ischaemia that is of
prognostic relevance.
The presence of intermediate grade left main stem (LMS) disease is
not infrequent and angiographic evaluation may be challenging.
Assessment using pressure-derived FFR is more challenging in compar-
ison with non-LMS stenosis due to the requirement for disengagement
of the guiding catheter and an inability to administer intracoronary
adenosine. Some observational data exist to support the use of FFR in
order to decide if revascularization should be deferred or performed.25
In the largest study, which included 230 patients with intermediate-
grade LMS stenosis, only 23% showed an FFR <0.80. Treatment was
deferred in patients with an FFR >_0.80 and bypass surgery was done in
patients with an FFR <0.80.26 Clinical outcomes at 5 years were similar
in both groups. However, it is important to consider the potential influ-
ence of any untreated downstream disease in the left anterior
descending (LAD) or left circumflex arteries, which may be associated
with an increased risk of a false negative FFR.27
The value of FFR to evaluate intermediate stenosis and guide selec-
tion of lesions for revascularization at the time of bypass surgery has
been shown in an observational study.28 Of the 627 patients with
intermediate stenosis that were evaluated, 429 had bypass without
FFR and 198 had bypass with FFR; in the latter group, the proportion
of patients with three-vessel disease was reclassified from 94 to 86%.
Outcomes were similar in both groups at 3 years [hazard ratio (HR)
for death/MI/target vessel revascularization (TVR) = 1.03, 95% CI
0.67–1.69], though the group with FFR guidance was associated with
a lower number of graft anastomoses and a lower rate of on-pump
surgery compared with angiography-guided CABG surgery.
3.2.1.2 Use of fractional flow reserve to identify lesions requiring revascu-
larization in patients with multivessel coronary artery disease undergoing
percutaneous coronary intervention
FFR may also be useful for the selection of lesions requiring revascula-
rization in patients with multivessel CAD. The FAME trial showed that
in patients with multivessel disease randomized to an FFR-guided PCI
strategy (using a cut-off <_0.80 to indicate requirement for PCI), out-
comes at 12 months in terms of death, non-fatal MI, and repeat revas-
cularization were superior compared with angiography-guided PCI
and utilized fewer resources.29 In addition, the 2 year composite risk
of death or MI was significantly lower with the FFR-guided PCI strat-
egy.30 Long-term follow-up at 5 years showed broadly consistent find-
ings, although differences between groups in relation to the primary
endpoint were no longer significant.31 This suggests that FFR-guided
PCI should be the preferred management strategy in these patients.
3.2.1.3 Fractional flow reserve-guided management vs. medical therapy
in patients with coronary artery disease
In patients with SCAD and at least one stenosis with FFR <_0.80, the
FAME 2 trial showed that PCI using drug-eluting stent (DES) implan-
tation improved the primary endpoint of death, non-fatal MI, or
urgent revascularization within 2 years compared with medical treat-
ment alone, which was driven by a lower need for urgent revasculari-
zation.32 The advantage of FFR-guided PCI over medical therapy
alone was maintained at 3 years.33
3.2.2 Other pressure-derived indices
FFR evaluation requires maximal and stable hyperaemia, which is usu-
ally obtained by the administration of intravenous (i.v.) adenosine.
Recently, there has been renewed interest in resting indices derived
from resting gradients alone [distal coronary to aortic pressure (Pd/
Pa) or instantaneous wave-free ratio (iwFR)]. Two recent large-scale
randomized trials showed broadly comparable results between FFR-
guided and iwFR-guided revascularization strategies in patients with
intermediate-grade stenosis.17,18 Revascularization was indicated in
both trials if FFR was <_0.80 or if iwFR was <_0.89. In the DEFINE-
FLAIR trial, the primary endpoint of MACE at 1 year occurred in
6.8% in patients randomized to iwFR-guided revascularization vs.
7.0% in patients randomized to FFR-guided revascularization (P
<0.001 for non-inferiority; HR 0.95, 95% CI 0.68–1.33, P = 0.78).17 In
the iFR-SWEDEHEART trial, the primary endpoint of death from any
cause, non-fatal MI, or unplanned revascularization was 6.7% in the
iwFR group and 6.1% in the FFR group (P = 0.007 for non-inferiority;
HR 1.12, 95% CI 0.79–1.58, P = 0.53).18 In this trial, 17.5% of patients
had ACS at the time of presentation. There was no interaction with



























..The SYNTAX II study (Synergy between Percutaneous Coronary
Intervention with TAXUS and Cardiac Surgery), a single-arm, pro-
spective study in patients with multivessel disease incorporating a
management strategy including combined iwFR/FFR assessment of
stenosis severity in addition to intravascular ultrasound (IVUS)-
guided stent implantation and guideline-directed medical therapy,
showed encouraging outcomes compared with a historical cohort
enrolled in the SYNTAX trial.34
Randomized trials comparing iwFR-guided revascularization with
angiography-guided revascularization or medical therapy are not
available. iwFR has not been extensively validated for patients with
LMS stenosis.
There is no adequate randomized controlled trial (RCT) data to
support the use of whole-cardiac cycle Pd/Pa for the guidance of
revascularization decisions.
3.2.3 Use of fractional flow reserve and pressure-derived
indices in patients with severe aortic stenosis
In patients with intermediate coronary stenosis and concomitant
severe aortic stenosis, although some observational studies exist (see
section 11), there are no adequate RCT data to support the use of
FFR or iwFR for the guidance of revascularization decisions.
3.2.4 Use of intravascular imaging for the diagnostic
assessment of stenosis
IVUS is an ultrasound-based modality of intravascular imaging with an
axial resolution of about 150 mm. IVUS imaging allows real-time
tomographic assessment of vessel size, lumen area, and plaque com-
position and volume. In comparison with optical coherence tomogra-
phy (OCT), it has more limited spatial resolution, but better
penetration depth and potential advantages in terms of vessel sizing.
OCT is a light-based modality of intravascular imaging with higher
axial resolution compared with IVUS (15 vs. 150 mm). The disadvan-
tages of OCT imaging are that it requires complete blood clearance
from the lumen for imaging and that it has more limited penetration,
which can limit the assessment of complete plaque burden and may
impair accurate vessel sizing.
Potential clinical uses of intravascular imaging for diagnostic assess-
ment in patients being considered for myocardial revascularization
are the evaluation of stenosis severity in lesions with intermediate-
grade stenosis, evaluation of lesion morphology in lesions ambiguous
with angiographic assessment, and the characterization of plaque
composition. The majority of the existing data from clinical trials
relate to the use of intravascular imaging guidance during PCI and are
discussed in section 16. The use of intravascular imaging to evaluate
patients with stent failure is discussed in section 13.
Regarding the assessment of intermediate-grade stenosis, a num-
ber of studies have evaluated the optimal cut-off of minimal lumen
area for the identification of haemodynamically relevant lesions. One
prospective registry showed overall moderate correlation of minimal
lumen area with FFR values, with cut-off values for detecting haemo-
dynamically relevant stenosis (<2.4, <2.7, and <3.6 mm2) dependent
on vessel size (reference vessel diameters <3.0, 3.0–3.5, and >3.5
mm, respectively).34a Generally, haemodynamic assessment with FFR
should be preferred for this indication.
The presence of intermediate-grade LMS disease is not infrequent
and angiographic assessment may be challenging. Assessment using
IVUS evaluation of intermediate-grade LMS disease in patients being
considered for bypass surgery or PCI is supported by data from a
number of observational studies.35–38 In a multicentre, prospective
study, revascularization was mainly deferred if the minimal luminal
area (MLA) was >_6 mm2 and performed in cases of an MLA <6
mm2.37 After a 2 year follow-up, cardiac death-free survival was simi-
lar in both groups (98 and 95%, respectively). Another study sug-
gested that deferral of intervention in 131 patients with an MLA >_7.5
mm2 showed favourable clinical outcomes.36 In Asian patients with
generally smaller heart sizes, studies have suggested that an IVUS
MLA of 4.5–4.8 mm2 may be the most appropriate.38
3.3 Gaps in the evidence
Further studies investigating the role of novel, combined, non-inva-
sive anatomical and functional imaging are needed, such as random-
ized clinical trials with CT-FFR in patients with suspected and known
CAD, as well as further clinical investigation of perfusion CT.
Randomized trials comparing iwFR-based management of patients
with intermediate-grade stenosis compared with medical therapy are
missing. Further study of whole-cardiac cycle Pd/Pa for the guidance of
revascularization in the setting of randomized clinical trials is also
required.
Further studies including randomized trials are needed to assess
the value of functional vs. anatomical guidance for CABG.
4 Process for decision-making and
patient information
4.1 Patient information and informed
consent
Informed consent requires transparency, especially if there is debate
over various treatment options. Active patient participation in the
Recommendations on functional testing and intravascu-
lar imaging for lesion assessment
Recommendations Classa Levelb
When evidence of ischaemia is not avail-
able, FFR or iwFR are recommended to
assess the haemodynamic relevance of
intermediate-grade stenosis.15,17,18,39
I A
FFR-guided PCI should be considered in
patients with multivessel disease under-
going PCI.29,31
IIa B
IVUS should be considered to assess the
severity of unprotected left main
lesions.35–37
IIa B
FFR = fractional flow reserve; iwFR = instantaneous wave-free ratio; IVUS =




























































































..decision-making process should be encouraged. Patient information
needs to be unbiased, evidence-based, up-to-date, reliable, accessible,
relevant, and consistent with legal requirements. Use of terminology
that the patient understands is essential. Short-term procedure-
related and long-term risks and benefits—such as survival, relief of
angina, quality of life, the potential need for late reintervention, the
need for prevention measures, and uncertainties associated with dif-
ferent treatment strategies—should be thoroughly discussed.
Although current recommendations are mostly based on the ability
of treatments to reduce adverse events including mortality, there is
growing interest in patient-reported outcome measures.40,41 Patients
are not only interested to know how recommended treatment
impacts on prognosis but also on their quality of life in the way they
perceive it. A written evidence-based patient information document
should be provided, potentially with decision aids.
Patients must have the time to reflect on the trade-offs imposed
by the outcome estimates. In order to seek a second opinion or to
discuss the findings and consequences with referring physicians,
enough time should be allowed—up to several days, as required—
between diagnostic catheterization and intervention. These recom-
mendations pertain to patients in a stable condition, for whom vari-
ous treatment options exist and who can make a decision without
the constraints of an urgent or emergent situation (Table 3). The
patient’s right to decline the treatment option recommended by the
Heart Team has to be respected. Patient refusal of a recommended
treatment should be acknowledged in a written document after the
patient has received the necessary information by the Heart Team
members. In this case, the patient may be offered an alternative treat-
ment option by the Heart Team.
The patient has the right to obtain information on the level of
expertise of the operator, the workload of the centre, whether all
treatment options—including surgery—are available on-site, and
local results in the performance of percutaneous and surgical myo-
cardial revascularization procedures. Patients considered for revascu-
larization should also be clearly informed of the continuing need for
medical therapy, as well as lifestyle modification and other secondary
prevention strategies (see section 19).42
4.2 Multidisciplinary decision-making
(Heart Team)
The Heart Team—comprising clinical or non-invasive cardiologists,
cardiac surgeons, and interventional cardiologists, as well as anaes-
thetists and other specialists if deemed necessary—should provide a
balanced, multidisciplinary decision-making process.43 Additional
input may be needed from other specialties involved in the care of
the patient. The Heart Team should meet on a regular basis to ana-
lyse and interpret the available diagnostic evidence, determine the
need for myocardial revascularization, and assess the relative short-
and long-term safety and effectiveness of the percutaneous and surgi-
cal options. Ad hoc meetings of the Heart Team should facilitate and
support efficient clinical workflows.
The need for an interdisciplinary approach is underlined by reports
on (i) the underuse of revascularization procedures in 18–40% of
patients with CAD44 and (ii) inappropriate use of revascularization
strategies with a lack of case discussions.45 The marked variability in
PCI-to-CABG ratios between European countries (ranging from
2.4–7.6 in 2013, for example) has raised concerns regarding the
appropriate selection of revascularization strategies.46 Rates for the
inappropriate use of PCI (10–15%)43,47,48 and CABG (1–2%) are
reported. Multidisciplinary decision-making in a Heart Team can mini-
mize specialty bias and prevent self-referral from interfering with
optimal patient care.49
Several reports from different centres have established that the
treatment recommendations made in multidisciplinary Heart Team
discussions are reproducible and implemented in the vast majority of
cases (93–95%).50,51
Interdisciplinary institutional protocols should be developed
for common case scenarios to avoid the need for systematic case-
by-case review of all diagnostic angiograms. However, complex
cases—defined by the protocols—should be discussed individu-
ally. In these cases, revascularization should not be performed at
the time of diagnostic angiography, to allow sufficient time to
assess all available information and clearly explain and discuss the
findings with the patient. The rationale for a decision and consen-
sus on the optimal revascularization treatment should be docu-
mented on the patient’s chart. In institutions without an on-site
cardiac surgery unit, collaboration with an external cardiac sur-
gery unit is required to design protocols that define when Heart
Team discussion is needed.
4.3 Timing of revascularization
Patients requiring myocardial revascularization may be at increased
risk of adverse events during the waiting period.52 A recent meta-
analysis of observational studies calculated that a waiting period of 3
months for surgical myocardial revascularization may be associated
with the risk of 1 death among 80 patients.53 Table 3 shows the pre-
ferred timing of revascularization depending on the clinical presenta-
tion and the extent and localization of CAD.54 Sections 7 and 8 show
additional and more specific information in this regard for patients
with ACS.
Ad hoc PCI is defined as a therapeutic intervention performed
within the same procedure as the diagnostic coronary angiography.
Ad hoc PCI is convenient, often cost-effective and safe, and is associ-
ated with fewer access site complications and lower radiation expo-
sure.55,56 However, in the USA, up to 30% of patients undergoing ad
hoc PCI are potential candidates for CABG.56 This number may be
lower in Europe.45 Although it is not advisable for ad hoc PCI to rep-
resent the default approach for complex SCAD, it may be justified if a
full diagnostic work-up, including functional testing, is available and
the patient is adequately informed on both percutaneous and surgical
myocardial revascularization options (see section 4.1). Institutional
protocols developed by the Heart Team in accordance with current
Guidelines should define specific anatomical criteria and clinical sub-
sets that may be—or should not be—treated ad hoc. Stable patients
with complex CAD, as reflected by a high SYNTAX score, should in




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.5 Revascularization for stable
coronary artery disease
5.1 Rationale for revascularization
The indications for revascularization in patients with SCAD who
receive guideline-recommended medical treatment are the persis-
tence of symptoms despite medical treatment and/or the improve-
ment of prognosis.1
Several studies have shown that myocardial revascularization by
PCI or CABG more effectively relieves angina, reduces the use of
anti-anginal drugs, and improves exercise capacity and quality of life
compared with a strategy of medical therapy alone during short- and
long-term follow-up (Supplementary Table 1).32,33,57–62 Recently, the
ORBITA (Objective Randomised Blinded Investigation with optimal
medical Therapy of Angioplasty in stable angina) trial randomly com-
pared PCI with placebo (sham procedure) in patients with SCAD
due to single-vessel CAD (diameter stenosis >70%) and preserved
LV function in the presence of moderate symptoms of angina
[Canadian Cardiovascular Society (CCS) class II in 59% of patients,
duration 9 months] for the first time.63 After 6 weeks of medication
optimization (mean number of anti-anginal drugs: 3) and baseline car-
diopulmonary exercise testing, 200 patients were randomized (105
PCI and 95 placebo). Following a 6-week post-randomization period,
the primary endpoint of increment in exercise time was not signifi-
cantly different, but estimates were imprecise (PCI minus placebo
16.6 sec, 95% CI –8.9 to 42.0, P = 0.20). The dobutamine stress echo-
cardiography peak stress wall motion score index improved with PCI
(-0.09, 95% CI -0.15 to -0.04, P = 0.001). ORBITA raises the issue of
whether the symptom relief of PCI in the specific setting of stable
single-vessel CAD may be related at least in part to a placebo effect.
Limitations of the study, as acknowledged by the investigators and
outlined elsewhere, include the short observation period (6 weeks),
the inclusion of patients with mild symptoms pre-randomization
(CCS class 0-I in 25% of patients), the group imbalance in ostial and
proximal lesions (37 vs. 57%, P = 0.005), loss to follow-up after ran-
domization, and the insufficient power to detect a true difference.64
This precludes definite conclusions at this stage. Nevertheless, the
ORBITA study underlines the value of optimal medical therapy in the
management of SCAD.
Three year follow-up of the FAME 2 study indicated yearly and
sustained improvement of angina (10.2 vs. 28.5% at 1 month and 5.2
vs. 9.7% at 3 years) in favour of FFR-guided PCI, despite considerable
crossover in the medical therapy arm.33 Among patients with multi-
vessel disease, the assessment of frequency of angina and quality of
life measures in the SYNTAX, FREEDOM (Future Revascularization
Evaluation in Patients with Diabetes Mellitus), and EXCEL (Evaluation
of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness
of Left Main Revascularization) trials consistently showed early and
sustained improvement for both PCI and CABG during long-term fol-
low-up.65–67
5.2 Evidence basis for revascularization
The indications for revascularization in patients with stable angina or
silent ischaemia are summarized in the recommendation table.
Recommendations for decision-making and patient information in the elective setting
Recommendations Classa Levelb
It is recommended that patients undergoing coronary angiography are informed about benefits and risks, as well as potential
therapeutic consequences, ahead of the procedure.
I C
It is recommended that patients are adequately informed about short- and long-term benefits and risks of the revascularization
procedure with information about local experience, and allowed enough time for informed decision-making.
I C
It is recommended that institutional protocols are developed by the Heart Team to implement the appropriate revasculariza-
tion strategy in accordance with current Guidelines.
I C
In PCI centres without on-site surgery, it is recommended that institutional protocols are established with partner institutions
providing cardiac surgery.
I C































































5.2.1 Revascularization with the use of percutaneous
coronary intervention
Several meta-analyses comparing a strategy of PCI with initial medical
therapy among patients with SCAD found no or only modest bene-
fits in terms of survival or MI for an invasive strategy, taking into
account the fact that up to 40% of patients crossed over after to
revascularization during longer-term follow-up.91,98,99 A network
meta-analysis of 100 trials with 93 553 patients and 262 090 patient-
years of follow-up comparing a strategy of initial medical therapy
with revascularization reported improved survival using PCI with
new-generation DES (everolimus: rate ratio 0.75, 95% CI 0.59–0.96;
zotarolimus: rate ratio 0.65, 95% CI 0.42–1.00) compared with initial
medical treatment.100
In the FAME 2 trial,32 patients with SCAD and at least one func-
tionally significant stenosis (invasive FFR <_0.80) were randomly
assigned to medical therapy or medical therapy plus FFR-guided PCI
using new-generation DES. The 3 year report of the FAME 2 trial
reported a lower incidence of the primary composite endpoints of
death, MI, and urgent revascularization (10.1 vs. 22.0%; P <0.001),
driven by a lower incidence of urgent revascularization in the PCI
group (4.3 vs. 17.2%; P <0.001) and without significant differences in
the rates of death and MI.33 At 2 years of follow-up, the rate of death
or MI was lower in the PCI than the medical therapy group (4.6 vs.
8.0%; HR 0.56, 95% CI 0.32–0.97, P = 0.04) in a landmark analysis
between 8 days and 2 years of follow-up, whereas event rates were
higher during days 0 - 7 due to periprocedural MI (for overview of
studies see Supplementary Table 2).97
5.2.2 Revascularization with the use of coronary artery
bypass grafting
The superiority of CABG over a strategy of initial medical therapy
was established in a meta-analysis of seven RCTs68 more than two
decades ago, demonstrating a survival benefit of CABG in patients
with SCAD and left main (LM) or three-vessel disease, particularly
when the proximal LAD coronary artery was involved, and has been
corroborated in more recent studies.100,101 A network meta-analysis
of 100 trials with 93 553 patients comparing a strategy of initial medi-
cal therapy with revascularization reported improved survival (RR
0.80, 95% CI 0.63–0.99) and a reduced risk of MI (RR 0.79, 95% CI
0.83–0.99) among patients undergoing CABG compared with initial
medical treatment.100
In the STICH trial, 1212 patients with CAD and an LV ejection
fraction (LVEF) <_35% were randomized to initial medical therapy or
CABG. The extended 10 year follow-up of the STICH trial reported
a significant reduction in all-cause (59 vs. 66%; HR 0.84, 95% CI
0.73–0.97; P ¼ 0.02) and cardiovascular mortality (41 vs. 49%; HR
0.79, 95% CI 0.66–0.93; P¼ 0.006).81 For an overview of studies, see
Supplementary Table 2.
5.3 Percutaneous coronary intervention
vs. coronary artery bypass grafting
The recommendations for the type of revascularization (CABG or
PCI) in patients with SCAD with suitable coronary anatomy for both
procedures and low predicted surgical mortality are summarized
below. The Heart Team should take into consideration the individual
cardiac and extracardiac characteristics, in addition to patient prefer-
ence, in the overall decision-making process (Figure 3). A summary of
trials comparing the outcomes of patients treated with angioplasty vs.
CABG and bare-metal stent (BMS) vs. CABG is shown in
Supplementary Table 3, and of studies comparing DES and CABG in
Table 4.
5.3.1 Criteria for decision-making
Predicted surgical mortality, the anatomical complexity of CAD, and
the anticipated completeness of revascularization are important cri-
teria for decision-making with respect to the type of revascularization
Indications for revascularization in patients with stable angina or silent ischaemia
Extent of CAD (anatomical and/or functional) Classa Levelb
For
prognosis
Left main disease with stenosis >50%.c 68–71 I A
Proximal LAD stenosis >50%.c 62,68,70,72 I A
Two- or three-vessel disease with stenosis >50% with impaired LV function (LVEF <_35%).c 61,62,68,70,73–83 I A
Large area of ischaemia detected by functional testing (>10% LV) or abnormal invasive FFR.d 24,59,84–90 I B
Single remaining patent coronary artery with stenosis >50%.c I C
For symptoms Haemodynamically significant coronary stenosisc in the presence of limiting angina or angina equivalent,
with insufficient response to optimized medical therapy.e 24,63,91–97
I A
CAD = coronary artery disease; FFR = fractional flow reserve; iwFR = instantaneous wave-free ratio; LAD = left anterior descending coronary artery; LV = left ventricular;
LVEF = left ventricular ejection fraction.
aClass of recommendation.
bLevel of evidence.
cWith documented ischaemia or a haemodynamically relevant lesion defined by FFR <_0.80 or iwFR <_0.89 (see section 3.2.1.1), or >90% stenosis in a major coronary vessel.
dBased on FFR <0.75 indicating a prognostically relevant lesion (see section 3.2.1.1).



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(CABG or PCI). Whether conservative therapy, PCI, or CABG is
preferred should depend on the risk-benefit ratios of these treatment
strategies, weighing up the risks of periprocedural complications (e.g.
cerebrovascular events, blood transfusions, renal failure, new onset
arrhythmias, or wound infections) against improvements in health-
related quality of life, as well as long-term freedom from death, MI, or
repeat revascularization.
5.3.1.1 Predicted surgical mortality
To assess the predicted surgical mortality, the European System for
Cardiac Operative Risk Evaluation (EuroSCORE II) (www.euroscore.
org/calc.html) and the Society of Thoracic Surgeons (STS) score
(http://riskcalc.sts.org) were both developed based on clinical varia-
bles to estimate the operative in-hospital or 30 day mortality
risk108–110 (Supplementary Table 4). Both scores have demonstrated
their value in specific cohorts of patients undergoing CABG.111
Calibration of the STS score is updated on a regular basis. It has been
suggested that the STS score outperforms the EuroSCORE II when
compared directly in a cohort of CABG patients,112 although other
studies have found comparable performance of both models.113,114
There are no established cut-offs for low predicted surgical mor-
tality based on the EuroSCORE II or STS score. Thus, individualized
treatment decisions are needed. These decisions should respect the
range of predicted surgical risks in the major RCTs that inform the
choice of revascularization modality (Table 5). In these studies,
the predicted surgical risk was assessed by the logistic EuroSCORE.
Compared with the more recent EuroSCORE II, the logistic
EuroSCORE has similar discrimination but poorer calibration and,
thus, overestimates surgical mortality by roughly two-fold.115
Despite the usefulness of these scores, there is not a single risk
model that provides perfect risk assessment because the scores are
limited by (i) the specific definitions used or the methodology applied,
(ii) the absence of important variables such as frailty, (iii) the practic-
ability of calculation, (iv) a failure to reflect all relevant mortality and
morbidity endpoints, and (v) limited external validation. Decision-
making should not be solely dependent on risk scores. These scores
should be used as a guide within the multidisciplinary Heart Team
discussion.
To combine clinical and anatomical risk estimation, the SYNTAX II
score was retrospectively derived from the SYNTAX cohort127 and
subsequently externally validated.120,128,129 Nevertheless, compared
with the SYNTAX score, its value in assigning patients to PCI or
CABG is less well investigated. The fact that the SYNTAX II score
failed to predict the outcome of the EXCEL trial raises additional
concern.130
5.3.1.2 Anatomical complexity of coronary artery disease
The SYNTAX score (http://www.syntaxscore.com) was prospec-
tively developed for the SYNTAX trial to grade the anatomical
complexity of coronary lesions in patients with LM or three-vessel
disease (Table 6 and Supplementary Table 4).116 In the cohort of
the SYNTAX trial, and subsequently in external validation cohorts,
the SYNTAX score was found to be an independent predictor of
long-term major adverse cardiac and cerebrovascular events
(MACCE) and of death in patients treated with PCI but not
CABG.117–120
In the SYNTAX trial, tertiles of SYNTAX score with low, inter-
mediate, and high anatomical complexity stratified patients into those
who had similar outcomes with both PCI and CABG and those who
derived significant benefit from CABG.121–123 In subsequent RCTs,
the interaction of the strata of SYNTAX score with the effect of the
randomized treatment was less pronounced and did not reach statis-
tical significance.105–107 However, in a recent collaborative individual
patient pooled analysis of randomized trials including 11 518
patients,124 the test for trend across the ordered tertiles of the
SYNTAX score of the SYNTAX study was positive at P = 0.0011
(unpublished analysis), confirming the strata of the SYNTAX score as
an effect modifier to be considered. There is concern about bias and
inter-individual variability in calculating the SYNTAX score.125 This
should be minimized by adequate training.
Table 5 Logistic EuroSCOREs in major randomized
trials comparing percutaneous coronary intervention
with coronary artery bypass grafting
Trial EuroSCORE PCI EuroSCORE CABG
SYNTAX 3.8 ± 2.6 3.8 ± 2.7
BEST 2.9 ± 2.0 3.0 ± 2.1
FREEDOM 2.7 ± 2.4 2.8 ± 2.5
PRECOMBAT 2.7 ± 1.8 2.8 ± 1.9
EXCEL Not reported Not reported
NOBLE 2 (2–4) 2 (2–4)
Numbers are presented as mean ± SD or median (interquartile range).
BEST = Randomised Comparison of Coronary Artery Bypass Surgery and
Everolimus-Eluting Stent Implantation in the Treatment of Patients with
Multivessel Coronary Artery Disease; CABG = coronary artery bypass grafting;
EuroSCORE = European System for Cardiac Operative Risk Evaluation; EXCEL
= Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for
Effectiveness of Left Main Revascularization; NOBLE = Nordic-Baltic-British Left
Main Revascularization Study; PCI = percutaneous coronary intervention;
PRECOMBAT = Premier of Randomised Comparison of Bypass Surgery versus
Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary
Artery Disease; SYNTAX = Synergy between Percutaneous Coronary
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Table 6 Guide for calculating the SYNTAX score
Steps Variable assessed Description
Step 1 Dominance The weight of individual coronary segments varies according to coronary artery dominance (right or left). Co-
dominance does not exist as an option in the SYNTAX score.
Step 2 Coronary segment The diseased coronary segment directly affects the score as each coronary segment is assigned a weight depend-
ing on its location, ranging from 0.5 (i.e. the posterolateral branch) to 6 (i.e. left main in case of left dominance).
Step 3 Diameter stenosis The score of each diseased coronary segment is multiplied by two in case of a stenosis 50–99% and by five in
case of total occlusion.
In case of total occlusion, additional points will be added as follows:
• Age >3 months or unknown þ1
• Blunt stump þ1
• Bridging þ1
• First segment visible distally þ1 per non-visible segment
• Side branch at the occlusion þ1 if <1.5 mm diameter
þ1 if both <1.5 mm and >_1.5 mm diameter
þ0 if >_1.5 mm diameter (i.e. bifurcation lesion)
Step 4 Trifurcation lesion The presence of a trifurcation lesion adds additional points based on the number of diseased segments:
 1 segment þ3
 2 segments þ4
 3 segments þ5





























































..5.3.1.3 Completeness of revascularization
The aim of myocardial revascularization is to minimize residual
ischaemia. In support of this concept, the nuclear substudy of the
COURAGE (Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation) trial demonstrated an incremental bene-
fit in reducing the risk of death and MI by reducing residual stress-
induced ischaemia from >10% of the myocardium to <_5%.86
In the SYNTAX trial, anatomical complete revascularization was
defined as PCI or bypass of all epicardial vessels with a diameter
exceeding >_1.5 mm and a luminal reduction of >_50% in at least one
angiographic view.131 A meta-analysis of 89 883 patients enrolled in
RCTs and observational studies revealed a lower long-term mortality
(RR 0.71, 95% CI 0.65–0.77, P <0.001), MI (RR 0.78, 95% CI
0.68–0.90; P = 0.001), and repeat myocardial revascularization (RR
0.74, 95% CI 0.65–0.83; P <0.001) by complete revascularization
(based on anatomical definition in 87% of the patients) as compared
with incomplete revascularization.132 The benefit of complete revas-
cularization was independent of the treatment modality. A more
recent meta-analysis suggested enhanced benefit when complete
revascularization is performed with state-of-the-art techniques in
high-risk patients.133 Likewise, in a post hoc analysis of the SYNTAX
trial, anatomical incomplete revascularization was associated with
inferior long-term outcomes after both CABG and PCI.131 A residual
SYNTAX score >8 after PCI was associated with significant increases
in the 5-year risk of death and of the composite of death, MI, and
stroke, and any residual SYNTAX score >0 was associated with the
risk of repeat intervention.134 In an observational study from the
New York State registry that compared CABG with PCI using new-
generation DES [everolimus-eluting stent (EES)] in 9223 pairs of
propensity-matched patients with multivessel CAD, the significantly
higher risk of MI associated with PCI as compared with CABG was
not seen among matched pairs of patients in which the PCI group had
complete revascularization (Pinteraction = 0.02).
135 Consistent findings
were obtained in a pooled analysis of 3212 patients of the SYNTAX,
BEST (Randomised Comparison of Coronary Artery Bypass Surgery
and Everolimus-Eluting Stent Implantation in the Treatment of
Patients with Multivessel Coronary Artery Disease), and
PRECOMBAT (Premier of Randomised Comparison of Bypass
Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients
with Left Main Coronary Artery Disease) trials.136 A mean SYNTAX
score of 27 and an LVEF of 59% were obtained. In a propensity-
matched analysis, mortality and the composite risk of death, MI, and
stroke were significantly lower after PCI with complete vs. incom-
plete revascularization. After PCI with complete revascularization,
the risk of death or of the composite of death, MI, or stroke was not
significantly different from that after CABG with complete revascula-
rization (adjusted HR 1.16, 95% CI 0.83–1.63, P = 0.39, and 1.14, 95%
CI 0.87–1.48, P = 0.35, respectively), whereas these risks were signifi-
cantly elevated after PCI with incomplete revascularization.
Functional complete revascularization is achieved when all lesions
causing resting or stress-induced ischaemia are bypassed or treated
by PCI. Given the limitations of non-invasive imaging techniques (see
section 3), these lesions are identified by FFR or iwFR during diagnos-
tic angiography. For PCI, the FAME study demonstrated that the
more restrictive selection of target lesions by functional guidance
conferred superior long-term outcomes compared with anatomically
guided lesion selection (see section 3).31 In contrast, leaving function-
ally relevant lesions untreated resulted in a high rate of reinterven-
tions in the FAME 2 study.33 Based on the data of the FAME and
FAME 2 studies, complete revascularization based on the functional
definition is the preferred strategy for PCI.
The role of functional guidance for CABG is less clear.28,137 One
of the potential benefits of CABG is protection against disease pro-
gression in proximal segments, which may be diminished by restrict-
ing the bypass targets to functionally relevant lesions. This has to be
weighed against the risk of bypass closure when native vessel flow is
high. Thus, for ambiguous lesions, functional testing may also help
guide the surgical revascularization strategy.
Step 5 Bifurcation lesion The presence of a bifurcation lesion adds additional points based on the type of bifurcation according to the
Medina classification:126
• Medina 1,0,0–0,1,0–1,1,0 þ1
• Medina 1,1,1–0,0,1–1,0,1–0,1,1 þ2
Moreover, the presence of a bifurcation angle <70 adds one additional point
Step 6 Aorto-ostial lesion The presence of aorto-ostial lesion segments adds one additional point
Step 7 Severe tortuosity The presence of severe tortuosity proximal of the diseased segment adds two additional points
Step 8 Lesion length Lesion length >20 mm adds one additional point
Step 9 Calcification The presence of heavy calcification adds two additional points
Step 10 Thrombus The presence of thrombus adds one additional point
Step 11 Diffuse disease/
small vessels
The presence of diffusely diseased and narrowed segments distal to the lesion (i.e. when at least 75% of the
length of the segment distal to the lesion has a vessel diameter <2 mm) adds one point per segment number
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Recommendation for the type of revascularization in patients with stable coronary artery disease with suitable coro-
nary anatomy for both procedures and low predicted surgical mortalityd
Recommendations according to extent of CAD CABG PCI
Classa Levelb Classa Levelb
One-vessel CAD
Without proximal LAD stenosis. IIb C I C
With proximal LAD stenosis.68,101,139–144 I A I A
Two-vessel CAD
Without proximal LAD stenosis. IIb C I C
With proximal LAD stenosis.68,70,73 I B I C
Left main CAD
Left main disease with low SYNTAX score (0 - 22).69,121,122,124,145–148 I A I A
Left main disease with intermediate SYNTAX score (23 - 32).69,121,122,124,145–148 I A IIa A
Left main disease with high SYNTAX score (>_33).c 69,121,122,124,146–148 I A III B
Three-vessel CAD without diabetes mellitus
Three-vessel disease with low SYNTAX score (0 - 22).102,105,121,123,124,135,149 I A I A
Three-vessel disease with intermediate or high SYNTAX score (>22).c 102,105,121,123,124,135,149 I A III A
Three-vessel CAD with diabetes mellitus
Three-vessel disease with low SYNTAX score 0–22.102,105,121,123,124,135,150–157 I A IIb A
Three-vessel disease with intermediate or high SYNTAX score (>22).c 102,105,121,123,124,135,150–157 I A III A
SYNTAX score calculation information is available at http://www.syntaxscore.com.
CABG = coronary artery bypass grafting; CAD = coronary artery disease; LAD = left anterior descending coronary artery; PCI = percutaneous coronary intervention;
SYNTAX = Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery.
aClass of recommendation.
bLevel of evidence.
cPCI should be considered if the Heart Team is concerned about the surgical risk or if the patient refuses CABG after adequate counselling by the Heart Team.
dFor example, absence of previous cardiac surgery, severe morbidities, frailty, or immobility precluding CABG (also see Table 5).
Recommendations on criteria for the choice between coronary artery bypass grafting and percutaneous coronary
intervention
Recommendations Classa Levelb
Assessment of surgical riskc
It is recommended that the STS score is calculated to assess in-hospital or 30 day mortality, and in-hospital morbidity
after CABG.112,114,138
I B
Calculation of the EuroSCORE II score may be considered to assess in-hospital mortality after CABG.112 IIb B
Assessment of CAD complexity
In patients with LM or multivessel disease, it is recommended that the SYNTAX score is calculated to assess the ana-
tomical complexity of CAD and the long-term risk of mortality and morbidity after PCI.117–124
I B
When considering the decision between CABG and PCI, completeness of revascularization should be prioritized.131,132,134–136 IIa B
EuroSCORE = European System for Cardiac Operative Risk Evaluation; CABG = coronary artery bypass grafting; CAD = coronary artery disease; LM = left main; PCI = percu-
taneous coronary intervention; STS = Society of Thoracic Surgeons; SYNTAX = Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery.
aClass of recommendation.
bLevel of evidence.
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CABG = coronary artery bypass grafting; Cx = circumflex; DAPT = dual antiplatelet therapy; EF = ejection fraction; LAD = left anterior descending 
coronary artery; LIMA = left internal  mammary artery; LV= left ventricular; MVD = multivessel coronary artery disease;  PCI = percutaneous 
coronary intervention; PDA = posterior descending artery; RA = radial artery; RIMA = right internal mammary artery; SYNTAX = Synergy between 
Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery. 




















Left internal thoracic 
artery to left anterior 
descending
Right internal thoracic
artery or radial artery
Sequential anastomosis




Presence of severe co-morbidity (not adequately reflected 
by scores)
Advanced age/frailty/reduced life expectancy
Restricted mobility and conditions that affect the 
rehabilitation process 
Anatomical and technical aspects
MVD with SYNTAX score 0–22
Anatomy likely resulting in incomplete revascularization 
with CABG due to poor quality or missing conduits
Severe chest deformation or scoliosis




Diabetes     
Reduced LV function (EF ≤35%)
Contraindication to DAPT
Recurrent diffuse in-stent restenosis
Anatomical and technical aspects
MVD with SYNTAX score ≥23
Anatomy likely resulting in incomplete revascularization 
with PCI
Severely calcified coronary artery lesions limiting lesion 
expansion
Need for concomitant interventions
Ascending aortic pathology with indication for surgery
Concomitant cardiac surgery
CABGPCI
Figure 3 Aspects to be considered by the Heart Team for decision-making between percutaneous coronary intervention and coronary artery
































































































5.3.2 Isolated proximal left anterior descending coronary
artery disease
Comparing CABG and PCI among patients with isolated proximal
LAD disease, the available evidence suggests similar outcomes in
terms of death, MI, and stroke, but a higher risk of repeat revasculari-
zation with PCI.68,70,73,101,139–144
5.3.3 Left main coronary artery disease
The available evidence from RCTs and meta-analyses comparing
CABG with PCI using DES among patients with LM disease suggests
equivalent results for the safety composite of death, MI, and stroke
up to 5 years of follow-up.148 A significant interaction with time is
notable, providing early benefit for PCI in terms of MI and peri-
interventional stroke, which is subsequently offset by a higher risk of
spontaneous MI during long-term follow-up. The need for repeat
revascularization is higher with PCI than with CABG.
The EXCEL trial compared CABG with PCI using new-generation
DES (EES) among 1905 patients with significant LM disease.107 At 3
years of follow-up, the primary endpoint of death, stroke, or MI
occurred with similar frequency in the CABG and PCI group (14.7 vs.
15.4%; HR 1.00, 95% CI 0.79–1.26, P = 0.98). The pre-planned land-
mark analysis from 30 days to 3 years showed a significant difference
for the primary endpoint in favour of CABG (7.9 vs. 11.5%, P = 0.02).
The NOBLE (Nordic-Baltic-British Left Main Revascularization
Study) trial compared CABG with PCI using new-generation DES
[biolimus-eluting stents (BES)] among 1201 patients with significant
LM disease (mean SYNTAX score of 23).106 At a median follow-up
of 3.1 years, the primary endpoint of death, non-procedural MI,
stroke, and repeat revascularization occurred more frequently in the
PCI than the CABG group (29 vs. 19%; HR 1.48, 95% CI 1.11–1.96,
P = 0.007).
A recent collaborative individual patient pooled analysis of
randomized trials including 11 518 patients reviewed the currently
available evidence from randomized trials comparing CABG with PCI
for LM or multivessel disease.124 The primary outcome was all-cause
mortality. In the overall cohort, CABG was associated with a signifi-
cant survival benefit during a mean follow-up of 3.8 ± 1.4 years (5
year all-cause mortality 11.2% after PCI vs. 9.2% after CABG; HR
1.20, 95% CI 1.06–1.37, P = 0.0038). There was a linear trend for
HRs of death increasing with increasing SYNTAX tertiles [P = 0.0011
for trend (unpublished analysis)]. However, among 4478 patients
with LM disease, those randomly assigned to CABG or PCI with a
mean follow-up of 3.4 ± 1.4 years reported similar risks for the pri-
mary outcome all-cause mortality (PCI 10.7 vs. CABG 10.5%; HR
1.07, 95% CI 0.87–1.33, P = 0.52) at 5 years. There were no signifi-
cant differences in mortality between PCI and CABG in subgroup
analyses according to SYNTAX scores. Nevertheless, in patients
with a high SYNTAX score, a trend towards better survival was
noted with CABG. The proportion of patients with a high SYNTAX
score was limited in view of the inclusion criteria of the respective
studies.
Current evidence indicates that PCI is an appropriate alternative
to CABG in LM disease and low-to-intermediate anatomical com-
plexity. Among patients with LM disease and low anatomical com-
plexity, there is evidence that the outcomes with respect to major
clinical endpoints are similar for PCI and CABG, resulting in a class I
recommendation. Among patients with LM disease and high
anatomical complexity, the number of patients studied in RCTs is
low due to exclusion criteria; the risk estimates and CIs are impre-
cise, but suggest a trend towards better survival with CABG.
Therefore, PCI in this setting cannot be endorsed as reflected by a
class III recommendation. For PCI in LM with intermediate anatomical
complexity, the previous class IIa recommendation was maintained in
view of the incomplete 5 year follow-up of the two largest RCTs in
this setting.
5.3.4 Multivessel coronary artery disease
The observation of a survival advantage of CABG over PCI has been
consistent among patients with severe three-vessel CAD (intermedi-
ate to high SYNTAX score), and has been attributed at least in part
to the placement of bypass grafts to the mid coronary vessels provid-
ing prophylaxis against the development of new proximal disease.
The BEST trial, comparing CABG with PCI using new-generation
DES (EES) among patients with multivessel CAD (77% three-vessel
CAD and 23% two-vessel disease, mean SYNTAX score 24), prema-
turely stopped enrolment after the inclusion of 880 patients due to
slow recruitment.105 At a median follow-up of 4.6 years, PCI was
associated with a higher incidence of the primary endpoint (death,
MI, and TVR) (15.3 vs. 10.6%; HR 1.47, 95% CI 1.01–2.13, P = 0.04)
than CABG. The risk of death, MI, and stroke was not statistically dif-
ferent between the two treatment groups (11.9 vs. 9.5%; HR 1.26,
95% CI 0.84–1.89, P = 0.26), whereas repeat revascularization of any
vessel (11.0 vs. 5.4%; HR 2.1, 95% CI 1.28–3.41, P = 0.003) but not
target lesion revascularization (5.7 vs. 3.8%; HR 1.51, 95% CI
0.82–2.80, P = 0.19) was more frequent in the PCI group. CABG
resulted in more complete revascularization (71.5 vs. 50.9%;
P <0.001) and a lower incidence of revascularization for new lesions
(5.5 vs. 2.3%; HR 2.47, 95% CI 1.18–5.17, P = 0.01).
Consistent with findings in the overall cohort (see section 5.3.3),
the collaborative individual patient pooled analysis found that in 7040
patients with multivessel disease, those assigned to CABG had signifi-
cantly lower 5 year all-cause mortality than those assigned to PCI
(PCI 11.5 vs. CABG 8.9%; HR 1.28, 95% CI 1.09–1.49, P = 0.0019).124
Outcomes for the endpoint all-cause mortality were modified by two
variables, diabetes and disease complexity, as assessed by the
SYNTAX score. Compared with patients without diabetes (8.7 vs.
8.0%; HR 1.08, 95% CI 0.86–1.36, P = 0.49), mortality was higher after
PCI than CABG in patients with diabetes (15.5 vs. 10.0%; HR 1.48,
95% CI 1.19–1.84, P = 0.0004, Pinteraction = 0.045). There was a gra-
dient of risk with a stepwise increase in mortality for PCI according
to SYNTAX score tertile (SYNTAX score 0 - 22: 10.5 vs. 8.4%; HR
1.11, 95% CI 0.77–1.62, P = 0.57; SYNTAX score 23 - 32: 14.0 vs.
9.5%; HR 1.50, 95% CI 1.09–2.08, P =0.0129; SYNTAX score >32:
19.2 vs. 11.2%; HR 1.70, 95% CI 1.13–2.55, P = 0.0094).
An individual patient data pooled analysis of SYNTAX and BEST,
comparing CABG with PCI using DES among 1275 patients with mul-
tivessel disease in the absence of diabetes (89% three-vessel CAD,
mean SYNTAX score 26), reported a lower risk of death (6.0 vs.
9.3%; HR 0.65, 95% CI 0.43–0.98, P = 0.04) and MI (3.3 vs. 8.3%; HR
0.40, 95% CI 0.24–0.65, P <0.001) in the CABG group at a median
follow-up of 61 months.149 The risk of death was not significantly dif-
ferent among patients with a low (0 - 22) SYNTAX score (6.0 vs.
7.5%, P = 0.66), whereas the benefit of CABG over PCI was greater
































































































vs. 11.6%, P = 0.02). Another individual patient data pooled analysis
of SYNTAX and BEST, comparing CABG with PCI using DES among
1166 patients with multivessel disease involving the proximal LAD
(88% three-vessel CAD, mean SYNTAX score 28), reported a higher
risk of the composite of death, MI, and stroke (16.3 vs. 11.5%; HR
1.43, 95% CI 1.05–1.96, P = 0.02), cardiac death, MI, and repeat revas-
cularization in the PCI group at 5 years of follow-up.147 Of note, out-
comes were not significantly different for CABG and PCI for any
endpoint except for MI among the subgroup of patients with low
SYNTAX score (0 - 22).
The available evidence suggests that in multivessel CAD without
diabetes and low anatomical complexity, PCI and CABG achieve sim-
ilar long-term outcomes with respect to survival and the composite
of death, MI, and stroke, justifying a class I recommendation for PCI.
In patients with multivessel CAD and intermediate-to-high anatomi-
cal complexity, the two large trials using DES, SYNTAX and BEST,
found a significantly higher mortality and a higher incidence of death,
MI, and stroke with PCI in the absence of diabetes. Consistent results
were also obtained for patients with multivessel CAD in the recent
individual patient-level meta-analysis.124 Thus, the previous class III
recommendation for PCI in multivessel CAD and intermediate-to-
high complexity was maintained.
5.4 Gaps in the evidence
It remains to be determined whether revascularization by PCI
improves prognosis in patients with SCAD. The ISCHEMIA
(International Study of Comparative Health Effectiveness With
Medical and Invasive Approaches) study (NCT01471522) is currently
recruiting 5000 patients with SCAD and evidence of moderate-to-
severe ischaemia detected by non-invasive imaging, who are random-
ized before coronary angiography to medical therapy or an invasive
strategy to detect differences in the primary endpoint of death or MI.
Current techniques rely on coronary angiography and the detection
of ischaemia-producing lesions. However, future adverse events are
related at least in part to non-flow limiting, vulnerable plaques. Better
identification of vulnerable plaques and the development of appropri-
ate treatment strategies is needed. Along the same lines, the com-
pleteness and timing of revascularization are not well defined, and
neither are the roles of residual ischaemia and lesions. Moreover, we
need more research on the use of the SYNTAX and other scores for
informing treatment allocation, as well as dedicated trials in specific
subsets. Very long-term, extended follow-up (10 years) of trials com-
paring PCI and CABG, particularly in the setting of LM disease, will





Myocardial revascularization in patients with non-ST-segment eleva-
tion ACS (NSTE-ACS) is addressed by prior Guidelines that are
endorsed by the current Task Force.158 In the present Guidelines, we
discuss new evidence where previous recommendations require an
update.
6.1 Early invasive vs. conservative
strategy
An invasive strategy has become the standard of care for high-risk
patients.158 This approach allows prompt diagnosis of the underlying
CAD, identification of the culprit lesion, guidance for antithrombotic
management, and the assessment of the suitability of coronary anat-
omy for PCI or CABG. Numerous factors interplay in the decision-
making process, including clinical presentation, comorbidities, risk
stratification (Figure 4), and high-risk features specific for a revasculari-
zation modality such as frailty, cognitive status, estimated life expect-
ancy, and the functional and anatomical severity of CAD.
Up to 40% of NSTE-ACS patients with obstructive CAD present
with multiple complex plaques159–162 and 25% with an acute
occluded coronary artery,163 so that identification of the culprit
lesion may be challenging. Correlation with ECG or echo changes
and the use of OCT in the 25% of NSTE-ACS patients with angio-
graphically normal epicardial coronary arteries164–166 may be helpful
for identifying the culprit lesion, or rule out other mechanisms such
as dissection or haematomas [MI with non-obstructive coronary
arteries (MINOCA)].167–169
A routine invasive strategy in NSTE-ACS has been shown to
improve clinical outcomes,170 and benefit was mainly confined to
biomarker-positive patients171 and patients with other high-risk fea-
tures as defined in Figure 4. Of importance, the use of a radial
approach, new-generation DES, and more effective P2Y12-inhibitors
were not available or broadly implemented in these trials, and led to
a magnified benefit in frail ACS populations.172,173
6.2 Timing of angiography and
intervention
The current recommendations on the timing of angiography and inter-
vention, as defined in Figure 4, are based on evidence discussed in detail
by the prior Guidelines on NSTE-ACS.158 Specifically, a reduction in
recurrent or refractory ischaemia and length of hospital stay was
found with early intervention.174,175 More recently, an updated collab-
orative meta-analysis on individual published and unpublished data
(n = 5324 patients with a median follow-up of 180 days) suggested
that early intervention might also be associated with decreased mor-
tality.176 This meta-analysis showed a statistical trend towards
decreased mortality with an early invasive strategy compared with a
delayed invasive strategy in unselected patients with NSTE-ACS (HR
0.81, 95% CI 0.64–1.03, P = 0.088). The survival benefit of the early
invasive strategy appeared more pronounced in high-risk subsets,
including elevated cardiac biomarkers at baseline (HR 0.76, 95% CI
0.58–0.996), diabetes (HR 0.67, 95% CI 0.45–0.99), a Global Registry
of Acute Coronary Events risk score >140 (HR 0.70, 95% CI
0.52–0.95), and age 75 years or older (HR 0.65, 95% CI 0.46–0.93),
although tests for interaction were inconclusive.
6.3 Type of revascularization
6.3.1 Percutaneous coronary intervention
6.3.1.1 Technical aspects
Implantation of new-generation DES is the standard treatment strat-
egy even when dual antiplatelet therapy (DAPT) cannot be sustained
beyond 1 month post-intervention173,177–179 (see section 17),






























.DAPT is recommended for 12 months irrespective of stent type,
while in patients at high ischaemic risk not experiencing bleeding
events, DAPT may be extended (see section 17). There is no evi-
dence for any additional benefit of thrombectomy in patients under-
going PCI in the setting of NSTE-ACS.180 While FFR is considered
the invasive gold standard for the functional assessment of lesion
severity in SCAD, it has been shown to be feasible, reliable, safe, and
effective in NSTE-ACS patients with multivessel disease, although its
prognostic value is unclear.22,137,181
6.3.1.2 Revascularization strategies and outcomes
Complete revascularization of significant lesions should be attempted
in multivessel disease NSTE-ACS patients, given that it was mandated
in trials testing early vs. late intervention171,182,183 and that the prog-
nosis of patients with incomplete revascularization is known to be
worse.131,184 In addition, it seems that complete one-stage revascula-
rization is associated with better clinical outcome than multistage
PCI.185 The risk of periprocedural complications of PCI defined as MI
or myocardial injury, as well as that of long-term ischaemia, remains
higher in NSTE-ACS than in stable patients.186,187 For ACS patients
who have undergone PCI, revascularization procedures represent
the most frequent, most costly, and earliest causes for rehospitaliza-
tion.188,189 As in ST-elevation myocardial infarction (STEMI), routine
treatment of non-culprit lesions during the primary intervention by
PCI is harmful in NSTE-ACS patients with cardiogenic shock, as
shown by the recently published CULPRIT-SHOCK (Culprit Lesion
Only PCI versus Multivessel PCI in Cardiogenic Shock) trial (see sec-
tion 7.3).190
6.3.2 Coronary artery bypass grafting
Approximately 5–10% of NSTE-ACS patients require CABG,191 and
they represent a challenging subgroup given their high-risk character-
istics compared with patients undergoing elective CABG.192 In the
absence of randomized data, optimal timing for non-emergent CABG
in NSTE-ACS patients should be determined individually. The risk of
ischaemic events possibly related to suboptimal antiplatelet therapy
while awaiting surgery is <0.1%, while that of perioperative bleeding
complications associated with platelet inhibitors is >10%.193 In
patients with ongoing ischaemia or haemodynamic instability with an
indication for CABG, emergency surgery should be performed and
not postponed as a consequence of antiplatelet treatment exposure.
6.3.3 Percutaneous coronary intervention vs. coronary
artery bypass grafting
There is no randomized comparison of PCI vs. CABG in the specific
setting of NSTE-ACS. The currently available evidence indirectly sug-
gests that the criteria applied to patients with SCAD to guide the
choice of revascularization modality should be applied to stabilized
patients with NSTE-ACS.100,121,150,194 Recent individual-patients data
analysis from the BEST, PRECOMBAT, and SYNTAX studies com-
pared the outcome of CABG with that of PCI in 1246 patients with
stabilized NSTE-ACS and multivessel or LM disease.194 The 5 year
incidence of the primary outcome—the composite of death, MI, or
stroke—was significantly lower with CABG than with PCI (13.4 vs.
18%, P = 0.036). The findings of this meta-analysis were consistent
with the main findings of the studies included, thus supporting the
concept that the principles of SCAD should apply to stabilized
patients with NSTE-ACS as well.
For complex cases, Heart Team discussion and use of the
SYNTAX score are recommended,195 given its ability to predict
death, MI, and revascularization in patients with NSTE-ACS and mul-
tivessel disease undergoing PCI. In patients with multivessel disease
and diabetes in particular, recent evidence suggests a greater benefit
of CABG vs. PCI.196
Recommendations for invasive evaluation and
revascularization in non-ST-elevation acute coronary
syndrome
Recommendations Classa Levelb
Urgent coronary angiography (<2 h) is rec-
ommended in patients at very high ischae-
mic risk (Figure 4).197
I C
An early invasive strategy (<24 h) is recom-
mended in patients with at least one high-
risk criterion (Figure 4).164,174,176
I A
An invasive strategy (<72 h after first
presentation) is indicated in patients
with at least one intermediate-risk crite-
rion (Figure 4) or recurrent
symptoms.170,171
I A
It is recommended to base the revasculari-
zation strategy (ad hoc culprit lesion PCI/
multivessel PCI/CABG) on the clinical status
and comorbidities, as well as the disease
severity [i.e. the distribution and angio-
graphic lesion characteristics (e.g. SYNTAX
score)], according to the principles for
SCAD.c 194
I B
In cardiogenic shock, routine revasculariza-
tion of non-IRA lesions is not recommended
during primary PCI.190
III B
CABG = coronary artery bypass grafting; IRA = infarct-related artery; NSTE-ACS
= non-ST-elevation acute coronary syndrome; PCI = percutaneous coronary
intervention; SCAD = stable coronary artery disease; SYNTAX = Synergy
Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery.
aClass of recommendation.
bLevel of evidence.




















































6.4 Gaps in the evidence
In the setting of NSTE-ACS, there are no dedicated prospective stud-
ies on the revascularization strategy with multivessel disease. Thus,
current recommendations on the choice of lesions to be treated and
treatment modality (PCI or CABG) are based on an analogy to find-
ings obtained in SCAD or STEMI. Likewise, the prognostic role of
FFR and iwFR in guiding myocardial revascularization needs additional
clarification.
7 Revascularization in ST-segment
elevation myocardial infarction
Myocardial revascularization in patients with STEMI is addressed by
the 2017 ESC Guidelines on STEMI. After reviewing the subsequent
literature, the current Task Force endorses most recommendations
of these Guidelines.198
7.1 Time delays
Delays in the timely implementation of reperfusion therapy are key
issues in the management of STEMI. Detailed recommendations on
timelines, logistics, and pre-hospital management have been provided
in the recent ESC STEMI Guidelines (Figure 5).198
A recent analysis of 12 675 STEMI patients in the FITT-STEMI
(Feedback Intervention and Treatment Times in ST-Elevation
Myocardial Infarction) trial emphasizes the strong impact of time
delays on mortality, particularly in STEMI patients with cardiogenic
shock or out-of-hospital cardiac arrest.199 In shock without out-of-
hospital cardiac arrest, every 10 min treatment delay between
60–180 min from the first medical contact resulted in 3.3 additional
deaths per 100 PCI-treated patients, and in 1.3 additional deaths after
out-of-hospital cardiac arrest without cardiogenic shock. In stable
STEMI patients, time delays were substantially less relevant (0.3 addi-
tional deaths per 100 PCI-treated patients for every 10 min delay
between 60–180 min from the first medical contact). Thus, high-risk
STEMI patients with cardiogenic shock or out-of-hospital cardiac
arrest are those who benefit most from expediting all steps of the
care pathway.
7.2 Selection of reperfusion strategy
Primary PCI, defined as percutaneous catheter intervention in the
setting of STEMI without previous fibrinolysis, is the preferred reper-
fusion strategy. It has replaced fibrinolysis in patients with STEMI, pro-
vided it can be performed in a timely manner in high-volume PCI
centres with experienced operators and 24 h/7 days a week catheter-
ization laboratory activation.198,200,201 In settings where primary
PCI cannot be performed in a timely fashion, fibrinolysis should be
administered as soon as possible. If first medical contact (FMC) is
out-of-hospital, lysis should be implemented pre-hospital (e.g. in the
ambulance) (Figure 5).202–206 It should be followed by transfer to
PCI-capable centres for routine coronary angiography in all patients,
and should be performed without delay for rescue PCI in the case of
unsuccessful fibrinolysis or within 2–24 h after bolus administra-
tion.198 Emergency CABG may be indicated in selected STEMI
patients unsuitable for PCI.


























..7.3 Primary percutaneous coronary
intervention
Key points for optimizing and guiding primary PCI are summarized
below.
The infarct-related artery (IRA) should be systematically treated
during the initial intervention. Patients with extensive CAD in vessels
remote from the IRA have an adverse prognosis following primary
PCI.207 Staged PCI in patients with multivessel disease and no haemo-
dynamic compromise is an independent predictor of survival, and
more frequent ischaemic events have been reported in direct vs.
staged revascularization of STEMI patients with multivessel
disease.208–210
Four major randomized trials-PRAMI (Preventive Angioplasty in
Acute Myocardial Infarction),211 CvLPRIT (Complete Versus Lesion-
Only Primary PCI trial),212 DANAMI-3-PRIMULTI (The Third
DANish Study of Optimal Acute Treatment of Patients with ST-
segment Elevation Myocardial Infarction: PRImary PCI in
MULTIvessel Disease),213 and Compare-Acute214-have consistently
shown a benefit of complete revascularization (performed immedi-
ately or staged) as compared with IRA-only PCI in patients with
STEMI and multivessel disease (for details see the Supplementary
Data). A recent meta-analysis of 10 trials has shown that complete
revascularization was associated with a lower risk of MACE (RR 0.57,
95% CI 0.42–0.77), due to a lower risk of urgent revascularization


























































































(RR 0.44, 95% CI 0.30–0.66), with no significant difference in mortal-
ity (RR 0.76, 95% CI 0.52–1.12) or MI (RR 0.54, 95% CI
0.23–1.27).215 This meta-analysis did not include Compare-Acute.
Yet, similar to earlier studies, the benefit of complete revasculariza-
tion over culprit-only revascularization seen in Compare-Acute was
driven by a lower need for unplanned reintervention, whereas the
incidences of death and recurrent MI were similar between the two
strategies.214
Most of the studies support the concept of full revascularization
either during the initial hospital stay for STEMI or a staged admis-
sion,215 but it remains to be determined how clinicians can identify
lesions that should be revascularized beyond the culprit lesion and
whether complete revascularization should be performed in single-
or multi-stage procedures. Moreover, there is a lack of evidence on
the optimal timing of staged procedures. In most of the studies,
staged procedures were performed during the initial hospital stay. At
present, one-stage multivessel PCI during STEMI without cardiogenic
shock should be considered in patients in the presence of multiple,
critical stenoses or highly unstable lesions (angiographic signs of pos-
sible thrombus or lesion disruption), and if there is persistent ischae-
mia after PCI on the supposed culprit lesion.
In patients with multivessel disease and AMI with cardiogenic
shock, the recently published CULPRIT-SHOCK trial showed that a
strategy with PCI of the culprit lesion only with possible staged revas-
cularization determined a lower 30 day risk of the composite of all-
cause mortality or severe renal failure compared with immediate
multivessel PCI.190 This was driven by a significant risk reduction in
30 day all-cause mortality by the culprit lesion-only strategy com-
pared with immediate multivessel PCI (43.3 vs. 51.6%; HR 0.84, 95%
CI 0.72–0.98, P = 0.03). These findings need to be interpreted in light
of a low 12.5% (43 out of 344 patients) crossover rate from culprit
lesion-only to immediate multivessel PCI based on physicians’ judg-
ment. Based on these findings, culprit lesion-only PCI is recom-
mended as the default strategy in patients with AMI with cardiogenic
shock. A more detailed discussion of the revascularization strategy in
MI patients with cardiogenic shock is found in the Supplementary
Data.
In patients with STEMI, DES (in particular new-generation DES)
have demonstrated better efficacy as compared with BMS and should
be used as the default strategy in STEMI patients, even when DAPT
cannot be sustained beyond 1 month.177,178,216–218 (see section
16.1.2). As discussed in section 16.4, radial access is preferred over
femoral access.
Delaying stenting in primary PCI has been investigated as an option
to reduce microvascular obstruction (MVO) and preserve microcir-
culatory function in two small trials with conflicting results.219,220
More recently, in the larger deferred vs. conventional stent implanta-
tion in patients with STEMI [The Third DANish Study of Optimal
Acute Treatment of Patients with ST-segment Elevation Myocardial
Infarction: DEFERred stent implantation in connection with primary
PCI (DANAMI 3-DEFER)] trial in 1215 STEMI patients, there was no
effect on the primary clinical outcome (composite of death, non-fatal
MI, or ischaemia-driven revascularization of non-IRA lesions) over a
median follow-up of 42 months.221 Routine deferred stenting was
associated with a higher risk of TVR.
Thrombus aspiration has been proposed as an adjunct during pri-
mary PCI to further improve epicardial and myocardial reperfusion
by the prevention of distal embolization of thrombotic material and
plaque debris.222 Two landmark RCTs, which were adequately pow-
ered to detect the superiority of routine manual thrombus aspiration
vs. conventional PCI, showed no benefit on clinical outcomes of the
routine aspiration strategy overall or in any subgroup of patients indi-
cating high thrombotic risk.223–226 A safety concern emerged in
TOTAL (Trial of Routine Aspiration Thrombectomy with PCI versus
PCI Alone in Patients with STEMI) trial with an increase in the risk of
stroke.225,227 Taken together, these results suggest that the routine
use of thrombus aspiration is not indicated. In the high-thrombus bur-
den subgroup, the trend towards reduced cardiovascular death and
increased stroke/transient ischaemic attack (TIA) provides a rationale
for future trials of improved thrombus aspiration technologies in this
high-risk subgroup (although statistical tests did not support signifi-
cant subgroup interaction).228
7.4 Percutaneous coronary intervention
after thrombolysis and in patients with
late diagnosis
The benefits of early, routine PCI after thrombolysis were seen in the
absence of an increased risk of adverse events (stroke or major
bleeding). Based on data from the four most recent trials, all of which
had a median delay between the start of thrombolysis and angiogra-
phy of 2–6 h, a time frame of 2–24 h after successful lysis is recom-
mended.206,229–231 In cases of failed fibrinolysis, or if there is evidence
of re-occlusion or reinfarction with recurrence of ST-segment eleva-
tion, the patient should undergo immediate coronary angiography
and rescue PCI.232 Patients presenting between 12 and 48 h after the
onset of symptoms, even if pain free and with stable haemodynamics,
may still benefit from early coronary angiography and possibly
PCI.233,234 In patients presenting days after the acute event with a
completed MI, only those with recurrent angina or documented
residual ischaemia—and proven viability on non-invasive imaging in a
large myocardial territory—may be considered for revascularization
when the infarct artery is occluded. Routine late PCI of an occluded
IRA after MI in stable patients has no incremental benefit over medi-
cal therapy.235
7.5 Gaps in the evidence
Patients undergoing primary PCI benefit from full revascularization,
but the optimal timing of treatment of the non-culprit lesion is not
known. More studies evaluating the assessment of non-culprit lesions
by FFR or iwFR at the time of acute PCI, and studies investigating
whether intravascular imaging guidance of primary PCI can improve
the outcomes of STEMI patients, are needed. Future trials of
improved thrombus aspiration technologies may address the role of
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Reperfusion therapy is indicated in all patients with time from symptom onset <12 h duration and persistent ST-seg-
ment elevation.200,201,236
I A
In the absence of ST-segment elevation, a primary PCI strategy is indicated in patients with suspected ongoing
ischaemic symptoms suggestive of MI and at least one of the following criteria present:
• haemodynamic instability or cardiogenic shock
• recurrent or ongoing chest pain refractory to medical treatment
• life-threatening arrhythmias or cardiac arrest
• mechanical complications of MI
• acute heart failure
• recurrent dynamic ST-segment or T-wave changes, particularly with intermittent ST-segment elevation.
I C
A primary PCI strategy is recommended over fibrinolysis within the indicated time frames.200,201,237,238 I A
In patients with time from symptom onset >12 h, a primary PCI strategy is indicated in the presence of ongoing
symptoms or signs suggestive of ischaemia, haemodynamic instability, or life-threatening arrhythmias.
I C




It is recommended that the pre-hospital management of STEMI patients should be based on regional networks that
are designed to deliver reperfusion therapy effectively in a timely fashion, and to offer primary PCI to as many
patients as possible.240,241
I B
It is recommended that all EMS, emergency departments, coronary care units, and catheterization laboratories have
a written updated STEMI management protocol, preferably shared within geographical networks.
I C
It is recommended that primary PCI-capable centres deliver a 24 h/7 day service and ensure that primary PCI is per-
formed as fast as possible.242–244
I B
It is recommended that patients transferred to a PCI-capable centre for primary PCI bypass the emergency depart-
ment and CCU/ICCU, and are transferred directly to the catheterization laboratory.245–247
I B
CCU = coronary care unit; EMS = emergency medical services; ICCU = intensive coronary care unit; MI = myocardial infarction; PCI = percutaneous coronary intervention;



































































8 Myocardial revascularization in
patients with heart failure
8.1 Chronic heart failure
8.1.1 Recommendations for myocardial revascularization
in patients with chronic heart failure
When compared with medical therapy alone, coronary revasculariza-
tion is superior in improving survival in patients with HF of ischaemic
origin and is recommended in clinical practice.81,248 However, the
optimal revascularization strategy is not defined. The choice between
CABG and PCI should be made by the Heart Team after careful eval-
uation of the patient’s clinical status and coronary anatomy, expected
completeness of revascularization (see section 5.3.1.3), myocardial
viability, coexisting valvular disease, and comorbidities.
Considerations relating to the need for viability testing prior to revas-
cularization are discussed in section 3.
Randomized clinical trial data comparing revascularization with
medical therapy exists only for CABG in the setting of the STICH
trial.81 One analysis from this trial showed that CABG can be per-
formed with acceptable 30 day mortality rates (5.1%) in patients with
LV dysfunction (LVEF <_35%).249 Extended follow-up in the STICH
Extension Study (STICHES) supports a significant survival benefit of
CABG combined with medical therapy vs. medical therapy alone in a
10 year observation period.81
There are currently no dedicated randomized clinical trials com-
paring PCI vs. medical therapy in patients with HF with reduced EF
(HFrEF). In addition, CABG vs. PCI randomized trials have excluded
patients with severe HF. In one prospective registry including 4616
patients with multivessel disease and severe HFrEF, propensity
score-matched comparison revealed similar survival (mean follow-up
2.9 years) with PCI (using EES) vs. CABG.250 PCI was associated with
a higher risk of MI, particularly in patients with incomplete revascula-
rization, and repeat revascularization. CABG was associated with a
higher risk of stroke. The conclusion of the study was that multivessel
PCI can be a valuable option in HF patients if complete revasculariza-
tion is possible. A systematic review of studies comparing
revascularization with medical therapy in patients with an EF <_40%
showed that there was a significant mortality reduction with CABG
(HR 0.66, 95% CI 0.61–0.72, P <0.001) and PCI (HR 0.73, 95% CI
0.62–0.85, P <0.001) vs. medical therapy, though these finding are
limited by the predominantly observational nature of the included
studies and missing information on the completeness of
revascularization.248
A recent observational study investigated outcomes with PCI or
CABG for multivessel CAD and LV dysfunction in 1738 propensity-
matched patients with diabetes mellitus.251 Similar to the findings in
the absence of LV dysfunction, when CABG was compared with PCI
it was associated with a significantly lower risk of MACE, which
included a significant reduction in mortality. Event curves separated
early during the first year and continued to separate out to 12 years.
PCI should be considered in older patients without diabetes in
whom complete revascularization can be achieved, whereas CABG is
preferred in younger patients with more extensive CAD or those
with diabetes. In patients with diabetes and LV moderate or severe
dysfunction (EF <50%), CABG is associated with better long-term
survival and reduced incidence of MACCE.250,251
8.1.2 Ventricular reconstruction and aneurysm resection
The aim of surgical ventricular reconstruction (SVR) is to restore
physiological volume, and achieve an elliptical shape of the LV, by scar
resection and LV wall reconstruction on a mannequin of predefined
size. The aim of ventricular aneurysmectomy is to remove fibrous
scars in cases of severe dilatation, thrombus formation, or as a source
of life-threatening ventricular arrhythmias.
The STICH trial revealed no difference in the primary outcome
(total mortality or cardiac hospitalization) between patients ran-
domly allocated to CABG vs. combined CABG and SVR.252
Subgroup analyses of patients with a less dilated LV and better LVEF
showed benefit from SVR.253 In the STICH trial, a post-operative LV
end-systolic volume index <_70 mL/m2, after CABG plus SVR,
resulted in improved survival compared with CABG alone.252,254 In
experienced centres, SVR may be done at the time of CABG if HF
Primary percutaneous coronary intervention for myocardial reperfusion in ST-elevation myocardial infarction: proce-
dural aspects (strategy and technique)
Recommendations Classa Levelb
Strategy
Routine revascularization of non-IRA lesions should be considered in patients with multivessel disease before hospital
discharge.211–214
IIa A
CABG should be considered in patients with ongoing ischaemia and large areas of jeopardized myocardium if PCI of the
IRA cannot be performed.
IIa C
In cardiogenic shock, routine revascularization of non-IRA lesions is not recommended during primary PCI.190 III B
Technique
Routine use of thrombus aspiration is not recommended.223–226,228 III A


































































































symptoms are more predominant than angina, and if myocardial scar
and moderate LV remodelling are present.
8.2 Acute heart failure and cardiogenic
shock
Acute myocardial ischaemia in the setting of AMI is the antecedent
event for the majority of patients with cardiogenic shock undergoing
percutaneous revascularization. Mechanical complications—such as
papillary muscle rupture with severe mitral valve regurgitation, ven-
tricular septal defect, or free wall rupture—are additional precipitat-
ing causes.
8.2.1 Revascularization
The SHOCK (Should We Emergently Revascularize Occluded
Coronaries for Cardiogenic Shock) trial demonstrated that in
patients with cardiogenic shock complicating AMI, emergency revas-
cularization with PCI or CABG improved long-term survival when
compared with initial intensive medical therapy. All-cause mortality
at 6 months was lower in the group assigned to revascularization
than in the medically treated patients (50.3 vs. 63.1%, respectively;
RR 0.80, 95% CI 0.65–0.98, P = 0.03).258
The revascularization strategy for patients with cardiogenic shock
and multivessel disease is addressed in section 7.
A subanalysis of the SHOCK trial comparing patients treated with
CABG or PCI showed similar survival rates between the two sub-
groups.259 There were more patients with diabetes (48.9 vs. 26.9%;
P = 0.02), three-vessel disease (80.4 vs. 60.3%; P = 0.03), and LM cor-
onary disease (41.3 vs. 13.0%; P = 0.001) in the CABG group. The
findings of this non-randomized comparison suggest that CABG
should be considered in patients with cardiogenic shock who have
suitable anatomy, particularly if successful PCI is not feasible.
8.2.2 Mechanical circulatory support
Short-term MCS devices that are currently available are the intra-
aortic balloon pump (IABP), veno-arterial extracorporeal membrane
oxygenation (ECMO), and percutaneous left ventricular assist devi-
ces (pLVADs). Short-term MCS may be considered in refractory car-
diogenic shock depending on patient age, comorbidities, neurological
function, and the prospects for long-term survival and quality of life.
8.2.2.1 Intra-aortic balloon pump
IABPs are low-cost devices that are easy to insert and remove. They
moderately increase cardiac output and coronary and cerebral perfu-
sion, while decreasing ventricular workload. In patients with cardio-
genic shock complicating acute MI, the IABP-SHOCK II (Intraaortic
Balloon Pump in Cardiogenic Shock II) randomized trial (600 patients)
showed that the use of IABPs did not reduce 30 day mortality and that
there was no evidence of long-term benefit.260,261 A recent Cochrane
review of seven trials (790 patients) showed that IABPs may have a
beneficial effect on some haemodynamic parameters but did not result
in survival benefits.262 Thus, the routine use of IABPs in patients with
cardiogenic shock complicating acute MI is not recommended.
8.2.2.2 Extracorporeal membrane oxygenation
Veno-arterial ECMO (VA-ECMO), also known as extracorporeal life
support (ECLS), in its current form is a modified form of cardiopul-
monary bypass. It decompresses the venous system; increases coro-
nary, cerebral, and peripheral perfusion; and also provides
supplementary blood oxygenation. When performed percutane-
ously, it does not allow for LV decompression and leads to increasing
LV afterload.
In patients with cardiac arrest, evidence from observational trials
supports better survival in patients treated with VA-ECMO com-
pared with those without.263 When compared with IABP, VA-
ECMO provides superior circulatory support.264,265 Moreover, a
meta-analysis of observational studies suggested that in patients with
cardiogenic shock post-ACS, VA-ECMO showed a 33% higher 30
day survival compared with IABP [95% CI 14–52%, P <0.001; number
needed to treat (NNT) 13].263 However, the low number of patients
included in the analysed studies and the non-random treatment allo-
cation are important limitations.
Recommendations on revascularizations in patients
with chronic heart failure and systolic left ventricular
dysfunction (ejection fraction 35%)
Recommendations Classa Levelb
In patients with severe LV systolic dysfunc-
tion and coronary artery disease suitable for
intervention, myocardial revascularization is
recommended.81,250
I B
CABG is recommended as the first revas-
cularization strategy choice in patients
with multivessel disease and acceptable
surgical risk.68,81,248,255
I B
In patients with one- or two-vessel dis-
ease, PCI should be considered as an
alternative to CABG when complete
revascularization can be achieved.
IIa C
In patients with three-vessel disease, PCI
should be considered based on the evalu-
ation by the Heart Team of the patient’s
coronary anatomy, the expected com-
pleteness of revascularization, diabetes
status, and comorbidities.
IIa C
LV aneurysmectomy during CABG should
be considered in patients with NYHA class
III/IV, large LV aneurysm, large thrombus
formation, or if the aneurysm is the origin of
arrhythmias.
IIa C
Surgical ventricular restoration during
CABG may be considered in selected
patients treated in centres with
expertise.252–254,256,257
IIb B
CABG = coronary artery bypass grafting; LV = left ventricular; NYHA = New
































..8.2.2.3 Percutaneous left ventricular assist devices
The majority of clinical experience with currently available pLVADs
is limited to two types of device: (i) a transaortic microaxial pump
(Impella) that directly unloads the LV providing 2.5 - 5 L/min blood
flow and (ii) a transseptal centrifugal assist device (TandemHeart)
that unloads the LV via a cannula introduced into the left atrium
through a transseptal puncture.
A recent meta-analysis on MCS in cardiogenic shock included four
randomized trials investigating the efficacy and safety of pLVADs vs.
IABP, and demonstrated similar short-term mortality despite initial
beneficial effects on arterial blood pressure and peripheral perfusion,
measured by serum lactate levels.266 In all trials, a higher rate of
bleeding from vascular access sites and a significantly higher incidence
of limb ischaemia following pLVAD was noted. Similar outcomes
were noted in an RCT of high-risk PCI in patients with impaired LV
function. The 30 day incidence of major adverse events was not dif-
ferent for patients with pLVAD vs. IABP.267
In summary, the evidence for pLVAD is insufficient to provide a
recommendation on its clinical use in cardiogenic shock.
8.2.2.4 Surgically implanted left ventricular assist devices
There are limited data on surgically-implanted LV assist device
(LVAD) therapy in patients with AMI and cardiogenic shock. One
multicentre registry showed that despite being more critically ill prior
to implantation, patients with acute MI managed with LVAD had out-
comes similar to other LVAD populations.268
A suggested algorithm for the management of patients with cardio-
genic shock is shown in Figure 6.
































































































8.3 Gaps in the evidence
There is no RCT comparing revascularization with PCI vs. CABG in
patients with HF.
There is limited evidence on the role of active MCS in patients
with cardiogenic shock compared with standard therapy.
9 Revascularization in patients
with diabetes
Patients with diabetes mellitus have a higher prevalence of CAD,
which often manifests earlier in life and confers a substantially worse
prognosis than for patients without diabetes.270 Patients with diabe-
tes who have suffered an MI have a worse prognosis, particularly
those requiring treatment with insulin, and the presence of diabetes
amplifies the risk of any cardiovascular event.271 Diabetes mellitus is
present in 25–30% of patients admitted with ACS and in up to 40%
of patients undergoing CABG.272
The anatomical pattern of CAD in patients with diabetes clearly
influences their prognosis and response to revascularization.
Angiographic studies have demonstrated that patients with diabetes
are more likely to have LM disease and multivessel CAD, with more
diffuse disease involving smaller vessels.273 In addition, patients with
diabetes have a greater atherosclerotic burden and an increased
number of lipid-rich plaques, which are prone to rupture,274,275 and
those with unstable angina have more fissured plaques and intracoro-
nary thrombi.276 Patients with diabetes undergoing revascularization,
either with CABG or PCI, are at greater risk of kidney injury than
patients without diabetes.
9.1 Evidence for myocardial
revascularization
In patients with diabetes, the indications for myocardial revasculariza-
tion are the same as those in patients without diabetes (see sections
5, 6, and 7). A meta-analysis of nine RCTs with 9904 ACS patients did
not show an interaction between diabetic status and the benefit from
invasive management and revascularization.277 Yet, absolute risk
reductions were larger in the diabetic subsets compared with non-
diabetic subsets. Consistent with the findings in the absence of diabe-
tes, the adverse impact of incomplete revascularization in patients
with diabetes was also demonstrated in the BARI-2D (Bypass
Angioplasty Revascularization Investigation 2 Diabetes) trial.278
Data from randomized trials on revascularization in patients with
diabetes are summarized in Supplementary Table 5.
9.2 Type of myocardial revascularization
The selection of the optimal myocardial revascularization strategy for
patients with diabetes and multivessel CAD requires particular con-
sideration. The recommendations are provided in section 5.
9.2.1. Randomized clinical trials
The FREEDOM trial compared elective revascularization with CABG
or PCI with first-generation DES (94%) in 1900 patients with diabetes
(6% of the screened population) with multivessel disease but without
LM stenosis.150 The primary endpoint of any-cause death, non-fatal
MI, or stroke at 5 years occurred in 26.6% in the PCI group, com-
pared with 18.7% in the CABG group (absolute difference 7.9%, 95%
CI 3.3–12.5%, P = 0.005). The incidences of death (16.3% in the PCI
group vs. 10.9% in the CABG group; absolute difference 5.4%, 95%
CI 1.5–9.2%, P = 0.049) and MI (13.9% in the PCI group vs. 6.0% in
the CABG group, P <0.001) were higher in the PCI group, but the
incidence of stroke was lower (2.4 vs. 5.2%; P =0.03). Within the
FREEDOM trial at 5 years, patients with diabetes treated with insulin
had higher event rates, but there was no significant interaction of
treatment and insulin requirement for the primary endpoint
(Pinteraction = 0.40), even after adjusting for SYNTAX score: the NNT
with CABG vs. PCI to prevent one event was 12.7 for insulin-treated
patients and 13.2 in those not requiring insulin.279
VACARDS (Veterans Affairs Coronary Artery Revascularization
in Diabetes Study) compared CABG with PCI in patients with diabe-
tes and extensive CAD in the USA.154 Only 198 patients with diabe-
tes were randomized due to early termination of the study. The
combined risk of death or non-fatal MI was 18.4% for the CABG arm
and 25.3% for the PCI arm (HR 0.89, 95% CI 0.47–1.71, P <0.05).154
Recommendations for the management of patients with
cardiogenic shock
Recommendations Classa Levelb
Emergency coronary angiography is indi-
cated in patients with acute heart failure or
cardiogenic shock complicating ACS.258,269
I B
Emergency PCI of the culprit lesion is indi-
cated for patients with cardiogenic shock
due to STEMI or NSTE-ACS, independent
of time delay of symptom onset, if coronary
anatomy is amenable to PCI.258
I B
Emergency CABG is recommended for
patients with cardiogenic shock if the coro-
nary anatomy is not amenable to PCI.258
I B
In cases of haemodynamic instability, emer-
gency surgical or catheter-based repair of
mechanical complications of ACS is indi-
cated, as decided by the Heart Team.
I C
In selected patients with ACS and cardio-
genic shock, short-term mechanical circula-
tory support may be considered, depending
on patient age, comorbidities, neurological
function, and the prospects for long-term
survival and predicted quality of life.
IIb C
Routine use of IABPs in patients with car-
diogenic shock due to ACS is not
recommended.260–262
III B
ACS = acute coronary syndrome; CABG = coronary artery bypass grafting; IABP
= intra-aortic balloon pump; NSTE-ACS = non-ST-elevation acute coronary syn-






























































































..In the CARDia (Coronary Artery Revascularization in Diabetes)
trial, 510 patients with diabetes and multivessel or complex single-
vessel CAD were randomly assigned to either CABG or PCI, with
the use of either BMS or DES and routine use of abciximab.156 There
were no differences between CABG and PCI for the primary end-
point of 1 year composite of death, MI, or stroke, but the trial was
underpowered to detect these differences. However, repeat revas-
cularization was more likely to occur in patients treated with PCI
(P <0.001).156
In the subset of 452 patients with diabetes and multivessel CAD
who were enrolled in the SYNTAX trial, there were no differences
in the composite safety endpoint of all-cause death, stroke, and MI at
5 year follow-up.155 However, the need for repeat revascularization
(HR 2.01, 95% CI 1.04–3.88, P <0.001) was significantly more fre-
quent in patients with diabetes treated with PCI than in those who
underwent CABG.155,275 Patients with diabetes had a higher rate of
repeat revascularization after PCI when compared with CABG in the
low (<_22) (38.5 vs. 18.5%, respectively, P = 0.014) and intermediate
(23 - 33) (27 vs. 13.4%, respectively, P = 0.049) SYNTAX score ter-
tiles. Further analyses according to treatment with either oral hypo-
glycaemic agents or insulin showed that the MACCE rate was
significantly greater after PCI in both the oral hypoglycaemic agent
group (PCI 40.4 vs. CABG 26.4%, P = 0.022) and the insulin-
dependent group (PCI 56.2 vs. CABG 32.6%, P = 0.002). A higher
incidence of cardiac death was noted in the insulin-dependent
patients treated with PCI (PCI 18.8 vs. CABG 7.1%, P = 0.023).
In the SYNTAX trial, diabetes was not an independent predictor
of outcomes once the SYNTAX score was entered into the multi-
variable model.127 Consequently, the SYNTAX 2 score does not
include diabetes as one of the eight variables that impacts on the pref-
erential selection of revascularization modality.127 Conflicting data
were seen in a patient-level pooled analysis of 6081 patients treated
with stents (75% newer generation DES), stratified according to dia-
betes status and SYNTAX score.157 After Cox regression adjust-
ment, SYNTAX score and diabetes were both associated with
MACE (P <0.001 and P = 0.0028, respectively). At 2 years, patients
with diabetes had higher MACE (HR 1.25, 95% CI 1.03–1.53, P =
0.026) and TVR, and similar death and MI rates.157
In the BEST trial, patients with diabetes treated with PCI had a
higher rate of the primary endpoint of death, MI, or TVR compared
with CABG (EES: n=177; CABG: n=186) (19.2 vs. 9.1%, P = 0.007)
(see section 5).105
9.2.2 Meta-analysis of coronary artery bypass grafting vs.
percutaneous coronary intervention in patients with
diabetes
A meta-analysis—restricted to four RCTs covering 3052 patients-
compared PCI with the use of early-generation DES vs. CABG in
patients with diabetes and multivessel CAD. It suggested a higher risk
of death and MI with revascularization by early-generation DES (RR
1.51, 95% CI 1.09–2.10; P <0.01), but a lower risk of stroke (2.3 vs.
3.8%; RR 0.59, 95% CI 0.39– 0.90; P <0.01).152 A sensitivity analysis
revealed that this superiority of CABG over early-generation DES for
the endpoint MACCE was most pronounced among patients with a
high SYNTAX score. A network meta-analysis had suggested that the
survival benefit of CABG over PCI in patients with diabetes might be
lost when using EES,151 though this was not confirmed in a subse-
quent meta-analysis that also included the direct comparison
between EES and CABG in the subset of BEST.153
In a collaborative, individual patient data pooled analysis of 11 518
patients with multivessel or LM disease randomized to CABG or PCI
with stents, all-cause death was significantly different after CABG
(9.2%) and PCI (11.2%) (P = 0.0038), which was evident in patients
with diabetes (10.7 vs. 15.7%, respectively; P = 0.0001) but not in
patients without diabetes (8.4 vs. 8.7%, respectively; P = 0.81)
(Pinteraction = 0.0077).
124 Similar results were found in the subgroup of
7040 patients with multivessel disease (Pinteraction = 0.0453), while the
interaction with diabetes was not significant in the 4478 patients with
LM disease (Pinteraction = 0.13).
A recent population-based analysis has confirmed the benefit of
CABG compared with PCI in patients with diabetes when patients
present with an ACS.196 Consequently, overall current evidence con-
tinues to favour CABG as the revascularization modality of choice
for patients with diabetes and multivessel disease. When patients
present with a comorbidity that increases surgical risk, the choice of
revascularization method is best decided by multidisciplinary individu-
alized risk assessment.
9.3 Revascularization with the use of
percutaneous coronary intervention
For the reasons discussed above, PCI in patients with diabetes is
often more complex than PCI in the absence of diabetes.
Nevertheless, irrespective of diabetic status, the same principles
apply as discussed in section 16. Placement of a new-generation DES
is the default strategy.
9.4 Antithrombotic pharmacotherapy
In the current context of the use of oral P2Y12-inhibitors, there is no
indication that antithrombotic pharmacotherapy should differ
between diabetics and patients without diabetes who are undergoing
revascularization. For detailed discussion refer to section 17.
9.5 Metformin
There is a theoretical risk of lactic acidosis and deteriorating renal
function in patients treated with metformin who are exposed to iodi-
nated contrast media.280 Consequently, it is generally recommended
that in elective cases, metformin should be withheld before angiogra-
phy or PCI for 48 h, as the plasma half-life of metformin is 6.2 h,280
and reintroduced 48 h later. However, clinical experience suggests
that the actual risk of lactate acidosis is very small, and that checking
renal function after angiography in patients on metformin and with-
holding the drug when renal function deteriorates appears to be an
acceptable alternative.280 In patients with renal failure, metformin
should be stopped before the procedure. Accurate recognition of
metformin-associated lactic acidosis based on arterial pH <7.35,
blood lactate >5 mmol/L (45 mg/dL), and detectable plasma metfor-























9.6 Gaps in the evidence
Following successful revascularization, the rate of events during
follow-up remains high in patients with diabetes, independent of the
mode of revascularization. Future research should be focused on
identifying new disease-modifying therapies to influence the progres-
sion of vascular disease in this high-risk cohort.
10 Revascularization in patients
with chronic kidney disease
10.1 Evidence base for revascularization
and recommendations
Myocardial revascularization in patients with chronic kidney disease
(CKD), specifically National Kidney Foundation stage 3 or higher, is
addressed by the 2014 ESC/EACTS Guidelines on myocardial revas-
cularization. After reviewing the subsequent literature, the current
Task Force has not found any evidence to support a major update. A
recent post hoc analysis of the SYNTAX trial on patients with CKD
confirms the principles for allocating patients to PCI or CABG,281 as
discussed in section 5 of this document.
10.2 Prevention of contrast-induced
nephropathy
The risk of contrast-induced nephropathy (CIN) depends on patient-
related factors, such as CKD, diabetes mellitus, congestive HF, hae-
modynamic instability, reduced plasma volume, female sex, advanced
age, anaemia, and periprocedural bleeding, as well as on the type and
volume of contrast administered.282–288 When the ratio of total con-
trast volume (in mL) to glomerular filtration rate (in mL/min) exceeds
3.7, the risk of CIN increases significantly.287,288
Adequate hydration remains the mainstay of CIN pre-
vention.289–294 High-dose statins, as indicated for secondary preven-
tion irrespective of the risk of CIN are also beneficial.293 All other
strategies for the prevention of CIN do not have sufficient evidence
to justify a recommendation in favour or against.293,294 For more
detailed discussion refer to the Supplementary Data.
10.3 Gaps in the evidence
Thus far, patients with CKD have been excluded from randomized
trials on myocardial revascularization, hence current data are based
on observational studies only. A randomized trial on optimal long-
term revascularization strategies in patients with moderate-to-severe
stress-induced ischaemia and severe CKD is currently ongoing
(ISCHEMIA-CKD, https://clinicaltrials.gov/ct2/show/NCT01985360).
Moreover, additional randomized evidence on optimal strategies for
CIN prevention is needed.
Recommendation for patients on metformin
Recommendation Classa Levelb
It is recommended to check renal function if
patients have taken metformin immediately
before angiography and withhold metformin
if renal function deteriorates.
I C
aClass of recommendation.
bLevel of evidence. Recommendations for the prevention of contrast-
induced nephropathy
Recommendations Dose Classa Levelb
Patients undergoing coronary angiography or MSCT
It is recommended that all
patients are assessed for






Patients with moderate or severe CKD (National
Kidney Foundation stages 3b and 4)





It is recommended that

















with isotonic saline should
be considered if the
expected contrast volume
is >100 mL.
1 mL/kg/h 12 h
before and con-







As an alternative to the
pre- and post- hydration
regimen, tailored hydra-



































































































11.1 Primary indication for valve
interventions
Myocardial revascularization in patients undergoing primary valve
interventions, either by surgery or transcatheter routes, is addressed
by the 2014 ESC/EACTS Guidelines on myocardial revascularization.
After reviewing the subsequent literature, the current Task Force
endorses the recommendations of the 2014 Guidelines and has not
found any evidence to support a major update. These recommenda-
tions are included below for ease of reference. Of note, the available
evidence on invasive functional assessment of CAD (with FFR or
iwFR) in patients with severe aortic stenosis (AS) is limited to a few
small-scale observational studies. These studies support the feasibility
of FFR and iwFR in this setting.302–304 Notwithstanding, the available
evidence is insufficient to support the use of invasive functional
assessment of coronary lesions in patients with AS, particularly in
consideration of the altered haemodynamic condition related to the
presence of AS. Therefore, the Task Force is in consensus that indica-
tions for myocardial revascularization based on angiographic assess-
ment of CAD should be maintained, consistent with the 2014 ESC/
EACTS Guidelines on myocardial revascularization and the 2017
ESC/EACTS Guidelines for the management of valvular heart
disease.305
11.2 Primary indication for myocardial
revascularization
11.2.1 Aortic valve disease
The recommendations for patients undergoing CABG for the clini-
cally leading problem of CAD, who also have coexisting severe aortic
stenosis or regurgitation, remain unchanged from those of the 2014
Guidelines and support replacement of the aortic valve.305 However,
in the current era of rapid developments in transcatheter valve
implantation technologies, a decision regarding replacement of the
aortic valve for moderate stenosis/regurgitation should be carefully
considered on a case-by-case basis in discussion with the Heart
Team. The patient’s age, type of prosthesis, pathogenesis of aortic
stenosis/regurgitation, aortic annular size, predicted size of implanted
valve, transcatheter aortic valve implantation (TAVI) access routes,
and technical feasibility of a TAVI procedure in the future in case of
disease progression should all be taken into account.306
11.2.2 Mitral valve disease
Patients with concomitant severe primary mitral regurgitation (MR)
should undergo mitral valve repair at the time of CABG in keeping
with guidance for the surgical repair of primary MR.305 There is also
consensus based on expert opinion on the surgical repair of severe
secondary MR at the time of CABG.305,307 However, considerable
controversy exists about the treatment of moderate secondary or
ischaemic MR in patients undergoing CABG. Until the publication of
2 year outcomes of the CTSN (Cardiothoracic Surgical Trials
Network) randomized trial on treatment of ‘moderate’ ischaemic
MR, the literature in this field was limited to small single-centre
randomized trials, observational studies, and case series, and failed to
provide clear direction. The CTSN trial showed that addition of sur-
gical mitral valve repair to CABG made no significant difference to
survival, overall reduction of adverse events, or LV reverse remodel-
ling at 2 years.308,309 Increased length of intensive care and hospital
stay and perioperative morbidity, including neurological complica-
tions and supraventricular arrhythmias, were reported in the CTSN
and other randomized trials in this group of patients.308–310 Because
the CTSN trial used a very broad definition of moderate MR, includ-
ing an effective regurgitant orifice area (EROA) <_0.2 cm2 plus addi-
tional criteria, no firm conclusions can be drawn concerning patients
with an EROA >0.2 cm2. Observational data suggest that in secon-
dary MR, an EROA >0.2 cm2 and regurgitant volume >30 mL indi-
cates greater risk of cardiovascular events.311,312 In the absence of
dedicated trials in this setting, the decision to combine mitral valve
surgery with CABG in patients with an EROA >0.2 cm2 and regurgi-
tant volume >30 mL needs to be made on a case-by-case basis by the
Heart Team. For a more detailed discussion of this issue, please refer
to the Supplementary Data.
11.3 Gaps in the evidence
In patients with concomitant valvular and coronary disease, the possi-
bility of future transcatheter therapy for the aortic and mitral valves
has made a significant impact on decision-making for patients with
predominantly coronary disease with moderate valve lesions.
However, there is currently little evidence on this topic. The need
Patients with severe CKD (National Kidney Foundation
stage 4)
Prophylactic haemofiltra-













Haemodialysis is not rec-
ommended as a preven-
tive measure.300,301
III B
CKD = chronic kidney disease; GFR = glomerular filtration rate; LVEF = left ven-
tricular ejection fraction; MSCT = multi-slice computed tomography; NYHA =
New York Heart Association; PCI = percutaneous coronary angiography.
aClass of recommendation.
bLevel of evidence.
cExample: 370 mL of contrast medium in a patient with a GFR of 100 mL/min will
yield a ratio of 3.7.
dOptions are: infusion of normal saline adjusted to central venous pressure295 or





























































































for and timing of PCI in patients undergoing TAVI is also an area with
limited evidence. The long-term outcomes of patients with concomi-
tant surgical repair of ischaemic MR are also awaited.
12 Associated peripheral artery
diseases
12.1 Prevention of stroke associated with
carotid artery disease and myocardial
revascularization
The early risk of stroke after myocardial revascularization is higher
after CABG than after PCI.313 After 30 days, stroke rates between
revascularization techniques were similar in a recent individual
patient data meta-analysis of 11 randomized trials.313
Ischaemic stroke after CABG is multifactorial: thrombo-embolism
from the aorta, its branches, or the heart; atrial arrhythmias; inflam-
matory pro-thrombogenic milieu; lower levels of antiplatelet therapy
perioperatively; and haemodynamic instability. However, the most
consistent predictor of perioperative stroke is previous stroke or
TIA. There is no strong evidence that carotid artery stenosis is a sig-
nificant cause of perioperative stroke except for bilateral severe car-
otid bifurcation stenosis.314 Therefore, indications for preoperative
carotid bifurcation screening by duplex ultrasound are limited.315
Also, there is no evidence that prophylactic revascularization of uni-
lateral asymptomatic carotid stenoses in CABG candidates reduces
the risk of perioperative stroke. It may be reasonable to restrict pro-
phylactic carotid revascularization to patients at highest risk of post-
operative stroke, i.e. patients with severe bilateral lesions or a history
of prior stroke/TIA.316 Hence, the indication for revascularization,
and the choice between carotid endarterectomy or carotid artery
stenting in these patients, should be made by a multidisciplinary team
including a neurologist.
The 2017 Guidelines on the diagnosis and treatment of peripheral
arterial diseases in collaboration with the European Society of
Vascular Surgery cover the screening for and management of carotid
artery disease in patients scheduled for CABG, including screening,
indications, and the timing and type of carotid revascularization.317 Its
recommendations are reproduced here.
Particularly for patients at high risk for perioperative stroke after
CABG, such as elderly patients or patients with previous TIA/stroke,
specific preventive measures have been suggested. CT scan screening
of the ascending aorta/arch atheroma has been proposed to better
assess risk stratification and guide the surgical strategy in elderly
patients.318 It is recommended that acetylsalicylic acid is restarted 6
h, or at the latest 24 h, after surgery, and that clopidogrel or ticagrelor
are added in patients with ACS. New-onset atrial fibrillation (AF) is
associated with a risk of stroke that increased two-to-three times
after CABG. Its management is discussed in section 14.
12.2 Associated coronary and peripheral
artery diseases
Of all patients with CAD, 7–16% have lower extremity artery disease
(LEAD), which is associated with a worse prognosis, even if it remains
frequently asymptomatic, masked by cardiac symptoms. On the
other hand, in patients with LEAD, CAD is present in up to 70% of
patients.317 The choice between CABG and PCI is controversial and,
in the absence of solid data, it should follow a multidisciplinary
Recommendations for combined valvular and coronary
interventions
Recommendations Classa Levelb
Primary valve intervention and coro-
nary revascularization
CABG is recommended in patients with a
primary indication for aortic/mitral valve
surgery and coronary artery diameter
stenosis >70%.
I C
CABG should be considered in patients
with a primary indication for aortic/mitral
valve surgery and coronary artery diameter
stenosis of 50–70%.
IIa C
PCI should be considered in patients with a
primary indication to undergo TAVI and
coronary artery diameter stenosis >70% in
proximal segments.
IIa C
PCI should be considered in patients with a
primary indication to undergo transcatheter
mitral valve interventions and coronary





SAVR is indicated in patients with
severe AS undergoing CABG, or
surgery of the ascending aorta or
another valve.
I C
Mitral valve surgery is indicated in patients
with severe secondary MR undergoing
CABG and LVEF >30%.
I C
Mitral valve surgery should be considered in
symptomatic patients with severe secondary
MR and LVEF <30%, but with evidence of
myocardial viability and an option for surgi-
cal revascularization.
IIa C
AS = aortic stenosis; CABG = coronary artery bypass grafting; LVEF = left ven-
tricular ejection fraction; MR = mitral regurgitation; PCI = percutaneous coronary


























































approach.127 In patients undergoing CABG, the saphenous vein
should be preserved or harvested guided by the results of clinical
examination including the ankle-brachial index. In addition, inter-arm
blood pressure asymmetry should lead to the investigation of subcla-
vian artery stenosis. Further details are provided in the 2017 periph-
eral arterial diseases Guidelines.317
13 Repeat revascularization
13.1 Early graft failure
Early graft failure after CABG is reported in up to 12% of grafts, as
evaluated by intraoperative angiography.323 However, only a minority
(around 3%) are clinically apparent. Graft failure can be due to con-
duit defects, anastomotic technical errors, poor native vessel run-off,
or competitive flow with the native vessel. When clinically relevant,
acute graft failure may result in MI with consequently increased mor-
tality and major cardiac events. The suspicion of early graft failure
should arise in the presence of ECG signs of ischaemia, ventricular
arrhythmias, biomarker changes, new wall motion abnormalities, or
haemodynamic instability.324,325 Owing to the low specificity of ECG
changes and echocardiographic wall motion abnormalities during the
post-operative course, and the delay in the appearance of biomarker
changes, a careful assessment of all variables will influence decision-
making for angiographic evaluation.
Perioperative angiography is recommended in cases of suspected
severe myocardial ischaemia to detect its cause and aid decision-
making on the most appropriate treatment.323,325,326 In symptomatic
patients, early post-operative graft failure can be identified as the
cause of ischaemia in 40 - 80% of cases.324,326–328 The optimal treat-
ment strategy in patients with acute graft failure should be decided by
ad hoc consultation between the cardiovascular surgeon and the
interventional cardiologist, on the basis of the patient’s clinical condi-
tion and the extent of myocardium at risk. In the case of early post-
operative graft failure, emergency ad hoc PCI may limit the extent of
infarction, if technically feasible. The target for PCI is the native vessel
or the internal mammary artery (IMA) graft, while the acutely
Recommendations on the management of carotid
stenosis in patients undergoing coronary artery bypass
grafting
Recommendations Classa Levelb
In patients scheduled for CABG, it is recom-
mended that the indication (and if so the
method and timing) for carotid revasculari-
zation be individualized after discussion
within a multidisciplinary team, including a
neurologist.
I C
In patients scheduled for CABG, with recent
(<6 months) history of TIA/stroke:
• Carotid revascularization should be con-
sidered in patients with 50 - 99% carotid
stenosis.319,320
• Carotid revascularization with CEA
should be considered as first choice in
patients with 50 - 99% carotid
stenosis.319,320
• Carotid revascularization is not recom-





In neurologically asymptomatic patients
scheduled for CABG:
• Carotid revascularization may be consid-
ered in patients with bilateral 70 - 99%
carotid stenosis or 70 - 99% carotid
stenosis and contralateral occlusion.
• Carotid revascularization may be consid-
ered in patients with a 70 - 99% carotid
stenosis, in the presence of one or more
characteristics that may be associated
with an increased risk of ipsilateral stro-
ke,c in order to reduce stroke risk
beyond the perioperative period.
• Routine prophylactic carotid revasculari-
zation in patients with a 70 - 99% carotid








cContralateral TIA/stroke, ipsilateral silent infarction on cerebral imaging, intraplaque
haemorrhage or lipid-rich necrotic core on magnetic resonance angiography, or any of
the following ultrasound imaging findings: stenosis progression (>20%), spontaneous
embolization on transcranial Doppler, impaired cerebral vascular reserve, large pla-
ques, echolucent plaques, or increased juxta-luminal hypoechogenic area.317
Preoperative strategies to reduce the incidence of
stroke in patients undergoing coronary artery bypass
grafting
Recommendations Classa Levelb
In patients undergoing CABG, carotid DUS
is recommended in patients with recent (<6
months) history of stroke/TIA.321,322
I B
In patients with no recent (<6 months) his-
tory of TIA/stroke, carotid DUS may be
considered before CABG in the following
cases: age >_70 years, multivessel coronary
artery disease, concomitant LEAD, or caro-
tid bruit.321,322
IIb B
Screening for carotid stenosis is not indi-
cated in patients requiring urgent CABG
with no recent stroke/TIA.
III C
CABG = coronary artery bypass grafting; DUS = duplex ultrasound; LEAD =


































































































occluded saphenous vein graft (SVG) and any anastomotic site should
be avoided, if possible, due to concerns regarding embolization or
perforation. Redo surgery should be favoured if the anatomy is
unsuitable for PCI, if several important grafts are occluded, or in the
case of clear anastomotic errors. In asymptomatic patients, repeat
revascularization should be considered if the artery is of an appropri-
ate size and supplies a large territory of myocardium.
Further details on the diagnosis and management of perioperative
MI are provided in a recent ESC position paper.329
13.2 Acute percutaneous coronary
intervention failure
The need for urgent surgery to manage PCI-related complications is
uncommon (<1%) and only required in patients with major complica-
tions that cannot be adequately resolved by percutaneous techni-
ques.330,331 The need for emergency CABG is mainly confined to
patients with a large, evolving MI due to iatrogenic vessel occlusion
that cannot be salvaged percutaneously, or in patients with recurrent
cardiac tamponade after pericardiocentesis following PCI-related
vessel rupture.330,332,333
13.3 Disease progression and late graft
failure
Ischaemia after CABG may be due to the progression of disease in
native vessels or de novo disease of bypass grafts.334 Repeat revascula-
rization in these patients is indicated in the presence of significant
symptoms despite medical treatment, and in asymptomatic patients
with objective evidence of large myocardial ischaemia (>10% of the
LV).32,87
13.3.1 Redo coronary artery bypass grafting or
percutaneous coronary intervention
PCI in patients with prior CABG has worse acute and long-term out-
comes than in patients without prior CABG.335,336 Likewise, redo
CABG has a two- to four-fold increased mortality compared with
first-time CABG, and repeat CABG is generally performed
infrequently.334,337–339 There are limited data comparing the efficacy
of PCI vs. redo CABG in patients with previous CABG. The propor-
tion of patients undergoing PCI, redo CABG, or conservative treat-
ment differs significantly between studies; in one study, PCI was
favoured in50% of patients with only 22% undergoing redo CABG,
while another study favoured CABG in 67% of patients.340,341 In the
AWESOME (Angina With Extremely Serious Operative Mortality
Evaluation) RCT and registry, overall 3 year mortality was compara-
ble between redo CABG and PCI.341,342 A more recent study also
found comparable rates of death and MI between redo CABG and
PCI, although there were significantly more repeat revascularizations
with PCI.341,343
In view of the higher risk of procedural mortality with redo CABG
and the similar long-term outcome, PCI is the preferred revasculari-
zation strategy in patients with amenable anatomy.340 PCI via the
bypassed native artery should be the preferred approach. If PCI in
the native vessel fails or is not an option, PCI in the diseased SVG
should be considered. CABG should be considered for patients with
extensively diseased or occluded bypass grafts and diffuse native ves-
sel disease, especially in the absence of patent arterial grafts.340
The IMA is the conduit of choice for revascularization during redo
CABG if not previously used, or can be salvaged and reused in spe-
cific cases.344,345
13.3.2 Percutaneous coronary intervention for saphenous
vein graft lesions
PCI in SVGs is associated with an increased risk of distal coronary
embolization, frequently resulting in periprocedural MI.346 PCI of de
novo SVG stenosis is considered a high-risk intervention because SVG
atheroma is friable and more prone to distal embolization. Several
different approaches have been evaluated to prevent the distal embo-
lization of particulate debris, including distal occlusion/aspiration,
proximal occlusion, suction, filter devices, or covered stents. Distal
protection devices using filters have shown the most encouraging
results. However, although a single randomized trial supports the use
of distal embolic protection during SVG PCI, observational studies
including data from large-scale registries are conflicting.347–349
Outcomes from studies with other devices used for SVG PCI are not
sufficient to recommend its use.350–353
Based on data from a small number of randomized trials, implanta-
tion of DES in SVG lesions is associated with a lower risk of repeat
revascularization than with BMS at 1 year follow-up.354–356 In the
only trial powered for a clinical endpoint—the ISAR-CABG (Is Drug-
Eluting-Stenting Associated with Improved Results in Coronary
Artery Bypass Grafts) trial354—the primary endpoint of death, MI,
and target lesion revascularization was significantly reduced with DES
vs. BMS. However, at 5 year follow-up, the advantage of DES over
BMS was lost due to a higher incidence of target lesion revasculariza-
tion between years 1 and 5 in patients treated with DES.357 Longer-
term follow-up of the two smaller trials is available; one suggested
sustained superiority of DES over BMS, while the other suggested
loss of the efficacy advantage of the DES.358,359
13.4 Repeat percutaneous coronary
intervention
Recurrence of symptoms or ischaemia after PCI is the result of reste-
nosis, incomplete initial revascularization, or disease progression.334
Patients may require repeat PCI due to late and very late stent
thrombosis.
13.4.1 Restenosis
Restenosis associated with angina or ischaemia should be treated by
repeat revascularization, and repeat PCI remains the strategy of
choice for most of these patients. In this setting, the results from DES
are superior to those obtained with balloon angioplasty, BMS implan-
tation, or brachytherapy.360–364
For restenosis within BMS, drug-coated balloon (DCB) proved
superior to plain balloon angioplasty365–367 and comparable to first-
generation DES.365,366,368–372 One trial showed inferior angiographic
outcomes in comparison to new-generation DES,373 while a second
trial showed comparable outcomes.374 For restenosis within DES,
DCBs also proved superior to plain balloon angioplasty367,369,371 and
comparable to first-generation DES.371 In one study, DCBs were infe-
rior to new-generation DES in terms of the primary angiographic out-
come measure.375 In a more recent study, including patients with any

















































.stenting with new-generation DES were comparable.376 A single
randomized trial of patients undergoing DCB for restenosis within
DES showed superior angiographic outcomes in patients who under-
went lesion preparation with scoring balloons vs. standard angio-
plasty balloons.377
Network meta-analysis suggests that repeat stenting with new-
generation DES (with EES) and DCB are ranked first and second as
the highest efficacy treatments.378,379 The superior angiographic anti-
restenotic efficacy of new-generation DES should be weighed against
a possible excess of long-term adverse events with repeat stenting
during longer-term follow-up of these trials.380,381 However, obser-
vations in relation to clinical events must be interpreted with caution,
as none of the trials was powered for clinical endpoints and the com-
parator stent in studies with long-term follow-up was an early-
generation DES.
The use of intracoronary imaging provides unique insights into the
underlying mechanisms of in-stent restenosis (see section 16.2).
OCT is able to detect the presence of neoatherosclerosis in a signifi-
cant number of these patients. Underexpanded stents should be
aggressively tackled with high-pressure dilatations using non-
compliant balloons. The optimization of the final results remains cru-
cial during reinterventions for in-stent restenosis and, in this regard,
the use of intracoronary imaging may be particularly helpful.
Outcomes of patients with in-stent restenosis after DES are poorer
than those in patients with BMS in-stent restenosis, independently of
the therapeutic modality.382 In patients with recurrent episodes of
diffuse in-stent restenosis in large vessels—and in those with
associated multivessel disease, especially in the presence of other
complex lesions such as chronic total occlusions—CABG should be
considered before a new PCI attempt.
13.4.2 Disease progression
Patients with symptomatic disease progression after PCI account for
up to 50% of reinterventions.383,384 They should be managed using
criteria similar to those applied to patients without previous
revascularization.
13.4.3 Stent thrombosis
Although stent thrombosis is very rare, particularly since the advent of
new-generation DES, it may have devastating clinical consequences.
Stent thrombosis usually presents as a large MI and patients should be
treated according to the principles outlined in section 8.385 Aggressive,
high-pressure balloon dilation should be used to correct underlying,
stent-related, predisposing mechanical problems.386,387 Liberal use of
intracoronary imaging in order to detect and modify underlying
mechanical factors is recommended (Figure 7) (see section 16.2).
Although repeat stenting in patients with stent thrombosis may be
avoided when satisfactory results are obtained with balloon dilation,
a new stent may be required to overcome edge-related dissections
and adjacent lesions, or to optimize final results.388
There is no evidence that the post-interventional management of
patients with stent thrombosis should differ from that of patients
with thrombosis of a de novo lesion resulting in STEMI.

























14.1.1 Revascularization for the prevention of sudden
cardiac death in patients with stable coronary artery
disease and reduced left ventricular function
Revascularization plays an important role in reducing the frequency
of ventricular arrhythmias in patients with normal or mildly reduced
LV function,389,390 as well as the risk of sudden cardiac death in
patients with CAD and LVEF <_35%.391 Indirect evidence for a pro-
tective effect of revascularization was demonstrated in the MADIT II
(Multicenter Automatic Defibrillator Implantation Trial II) and SCD-
HEFT studies (Sudden Cardiac Death in Heart Failure Trial), where
the efficacy of implantation cardioverter defibrillators (ICDs) was
reduced if revascularization was performed prior to implanta-
tion.392,393 CABG in patients with reduced EF reduces cardiac and
overall mortality for a follow-up of 10 years.78,81 In view of the pro-
tective effect of revascularization on ventricular arrhythmias, patients
Recommendations on repeat revascularization
Recommendations Classa Levelb
Early post-operative ischaemia and graft failure
Coronary angiography post-CABG is recommended for patients with:
• symptoms of ischaemia and/or abnormal biomarkers suggestive of perioperative MI
• ischaemic ECG changes indicating large area of risk
• new significant wall motion abnormalities
• haemodynamic instability.
I C
It is recommended that either emergency reoperation or PCI is decided upon by ad hoc consultation in the Heart
Team, based on the feasibility of revascularization, area at risk, comorbidities, and clinical status.
I C
Disease progression and late graft failure
Repeat revascularization is indicated in patients with a large area of ischaemia or severe symptoms despite medical
therapy.84,334
I B
If considered safe, PCI should be considered as first choice over CABG. IIa C
Procedural aspects of the revascularization modalities
CABG
IMA is the conduit of choice for redo CABG in patients in whom the IMA was not used previously.344 I B
Redo CABG should be considered for patients without a patent IMA graft to the LAD.340,341,344 IIa B
PCI
Distal protection devices should be considered for PCI of SVG lesions.348,350,351 IIa B
PCI of the bypassed native artery should be considered over PCI of the bypass graft. IIa C
Restenosis
DES are recommended for the treatment of in-stent restenosis of BMS or DES.373,375,378,379 I A
Drug-coated balloons are recommended for the treatment of in-stent restenosis of BMS or DES.373,375,378,379 I A
In patients with recurrent episodes of diffuse in-stent restenosis, CABG should be considered by the Heart Team over
a new PCI attempt.
IIa C
IVUS and/or OCT should be considered to detect stent-related mechanical problems leading to restenosis. IIa C
BMS = bare-metal stent; CABG = coronary artery bypass grafting; DES = drug-eluting stent; ECG = electrocardiogram; IMA = internal mammary artery; IVUS = intravascular

























































































..with ischaemic LV dysfunction (LVEF <_35%) who are considered for
primary preventive ICD implantation should be evaluated for ischae-
mia and/or for potential revascularization targets.
14.1.2 Revascularization for the treatment of electrical
storm
Electrical storm is a life-threatening syndrome related to incessant
ventricular arrhythmias, which is most frequently observed in
patients with ischaemic heart disease, advanced systolic HF, valve dis-
ease, corrected congenital heart disease, and genetic disorders such
as Brugada syndrome, early repolarization, and long QT syn-
drome.394 Urgent coronary angiography and revascularization should
be part of the management of patients with electrical storm, as well
as antiarrhythmic drug therapy and/or ablation of ventricular
tachycardia.
14.1.3 Revascularization after out-of-hospital cardiac
arrest
Approximately 70% of survivors of out-of-hospital cardiac arrest
have CAD, with acute vessel occlusion observed in 50%.395 Multiple
non-randomized studies suggest that emergency coronary angiogra-
phy and, if appropriate, PCI after out-of-hospital cardiac arrest yield a
favourable survival rate of <_60% at 1 year, which is considerably
higher than the 25% overall survival rate in patients with aborted car-
diac arrest.396,397 More recent data suggest that almost one-quarter
of patients, resuscitated from cardiac arrest but without ST-segment
elevation, show a culprit lesion (either vessel occlusion or irregular
lesion).398–401 Recent large-scale observational studies have shown
an impact on mortality of early angiography after out-of-hospital car-
diac arrest.402,403 Thus, in survivors of out-of-hospital cardiac arrest,
early coronary angiography and PCI, if appropriate, should be per-
formed irrespective of the ECG pattern if no obvious non-cardiac
cause of the arrhythmia is present.404
14.2 Atrial arrhythmias
The management of AF in patients with ischaemic heart disease is
addressed by the 2016 ESC Guidelines for the management of AF
developed in collaboration with EACTS.405 After reviewing the sub-
sequent literature, the current Task Force endorses the recommen-
dations of the 2016 Guidelines and has not identified a need for any
major update. Accordingly, the recommendation tables are taken
from the 2016 Guidelines. For a detailed discussion, we refer to the
previous Guidelines.405
14.2.1 Atrial fibrillation complicating percutaneous
coronary intervention
New-onset AF in patients undergoing PCI occurs in 2–6% of proce-
dures and increases with age, pre-existing HF, AMI, and arterial
hypertension.406–409 Notably, new-onset AF [defined as change from
sinus rhythm (SR) at admission to AF during/after PCI] typically
occurs during the first 4 days after AMI, and is associated with
impaired prognosis and a more than doubling of the risk of death,
congestive HF, and stroke.403
The use of oral anticoagulation (OAC) for stroke prevention in
patients with AF occurring during or after PCI should follow the ESC
Guidelines on Atrial Fibrillation for antithrombotic treatment of AF
that occurs outside the setting of PCI,405 although prospective stud-
ies are scarce. The combination and duration of anticoagulation and
antiplatelet therapy should be assessed according to the clinical situa-
tion, as outlined in section 17 as well as in the ESC Guidelines on
Atrial Fibrillation405 and the ESC Focused Update on Dual
Antiplatelet Therapy.410
14.2.2 Atrial fibrillation complicating coronary artery
bypass grafting
Post-operative AF affects one-third of patients undergoing cardiac
surgery.411–414 The main risk factor for post-operative AF is age, and
it is associated with an increased immediate risk of stroke, increased
morbidity, and 30 day mortality.415–417 In the long-term, patients
with an episode of post-operative AF have a two-fold increase in car-
diovascular mortality, and a substantially increased risk of future AF
and ischaemic stroke compared with patients who remain in SR after
surgery.416,418–422
Post-operative AF is a common complication, in which prophylac-
tic treatment has a moderate effect. Pre-operative anti-arrhythmic
drug treatment may be initiated but will have to be weighed against
side effects. Beta-blockers decrease the incidence of post-operative
AF after CABG.412,423–429
14.2.3 Post-operative atrial fibrillation and stroke risk
Patients with post-operative AF have an increased stroke risk post-
operatively as well as during follow-up,419,430 and warfarin medication
at discharge has been associated with a reduced long-term mortal-
ity.431 To date, there are no studies indicating that post-operative AF
is less harmful than any other form of AF, and good quality data are
needed. Anticoagulation treatment with warfarin or non-vitamin K
antagonist oral anticoagulants (NOACs) for stroke prevention in
patients with post-operative AF should therefore follow the guide-
lines for the antithrombotic treatment of AF occurring outside the
setting of CABG using the CHA2DS2-VASc [Cardiac failure,
Hypertension, Age >_75 (Doubled), Diabetes, Stroke (Doubled) –
Vascular disease, Age 65–74 and Sex category (Female)] score. The
duration and timing of OAC in post-operative AF patients should be
assessed individually.
Whether or not surgical left atrial appendage (LAA) obliteration
reduces stroke risk has been studied in smaller trials and registry
studies with conflicting results,432–434 and is currently under investi-
gation in a large randomized trial.435 Removal or closure of the LAA
should be considered as an adjunct to anticoagulation and not as an



























..14.3 Gaps in the evidence
The duration of anticoagulation and their combination with antiplate-
let therapy in patients with new-onset AF after PCI or CABG has not
been studied sufficiently. Likewise, the role of routine left atrial exclu-
sion at surgery for the prevention of stroke is currently unclear.
15 Procedural aspects of coronary
artery bypass grafting
CABG remains the most common cardiac surgical procedure, and
the techniques have been refined during 50 years of evolution.443
Perioperative medication and blood management are covered in sep-
arate Guidelines.410,444
15.1 Surgical techniques
15.1.1 Completeness of revascularization
Current surgical practice is largely based on an anatomical definition
of complete revascularization, and aims to bypass all epicardial vessels
with a diameter exceeding >_1.5 mm and a luminal reduction of >_50%
in at least one angiographic view.131 Depending on the definition of
completeness of revascularization, the outcome after CABG in
patients with incomplete revascularization was either similar445–449
or inferior131,132,449–451 to that of patients with complete
Recommendations for the prevention and treatment of atrial fibrillation in the setting of myocardial revascularization
Recommendations Classa Levelb
Perioperative oral beta-blocker therapy is recommended for the prevention of post-operative AF after CABG surgery.412,438 I B
Restoration of sinus rhythm by electrical cardioversion or antiarrhythmic drugs is recommended in post-operative AF with hae-
modynamic instability.
I C
Perioperative amiodarone should be considered as prophylactic therapy to prevent AF after CABG surgery.412,439 IIa A
Long-term anticoagulation should be considered in patients with AF after CABG or PCI who are at risk of stroke, considering
the individual stroke and bleeding risk.440,441
IIa B
Rate control and anticoagulation should be considered as the initial management of asymptomatic post-operative AF.442 IIa B
Antiarrhythmic drugs should be considered for symptomatic post-operative AF after CABG or PCI in an attempt to restore
sinus rhythm.
IIa C
Surgical occlusion or exclusion of the LAA may be considered for stroke prevention in patients with AF undergoing CABG
surgery.432–434
IIb B
AF = atrial fibrillation; CABG = coronary artery bypass grafting; LAA = left atrial appendage; PCI = percutaneous coronary intervention.
aClass of recommendation.
bLevel of evidence.
Recommendations for the prevention of ventricular arrhythmias by revascularization
Recommendations Classa Levelb
A primary PCI strategy is recommended in patients with resuscitated cardiac arrest and an ECG consistent with
STEMI.395,397,436,437
I B
Urgent angiography (and PCI if indicated) should be considered in patients with resuscitated cardiac arrest without diagnostic
ST-segment elevation but with a high suspicion of ongoing myocardial ischaemia.
IIa C
In patients with electrical storm, urgent coronary angiography and revascularization (as required) should be considered. IIa C



















































































..revascularization. Certainly, in some patients with a stenosis in small
vessels with little myocardium at risk, complete revascularization may
not be necessary.
FFR-guided surgical revascularization has been associated with
improved graft patency, but more studies are needed to investigate
whether it improves clinical outcomes.28,452 Further discussion of
FFR-guided revascularization is provided in sections 3.2.1.1 and
5.3.1.3.
15.1.2 Conduit selection
In addition to patient-related factors, the outcome following CABG
is related to the long-term patency of grafts and therefore is maxi-
mized with the use of arterial grafts, specifically the IMA.453,454
Except in rare circumstances, all patients should receive at least one
arterial graft—the left IMA (LIMA)— preferentially to the LAD.453,455
SVG patency rates for non-LAD targets have been reported to be
suboptimal.456 Bilateral IMA (BIMA) and radial artery for non-LAD
targets have been shown to provide better patency rates than SVG,
particularly for the left coronary artery system.457 Therefore, a sec-
ond arterial graft should be considered depending on the patient’s life
expectancy, risk factors for sternal wound complications, coronary
anatomy, degree of target vessel stenosis, graft quality, and surgical
expertise.
Whether or not the use of additional arterial grafts can translate
into prolonged survival remains debatable. Data from non-
randomized studies suggest that the use of BIMA over single IMA
(SIMA) use is associated with improved long-term survival, as well as
fewer non-fatal events such as MI, recurrent angina, and the need for
re-operation.458–465 However, observational studies are subject to
selection bias, despite propensity matching, and the effect of pro-
longed survival with additional arterial grafts has not been confirmed
in randomized trials.466
The ART trial (Arterial Revascularization Trial) has been designed
to answer the question of whether BIMA can improve 10 year sur-
vival when compared with SIMA. Interim analysis showed no differ-
ence at 5 years in the rate of death or the composite of death, MI, or
stroke, and 10 year results are warranted to draw final conclu-
sions.467 Limitations of the ART trial include a high crossover rate
from the BIMA arm to the SIMA arm and a high rate of radial artery
use in the SIMA arm that may have diluted the benefit of
BIMA.468–470 The use of BIMA grafting is associated with an increase
in sternal dehiscence, and an increased rate of mediastinitis in obese
patients and patients with diabetes.458,464,471–475 In the ART trial, the
use of BIMA was associated with a 1.0 - 1.5% absolute risk increase in
the need for sternal would reconstruction, and a subsequent subanal-
ysis has found that this risk is minimized with skeletonized harvest-
ing.476 While we await the 10 year data of the ART trial, BIMA
grafting should be considered in patients with a reasonable life
expectancy and a low risk of sternal wound complications.
The radial artery constitutes an alternative as the second arterial
graft in patients in whom BIMA grafting is not feasible, patients with a
high risk of sternal wound complications, or as a third arterial graft.
There is a strong, adverse influence on radial artery patency when
the native coronary artery stenosis is <70%, and therefore its use
should be limited to coronary artery stenosis >70% and ideally
>90%.477 Use of the radial artery as the second conduit of choice has
been linked to improved survival in registry studies.478–480 Available
RCTs testing the radial artery vs. saphenous vein graft used angio-
graphic patency as the primary endpoint, and none was powered to
detect differences in clinical outcomes.481 A recently published
patient-level meta-analysis pooling six RCTs comparing radial artery
vs. saphenous vein graft showed that the use of the radial artery was
associated with a lower rate of the primary endpoint (composite of
death, myocardial infarction, and repeat revascularization) at mean
follow-up of 50 months, mainly driven by a significantly strong reduc-
tion of need for reintervention and a more modest reduction in sub-
sequent MI.482 Despite a significantly lower risk of occlusion at
follow-up angiography, no difference in all-cause mortality was found.
15.1.3 Mammary artery harvesting
While the skeletonized technique of harvesting the IMA has a higher
theoretical potential for injury, the potential benefits include a longer
conduit, more versatility (sequential anastomosis), higher blood flow,
and fewer wound-healing problems.471,483–488 Therefore, in patients
at higher risk of sternal wound complications, skeletonization is
recommended.
15.1.4 Radial artery harvesting
Radial artery harvesting is associated with negligible morbidity if pre-
ceded by assessment of the hand’s collateral circulation. Endoscopic
radial harvesting is possible, but robust evidence concerning its safety
and efficacy is scarce.489,490 Use of the radial artery after recent coro-
nary angiography with radial access should be discouraged due to
potential endothelial damage.491 Harvesting of the whole radial artery
pedicle, together with the intraluminal and subadventitial injection of
vasodilators, are useful steps to prevent spasm.
15.1.5 Saphenous vein harvesting
Saphenous vein harvesting can be accomplished using open and mini-
mally invasive techniques, which include interrupted incisions and
partial or full endoscopic procedures. Endoscopic vein graft harvest-
ing leads to a reduced rate of leg wound complications,492–495 but
the short- and long-term patency of endoscopically harvested vein
grafts, compared with openly harvested grafts, has been
















































































..concerning patency rates, most data from meta-analyses and
randomized and non-randomized trials do not demonstrate inferior
clinical outcomes with endoscopic vein harvest.492,493,499,500 If an
endoscopic vein graft harvest is performed, it should be undertaken
by experienced surgeons or physician assistants with appropriate
training and reasonable caseloads.501–503 If an open technique is used,
the ‘no-touch’ technique has shown superior patency rates in multi-
ple randomized trials,504–507 with a patency rate >80% after 16
years.507
15.1.6 Cross-Clamping
A single cross-clamp technique may be preferred to multiple manipu-
lations of the aorta, with the aim of reducing atheroembolic events,
but a strict no-touch technique most effectively reduces embolization
of atherosclerotic material.508–510 In cases of off-pump surgery, devi-
ces that allow a clampless procedure may help reduce the incidence
of cerebral vascular complications.511,512
15.1.7 Intraoperative quality control
Besides continuous ECG monitoring and transoesophageal echocar-
diography immediately after revascularization, intraoperative quality
control may also include graft flow measurement to confirm or
exclude a technical graft problem.513 Transit-time flow measurement
is the most frequently used technique for graft assessment and has
been able to detect 2 - 4% of grafts that require revision.513,514
In observational studies, the use of intraoperative graft assessment
has been shown to reduce the rate of adverse events and graft failure,
although interpretation can be challenging in sequential and T-graft
configurations.513,515–517
15.1.8 On-pump and off-pump procedures
Two large, international randomized trials have shown no difference
in 30 day or 1 year clinical outcomes between on- and off-pump sur-
gery when performed by experienced surgeons.518–520 There is also
evidence to conclude that, for most patients and surgeons, on-pump
surgery provides excellent short- and long-term outcomes.518,520–523
For some surgeons, off-pump surgery is associated with inferior early
and late graft patency rates, and possibly compromised long-term
survival; however, aortic no-touch/clampless off-pump procedures in
the hands of highly trained teams appear to be associated with a
reduced risk of early morbidity, such as stroke, and fewer trans-
fusions.508–510,524–528 In the subgroup of patients with end-stage
CKD, there is some evidence that off-pump surgery is associated
with lower in-hospital mortality and less need for new renal replace-
ment therapy.529
A summary of these technical aspects can be found in Figure 8.
15.1.9 Minimally invasive and hybrid procedures
Minimally invasive coronary surgery with LIMA, harvested either
directly or under video-assisted vision, may represent an attractive
alternative to a sternotomy.530 It has a similar safety and efficacy pro-
file to conventional on-pump and off-pump procedures, with a mark-
edly reduced post-operative length of stay and an early quality of life
benefit, although spreading of the ribs is associated with increased
post-operative pain.531–533 It has been shown to be safe and effective
in the treatment of proximal LAD stenosis or chronically occluded
LAD arteries.144 Moreover, when compared with PCI in a setting of
single-vessel proximal LAD disease, minimally invasive coronary sur-
gery was associated with less need for coronary reinterven-
tion.143,534,535 When combined with PCI to non-LAD vessels, it
provides the opportunity for hybrid coronary revascularization to be
performed in selected patients with multivessel disease.536
Hybrid revascularization can be performed consecutively in a
hybrid operating room, or sequentially on separate occasions in the
conventional surgical and PCI environments.537–540 In a small
randomized trial of 200 patients, 1 year and 5 year rates of death, MI,
stroke, and major bleeding or repeat revascularization were not sig-
nificantly different between hybrid revascularization and
CABG.536,541 Heart Team discussion and the prospective planning of
a joint strategy are critical for the success of a hybrid revascularization
strategy.542
15.2 Reporting perioperative outcomes
Perioperative reporting of outcomes after CABG procedures should
be done on a risk-adjusted basis. The early risk period after CABG
extends up to 3 months, is multifactorial, and depends on the inter-
face between technical variability and patient comorbidity.543
15.3 Gaps in the evidence
The role of FFR and iwFR in guiding surgical revascularization needs
further investigation into whether it improves clinical outcomes.
Likewise, there are insufficient data on the impact of intraoperative
assessment of graft flow on outcomes.
In view of the limitations of observational studies comparing BIMA
with SIMA and the limitations of the ART trial, the ROMA
(Randomization of Single vs. Multiple Arterial Grafts) trial is recruiting
to answer the question of whether the use of additional arterial con-
duits (either BIMA or radial artery) translates into superior clinical
outcomes when compared with SIMA supplemented by SVG only.
Hybrid procedures, which combine minimally invasive arterial
grafting with PCI, proved feasible and safe. However, multicentre
studies are required to prove the efficacy and superiority of this
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Recommendations on procedural aspects of coronary artery bypass grafting
Recommendations Classa Levelb
General considerations
Complete myocardial revascularization is recommended.c 131,132 I B
Minimization of aortic manipulation is recommended.508,509,544,545 I B
Routine intraoperative graft flow measurement should be considered.516,517 IIa B
CT scans of the ascending aorta should be considered in patients over 70 years of age and/or with signs of extensive
generalized atherosclerosis.
IIa C




Arterial grafting with IMA to the LAD system is recommended.453,454,546 I B
An additional arterial graft should be considered in appropriate patients.467,482,547–551 IIa B
The use of the radial artery is recommended over the saphenous vein in patients with high-grade coronary artery
stenosis.d 482,549,550,552,553
I B
BIMA grafting should be considered in patients who do not have a high risk of sternal wound infection.e 467,547,548,551 IIa B
Vessel harvesting
Skeletonized IMA dissection is recommended in patients with a high risk of sternal wound infection.471,484,485 I B
Endoscopic vein harvesting, if performed by experienced surgeons, should be considered to reduce the incidence of
wound complications.490,493,494,500,554
IIa A
No-touch vein harvesting should be considered when an open technique is used.506,507,555,556 IIa B
Minimally invasive techniques
Off-pump CABG and preferably no-touch techniques on the ascending aorta, by experienced operators, are recom-
mended in patients with significant atherosclerotic aortic disease.508,509,544,557–559
I B
Off-pump CABG should be considered for subgroups of high-risk patients by experienced off-pump teams.525,557–560 IIa B
Where expertise exists, minimally invasive CABG through limited thoracic access should be considered in patients with
isolated LAD lesions or in the context of hybrid revascularization.143,534,535,561
IIa B
Hybrid procedures, defined as consecutive or combined surgical and percutaneous revascularization, may be consid-
ered in specific patient subsets at experienced centres.536,561–563
IIb B




cDefinitions of complete revascularization are provided in section 5.3.1.3.
dParticularly in patients with poor vein grafts. The radial artery should not be used if previously catheterized, if the Allen test is positive or if calcific degeneration is present.




























16 Procedural aspects of
percutaneous coronary
intervention
16.1 Percutaneous coronary intervention
devices
16.1.1 Balloon angioplasty
Plain balloon angioplasty has been superseded in the treatment of de
novo coronary lesions after demonstration of the superiority of stent-
ing in terms of the requirement for repeat revascularization.564
Balloon angioplasty might be considered for the treatment of
selected patients in whom implantation of stents is not technically
feasible, or in a vessel that is considered to be too small to be stented.
Balloon angioplasty is no longer preferred to stenting with DES for
patients who require urgent non-cardiac surgery as short-duration
DAPT may be reasonable with both strategies.565,566
16.1.2 Choice of coronary stents
Stenting with BMS results in an approximately 30% lower rate of resteno-
sis in comparison with plain balloon angioplasty.564 Although many efforts
have been made to further reduce restenosis by the modification of stent
designs and materials, reducing the thickness of stent struts has been the
only proven modification capable of reducing restenosis of BMS.567,568
LIMA to LAD IB
BIMA if low risk of sternal 
complications IIaB
Skeletonize if risk of 
sternal complications IB
Complete revascularization IB
Graft flow measurement IIaB
Minimize aortic manipulation IB
Off-pump if calcified aorta IB




Endoscopic vein harvesting IIaA























Figure 8 Technical aspects of CABG. BIMA = bilateral internal mammary artery; CABG = coronary artery bypass grafting; IMA = internal mam-
































































































A major reduction in the risk of restenosis has been achieved with
DES technology. Early-generation DES released sirolimus569 or pacli-
taxel570 from a permanent polymer matrix coating on a relatively
thick-strut (120–140 mm) stainless steel backbone. These devices
reduced angiographic and clinical restenosis by approximately
50–70%, but increased the risk of very late stent thrombosis com-
pared with BMS.336,571
Early-generation DES have now been supplanted by new-generation
DES. These stents represented an iterative development of early gener-
ation technology, including polymers with enhanced biocompatibility
(permanent or biodegradable), exclusively sirolimus-analogue active
drugs, and stent backbones with thin struts (50–100 mm) composed of
stainless steel, cobalt chromium, or platinum chromium.572–577 New-
generation DES have higher efficacy and safety in comparison with both
early-generation DES and BMS.336,571,578 Although stenting with new-
generation DES confers a similar risk of death or MI at mid- to long-
term follow-up in comparison with BMS,579 the risk of subacute and late
stent thrombosis is significantly lower.579,580 Moreover, the risk of very
late stent thrombosis is at least comparable to that of BMS and lower
than that of early-generation DES.336,571,579,580 These observations
were confirmed in a recent trial enrolling patients aged 75 years or older
and demonstrating superior outcomes (composite of all-cause mortal-
ity, MI, stroke, or ischaemia-driven target lesion revascularization) with
DES as compared with BMS with similar duration of intended DAPT (1
month or 6 months) in both treatment arms.581 Similarly, there is no
clear evidence of a difference between DES and BMS on the risk of stent
thrombosis following unplanned disruption of DAPT.565 Accordingly,
new-generation DES should be preferred to BMS for routine use.
A large number of new-generation DES have received approval
for use and CE mark in Europe.578 Supplementary Table 6 displays a
list of new-generation DES with the CE mark and evidence from
large-scale clinical trials powered for clinical primary endpoints.
Biodegradable polymer and polymer-free DES offer the potential to
reduce late adverse events after PCI by eliminating inflammatory reac-
tions to permanent polymer coatings. A number of large-scale trials
showed comparable efficacy and safety compared with permanent poly-
mer stents.575,576,582–590 However, at the moment, there is no evidence
of differential efficacy with new-generation biodegradable polymer DES
in comparison with new-generation permanent polymer DES in large-
scale randomized trials with follow-up out to 5 years.591–594
Regarding polymer-free DES, two large-scale trials with different
devices showed comparable results with new-generation DES and
superior results to BMS.173,577 Long-term follow-up from randomized
trials vs. new-generation permanent polymer DES is only available for a
single device and shows comparable outcomes between the devices.591
The high clinical efficacy and safety of new-generation DES support
their preferred use in patients with an indication for PCI, including
patients with diabetes, CKD, multivessel and LMS disease, AMI, vein
grafts, restenotic lesions, and chronic total occlusions. New-
generation DES should therefore be considered as the default stent
type for PCI regardless of clinical presentation, lesion subtype, con-
comitant therapies, or comorbidities.
16.1.3 Bioresorbable scaffolds
Completely bioresorbable scaffolds (BRS), which degrade to predomi-
nantly inert end products after fulfilling their scaffold function in the
lesion site of the coronary vessel, have been developed with the goal
of reducing or eliminating stent-related adverse events at long-term
follow-up. Current scaffold platforms to have reached clinical testing
are based on two different technologies: bioresorbable, polymer-
based scaffolds (resorption up to 3–4 years) and resorbable, metallic
(magnesium) scaffolds (resorption up to 1 year).595 Although a num-
ber of devices have received approval for use in Europe (see
Supplementary Table 7), randomized trial data are available only with
the Absorb bioresorbable vascular scaffold (BVS) (Abbott Vascular).
The safety and efficacy profile of the Absorb BVS has been com-
pared with contemporary DES in several trials. Findings of these trials
as well as meta-analyses consistently indicate the inferior efficacy and
safety of Absorb BVS compared with contemporary DES during
long-term follow-up. Specifically, the Absorb BVS is associated with a
significantly increased risk of target lesion revascularization and
device thrombosis, with numbers needed to harm of 40–60.596,597
Of note, commercial use of the Absorb BVS was stopped in 2017
(for additional details see the Supplementary Data).
Available evidence on the magnesium scaffold is limited to small
observational studies. Initial results appear encouraging, but further
evaluation is needed. Therefore, the Task Force endorses the recom-
mendation of the recent ESC/European Association for Percutaneous
Cardiovascular Interventions (EAPCI) document on bioresorbable
scaffolds that any BRS should not be used outside well-controlled clin-
ical studies. In patients who have been treated with BRS, prolonged-
duration DAPT for 3 years or longer may be considered.
16.1.4 Drug-coated balloons
The rationale for using DCBs is based on the concept that with highly
lipophilic drugs, even short contact times between the balloon surface
and the vessel wall are sufficient for effective drug delivery. There are
various types of DCB that are approved for use in Europe and their
main characteristics are listed in Supplementary Table 8. Although spe-
cifically designed comparative randomized trials are lacking, a class effect
for all DCBs cannot be assumed.598 Randomized trial data supporting
the use of DCB angioplasty are limited to the treatment of in-stent
restenosis (see section 13.4). In terms of the use of DCB angioplasty for
de novo disease, a number of small randomized trials have been reported
with somewhat conflicting results.599–601 At present, there are no con-
vincing data to support the use of DCB angioplasty for this indication.
16.1.5 Devices for lesion preparation
Lesion preparation is critical for successful PCI. In addition to plain
balloon angioplasty (with standard or non-compliant balloons), cut-
ting or scoring balloon angioplasty or rotational atherectomy may be
required in selected lesions—particularly those with heavy
calcification—in order to adequately dilate lesions prior to stent
implantation. However, studies investigating the systematic use of
these adjunctive technologies, such as rotational atherectomy, have
failed to show clear clinical benefit.602
16.2 Invasive imaging tools for
procedural guidance
16.2.1 Intravascular ultrasound
The majority of the existing clinical trial data relate to the use of IVUS
guidance during PCI. In the BMS era, several RCTs addressed the
































































































stenting, with somewhat conflicting results. Findings from one meta-
analysis of randomized trials suggested better outcomes with IVUS
guidance in terms of acute procedural results and reduced angiographic
restenosis, repeat revascularization, and MACE, with no effect on
death and MI.603,604 In the DES era, meta-analysis of randomized and
observational studies also suggests better clinical outcomes with IVUS-
guided vs. angiography-guided PCI.605,606 However, the contribution of
findings from observational studies must be weighed against the likeli-
hood of considerable residual confounding due to treatment selection
bias. Similarly, findings of improved outcome in patients undergoing LM
stem PCI with IVUS-guided PCI vs. angiography-guided PCI from a pro-
pensity score matched analysis must be interpreted with caution.35
In cases of stent failure, including restenosis and stent thrombosis,
the use of IVUS should be considered in order to identify and correct
underlying mechanical factors (see section 13).386
16.2.2 Optical coherence tomography
A number of studies have assessed OCT imaging for PCI guidance. Two
observational studies show that while OCT imaging changes operator
behaviour, its impact on clinical outcomes is unclear.607,608 Indeed, OCT
is more accurate than angiography or IVUS in detecting subtle morpho-
logical details including malapposition, residual thrombus, plaque prolapse,
and residual dissections, although many of these additional findings may
have a benign course.609,610 A single randomized trial compared OCT
with IVUS and coronary angiography, and showed that OCT-guided PCI
was safe and resulted in a similar minimum stent area to that of IVUS-
guided PCI.611 However, OCT guidance was not superior to either IVUS
or angiography alone. An additional randomized trial that enrolled
patients with NSTE-ACS compared OCT-guided PCI with angiography-
guided PCI and found no signal of impact on clinical outcomes.612
A number of observational studies have shown that OCT is feasi-
ble and safe in the assessment of stent failure due to thrombosis, and
may yield information that may be clinically useful.386,387,613,614
Likewise, in cases of in-stent restenosis, intrastent neointimal tissue
may be characterized by OCT, enabling for example the detection of
neoatherosclerosis.386,615,616 In cases of stent failure, the use of OCT
should be considered in order to identify and correct underlying
mechanical factors (see section 13).
16.3 Specific lesion subsets
16.3.1 Bifurcation stenosis
A number of RCTs have investigated the optimal intervention strategy in
patients with bifurcation lesions and showed no benefit for the systematic
two-stent approach vs. main branch-only stenting with provisional stent-
ing of the side branch in terms of clinical outcomes.617 A recent pooled
analysis of two RCTs showed lower 5 year survival in patients random-
ized to a systematic two-stent approach.618 In addition, procedure time,
contrast volume, radiation exposure, and cost are higher with a two-
stent approach.618 The EBC TWO (European Bifurcation Coronary
TWO) trial found no difference between a provisional T-stent strategy
and a systematic two-stent strategy (culotte technique) in terms of the
composite endpoint of death, MI, and TVR at 12 months among 200
patients with large-calibre true bifurcation lesions (side branch diameter
>_2.5 mm) and significant ostial disease length (>_5 mm).619 Thus, main
branch-only stenting with provisional stenting of the side branch should
be the preferred approach for most bifurcation lesions. Exceptions to
this rule, where upfront side branch stenting may be preferable, include
the presence of a large side branch (>_2.75 mm) with a long ostial side
branch lesion (>5 mm) or anticipated difficulty in accessing an important
side branch after main branch stenting, and true distal LM bifurcations.
Recently, a multicentre trial conducted in China directly compared a
double-kissing crush two-stent strategy with provisional stenting of the
main branch in 482 patients with distal LM bifurcation disease. Double-
kissing crush resulted in a lower risk of the primary endpoint target lesion
failure at 1 year compared with provisional stenting.620
When a two-stent strategy is necessary, which two-stent technique
should be preferred is debated. The three most widely used contem-
porary two-stent techniques are culotte, crush (classic or double-
kissing crush), and T and protrusion (TAP).621,622 Several RCTs have
compared these techniques. In non-LM bifurcation lesions, there is no
compelling evidence that one technique is superior to the others in
terms of major clinical endpoints.621,622 In LM true bifurcation lesions,
double-kissing crush has the most favourable outcome data.623
Final ‘kissing’ balloon dilation is generally recommended when two
stents are eventually required, with no advantage from final kissing
with the one-stent technique.624,625 Several stents, designed specifi-
cally for the treatment of bifurcation lesions, have undergone exten-
sive evaluation with promising angiographic and clinical results,
though RCTs against current recommended therapy are limited.626
Further technical details relating to bifurcation PCI are described in
the consensus document of the European Bifurcation Club.627
16.3.2 Chronic total coronary occlusion
Dedicated RCTs examining the outcomes of patients with chronic
total occlusion (CTO) allocated to revascularization or conservative
therapy are scarce. One trial randomized patients with STEMI and
CTO in a non-culprit vessel to CTO-PCI vs. conservative therapy, and
found no difference in the primary endpoint of LVEF and LV end-
diastolic volume at 4 months.628 More recently, the prospective
randomized EUROCTO (Randomized Multicentre Trial to Compare
Revascularization With Optimal Medical Therapy for the Treatment
of Chronic Total Occlusions) trial showed symptomatic improvement
by PCI of CTO.629 This trial included 396 patients who were ran-
domly assigned to PCI of CTO with optimal medical therapy, or opti-
mal medical therapy alone. During the 12 month follow-up, the
primary endpoint-the change in health status assessed by the Seattle
angina questionnaire-showed significantly greater improvement of
angina frequency and quality of life with CTO PCI as compared with
optimal medical therapy alone. Yet, MACE were comparable between
the two groups. A systematic review of 25 observational studies
showed that at median follow-up of 3 years, successful CTO-PCI was
associated with improved clinical outcomes in comparison with failed
revascularization, including overall survival, angina burden, and the
requirement for bypass surgery.630 Broadly speaking, the treatment of
CTOs may be considered analogous to the treatment of non-CTO
lesions (see recommendations in section 5). In cases of regional wall
motion abnormalities in the territory of the CTO, objective evidence
of viability should be sought. The decision to attempt CTO-PCI
should be considered against the risk of greater contrast volume, lon-
ger fluoroscopy time, and higher MACE rates in comparison with
non-CTO PCI patients.631 Ad hoc PCI is generally not recommended
for CTOs, although it may be necessary in selected cases (e.g. acute




































..Recent developments in catheter and wire technology, and
increasing operator expertise with both antegrade and retrograde
approaches as well as wire escalation and dissection/re-entry techni-
ques, have translated into increasing success rates of CTO-PCI with
low rates of MACE.631–633 Success rates are strongly dependent on
operator skills, depending on experience with specific procedural
techniques, and the availability of dedicated equipment, and vary
from 60–70% to >90%.631–633
16.3.3 Ostial lesions
In ostial coronary lesions, additional judgement and caution is essen-
tial before proceeding to PCI. In particular, a catheter-induced coro-
nary spasm must be rigorously excluded. Lesion assessment with
IVUS may be helpful, particularly in LM ostial stenosis. FFR measure-
ment may also be valuable in the assessment of ostial lesions of bor-
derline significance,634 taking special care to avoid a wedge position
of the guiding catheter and using i.v., rather than intracoronary,
adenosine. When performing an intervention, due to interaction
between the guide catheter and the proximal stent edge, the risk of
longitudinal stent deformation must be considered635 and avoided
with careful catheter manipulation. The accurate positioning of the
stent, precisely in the coronary ostium, may be technically challenging
and some specialized techniques that may help to achieve optimal
stent placement have been described.636,637
16.4 Vascular access
A number of RCTs have compared radial access with femoral access
for diagnostic angiography and PCI. The two largest were RIVAL
(Radial versus femoral access for coronary angiography and interven-
tion in patients with acute coronary syndromes) and MATRIX
(Minimizing Adverse Haemorrhagic Events by Transradial access Site
and Systemic Implementation of AngioX).172,638 In the RIVAL trial,
which enrolled 7021 patients, the primary outcome of death, MI,
stroke, or non-CABG-related major bleeding at 30 days occurred at a
similar rate in radial vs. femoral access (HR 0.92, 95% CI 0.72–1.17, P =
0.50).638 In the MATRIX trial, 8404 ACS patients were randomly allo-
cated to radial or femoral access.172 In terms of the first co-primary
endpoint of 30 day MACE, there was no significant difference between
radial access and femoral access (RR 0.85, 95% CI 0.74–0.99, two-
sided P = 0.031; non-significant at a pre-specified a of 0.025). The sec-
ond co-primary outcome of 30 day net adverse clinical events [MACE
or non-CABG BARC (Bleeding Academic Research Consortium
(major bleeding] was significantly lower with radial access (RR 0.83,
95% CI 0.73–0.96; P = 0.009). Major BARC 3 or 5 bleeding was signifi-
cantly reduced in the radial group (1.6 vs. 2.3%; RR 0.67, 95% CI
0.49–0.92; P = 0.013), and radial access was associated with a lower
risk of all-cause mortality (1.6 vs. 2.2%; RR 0.72, 95% CI 0.53–0.99,
P = 0.045). However, the benefit of radial over femoral access depends
upon the operator’s expertise in the radial technique.639
Treatment of restenotic and saphenous vein graft lesions are dis-
cussed in section 13.3.
Recommendations on choice of stent and access site
Recommendations Classa Levelb




• planned non-cardiac surgery




Radial access is recommended as the stand-
ard approach, unless there are overriding
procedural considerations.172,638,641
I A
BRS are currently not recommended for
clinical use outside of clinical studies.642–650
III C
BMS = bare-metal stents; BRS = bioresorbable scaffolds; DAPT = dual antiplatelet
therapy; DES = drug-eluting stents; PCI = percutaneous coronary intervention.
aClass of recommendation.
bLevel of evidence.
Recommendations on intravascular imaging for proce-
dural optimization
Recommendations Classa Levelb
IVUS or OCT should be considered in
selected patients to optimize stent
implantation.603,612,651–653
IIa B
IVUS should be considered to optimize
treatment of unprotected left main
lesions.35
IIa B
IVUS = intravascular ultrasound; OCT = optical coherence tomography.
aClass of recommendation.
bLevel of evidence.
Recommendations on specific lesion subsets
Recommendations Classa Levelb
Stent implantation in the main vessel only,
followed by provisional balloon angioplasty
with or without stenting of the side branch,
is recommended for PCI of bifurcation
lesions.654–658
I A
Percutaneous revascularization of CTOs
should be considered in patients with angina
resistant to medical therapy or with a large
area of documented ischaemia in the terri-
tory of the occluded vessel.629,659–663
IIa B
In true bifurcation lesions of the left main,
the double-kissing crush technique may be
preferred over provisional T-stenting.620
IIb B























Antithrombotic treatment is mandatory in CAD patients undergoing
myocardial revascularization. The choice of treatment, the combination,
the time point of initiation, and the duration depend on the patient’s
characteristics, comorbidities, the clinical setting (elective revasculariza-
tion vs. ACS), and the mode (PCI vs. CABG) of revascularization. Both
ischaemic and bleeding events significantly influence the outcome
of CAD patients and their overall mortality risk during and after
myocardial revascularization.664 Thus, the choice of treatment should
reflect the ischaemic and bleeding risk. The recommended drugs
(Figure 9) and doses (Table 7) for anticoagulant and antiplatelet
drugs used in conjunction with myocardial revascularization are
summarized below.
Figure 9 Antithrombotic treatment for myocardial revascularization and its pharmacological targets.
Table 7 Doses of antiplatelet and anticoagulant drugs used during and after myocardial revascularization
Antiplatelet drugs
Aspirin Loading dose of 150–300 mg orally or 75–150 mg i.v. if oral ingestion is not possible, followed by
a maintenance dose of 75–100 mg/day.
Clopidogrel Loading dose of 600 mg orally, followed by a maintenance dose of 75 mg/day.
Prasugrel Loading dose of 60 mg orally, followed by a maintenance dose of 10 mg/day.
In patients with body weight <60 kg, a maintenance dose of 5 mg is recommended.
In patients aged >75 years, prasugrel is generally not recommended, but a dose of 5 mg should















































17.1 Percutaneous coronary intervention
in stable coronary artery disease
17.1.1 Choice of treatment and pre-treatment
DAPT consisting of aspirin and a P2Y12 receptor inhibitor represents
the cornerstone of treatment in patients undergoing elective PCI.665
The P2Y12 receptor inhibitor clopidogrel is recommended for elec-
tive stenting procedures. For routine clopidogrel pre-treatment
(administration of the drug when the coronary anatomy is unknown),
there is no compelling evidence for a significant clinical benefit in
SCAD patients.666–668 Thus, pre-treatment may only be an option in
selected patients with high probability of PCI or before staged PCI
procedures. Figures 9 and 10 summarize the commonly used antipla-
telet and anticoagulant drugs in SCAD patients undergoing PCI.
17.1.2 Peri-interventional treatment
While aspirin and clopidogrel are indicated for elective stenting pro-
cedures, prasugrel or ticagrelor may only be considered in selected
patients for specific high-risk situations of elective stenting (e.g. com-
plex PCI procedures such as LM stenting and CTO procedures) or in
patients with a history of stent thrombosis on clopidogrel treatment.
In parallel with antiplatelet treatment, the use of anticoagulants is
standard of care during elective PCI to inhibit thrombin generation
and activity. Different agents, including unfractionated heparin (UFH)
and bivalirudin, have been evaluated for their use in clinical practice.
The REPLACE-2 (Randomised Evaluation in PCI Linking Angiomax to
Reduced Clinical Events 2) trial demonstrated that the outcome with
bivalirudin and provisional glycoprotein (GP) IIb/IIIa blockade is simi-
lar to that of UFH plus planned GP IIb/IIIa inhibition during elective
PCI.669 The ISAR-REACT (Intracoronary Stenting and
Antithrombotic Regimen Rapid Early Action for Coronary
Treatment) 3 trial also showed a similar outcome for bivalirudin vs.
UFH treatment.670 In ISAR REACT 3A,671 evaluating a lower dose of
100 U/kg UFH, this lower dose showed net clinical benefit compared
with the historical control cohort and this benefit was mostly driven
by a reduction in bleeding events. In view of the primary endpoint
results of the RCTs and in view of a trend towards a lower risk of MI,
UFH remains the standard anticoagulant for elective PCI. Based on
the results of the STEEPLE (Safety and Efficacy of Intravenous
Enoxaparin in Elective Percutaneous Coronary Intervention
Randomised Evaluation) trial, enoxaparin should be considered as an
alternative anticoagulant drug.672
Drugs for parenteral antiplatelet treatment include cangrelor
and GP IIb/IIIa inhibitors. Cangrelor is a direct reversible, short-
acting P2Y12-inhibitor that has been evaluated during PCI for
SCAD and ACS in clinical trials comparing cangrelor with clopi-
dogrel, administered before PCI [CHAMPION (Cangrelor versus
Standard Therapy to Achieve Optimal Management of Platelet
Ticagrelor Loading dose of 180 mg orally, followed by a maintenance dose of 90 mg b.i.d.
Abciximab Bolus of 0.25 mg/kg i.v. and 0.125 lg/kg/min infusion (maximum 10 lg/min) for 12 h.
Eptifibatide Double bolus of 180 lg/kg i.v. (given at a 10 min interval) followed by an infusion of 2.0 lg/kg/min
for up to18 h.
Tirofiban Bolus of 25 lg/kg over 3 min i.v., followed by an infusion of 0.15 lg/kg/min for up to 18 h.
Cangrelor Bolus of 30 mg/kg i.v. followed by 4 mg/kg/min infusion for at least 2 h or duration of procedure,
whichever is longer.
Anticoagulant drugs for PCI
Unfractionated heparin • 70–100 U/kg i.v. bolus when no GP IIb/IIIa inhibitor is planned.
• 50–70 U/kg i.v. bolus with GP IIb/IIIa inhibitors.
Enoxaparin 0.5 mg/kg i.v. bolus.
Bivalirudin 0.75 mg/kg i.v. bolus followed by i.v. infusion of 1.75 mg/kg/h for up to 4 h after the procedure
as clinically warranted.
Oral anticoagulant drugs (concomitant treatment after PCI)
Vitamin K antagonists (e.g. warfarin,
phenprocoumon)
Dosing is based on INR value and the respective clinical indication.
Apixaban Maintenance doses of 5 and 2.5a mg b.i.d.
Dabigatran Maintenance doses of 150 and 110 mg b.i.d.
Edoxaban Maintenance doses of 60 and 30a mg/day
Rivaroxaban Maintenance doses of 20 and 15a mg/day, and 2.5 mg b.i.d. (vascular dose).
aSpecific criteria for reduced dose apply (see recommendation table on page 61).








































..Inhibition) PCI] or after PCI (CHAMPION PLATFORM and
CHAMPION PHOENIX).673 A meta-analysis showed a benefit
with respect to major ischaemic endpoints that is counter-
balanced by an increase in relevant bleeding.673 Moreover, the
benefit of cangrelor with respect to ischaemic endpoints was atte-
nuated in CHAMPION PCI with upfront administration of clopi-
dogrel. Nevertheless, due to its proven efficacy in preventing
intraprocedural and post-procedural stent thrombosis in P2Y12-
inhibitor naı̈ve patients, cangrelor may be considered in P2Y12-
inhibitor naı̈ve patients undergoing PCI (for more detailed discus-
sion see the Supplementary Data).
Available GP IIb/IIIa inhibitors include abciximab, eptifibatide, and tir-
ofiban. In a setting of elective PCI, clinical trials did not demonstrate an
additional benefit of GP IIb/IIIa inhibitor administration in SCAD
patients in a setting of DAPT treatment that includes loading with clo-
pidogrel.674,675 A meta-analysis on this topic revealed no mortality ben-
efit of GP IIb/IIIa treatment and while non-fatal MIs were reduced,
(minor) bleeding events were significantly higher when utilizing these
agents.676 Thus, GP IIb/IIIa inhibitors may only be considered in specific
‘bail-out’ situations including high intraprocedural thrombus burden,
slow flow, or no-flow with closure of the stented coronary vessel.
An algorithm for the use of antithrombotic drugs in patients under-
going PCI is shown in Figure 10.
17.1.3 Post-interventional and maintenance treatment
Following elective stenting, DAPT consisting of clopidogrel in addi-
tion to aspirin is generally recommended for 6 months, irrespective
of the stent type. In specific clinical scenarios, this standard DAPT
duration can be shortened (<6 months) or extended (>6–12
months). For a more detailed description of the pertinent clinical tri-
als in the field of DAPT duration, we refer the reader to the 2017
ESC Focused Update on Dual Antiplatelet Therapy in Coronary
Artery Disease.410 Following DAPT, a life-long single antiplatelet
therapy (usually with aspirin) is recommended, and patients should
be advised not to prematurely discontinue oral antiplatelet therapy
after stenting due to the risks of stent thrombosis and recurrent
MI.677 Recently, the value of a vascular dose of rivaroxaban (2.5 mg
b.i.d.) in conjunction with aspirin was demonstrated in the large-scale
COMPASS (Rivaroxaban for the Prevention of Major Cardiovascular
Events in Coronary or Peripheral Artery Disease) trial.678 However,
its utilization in SCAD patients is a matter of secondary prevention
and is not linked to myocardial revascularization procedures.
Figure 10 Algorithm for the use of antithrombotic drugs in patients undergoing percutaneous coronary intervention. High bleeding risk is consid-
ered as an increased risk of spontaneous bleeding during DAPT (e.g. PRECISE-DAPT score >_25). Colour-coding refers to the ESC classes of recom-
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Recommendations for antithrombotic treatment in stable coronary artery disease patients undergoing percutaneous
coronary intervention
Recommendations Classa Levelb
Pre-treatment and antiplatelet therapy
Treatment with 600 mg clopidogrel is recommended in elective PCI patients once the coronary anatomy is known and
a decision is made to proceed with PCI.667,679,680
I A
Pre-treatment with clopidogrel may be considered if the probability of PCI is high. IIb C
In patients on a maintenance dose of 75 mg clopidogrel, a new loading dose of 600 mg may be considered once the indi-
cation for PCI is confirmed.
IIb C
Peri-interventional treatment
Aspirin is indicated before elective stenting.681–683 I A
An oral loading dose of aspirin (150–300 mg p.o. or 75–250 mg i.v.) is recommended if the patient is not pre-treated. I C
Clopidogrel (600 mg loading dose, 75 mg daily maintenance dose) is recommended for elective stenting.684–688 I A
Glycoprotein IIb/IIIa antagonists should be considered only for bail-out. IIa C
Prasugrel or ticagrelor may be considered in specific high-risk situations of elective stenting (e.g. history of stent throm-
bosis or left main stenting).
IIb C
Unfractionated heparin is indicated as the standard anticoagulant (70–100 U/kg).670,671 I B
Bivalirudin (0.75 mg/kg bolus, followed by 1.75 mg/kg/h for up to 4 h after the procedure) is indicated in the case of hep-
arin-induced thrombocytopenia.
I C
Enoxaparin (i.v. 0.5 mg/kg) should be considered as an alternative agent.672,689 IIa B
Cangrelor may be considered in P2Y12-inhibitor naı̈ve patients undergoing PCI.
673 IIb A
Post-interventional and maintenance treatment
Life-long single antiplatelet therapy, usually aspirin, is recommended.681,683 I A
Instruction of patients about the importance of complying with antiplatelet therapy is recommended. I C
In patients with SCAD treated with coronary stent implantation, DAPT consisting of clopidogrel in addition to aspirin is
generally recommended for 6 months, irrespective of the stent type.c 690–694
I A
In patients with SCAD treated with BRS, DAPT should be considered for at least 12 months and up to the presumed
full absorption of the BRS, based on an individual assessment of bleeding and ischaemic risk.
IIa C
In patients with SCAD treated with DCB, DAPT should be considered for 6 months.369,371 IIa B
In patients with SCAD considered at high bleeding risk (e.g. PRECISE-DAPT >_25), DAPT should be considered for 3
months.d 695,696
IIa A
In patients with SCAD who have tolerated DAPT without a bleeding complication and who are at low bleeding risk but
high thrombotic risk, continuation of DAPT with clopidogrel for >6 months and up to 30 months may be
considered.697–700
IIb A
In patients with SCAD in whom 3 month DAPT poses safety concerns, DAPT may be considered for 1 month. IIb C
BRS = bioresorbable scaffold; CAD = coronary artery disease; DAPT = dual antiplatelet therapy; DCB = drug-coated balloon; i.v. = intravenous; MI = myocardial infarction;
PCI = percutaneous coronary intervention; p.o. = orally; PRECISE-DAPT = PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual
Anti Platelet Therapy; SCAD = stable coronary artery disease.
aClass of recommendation.
bLevel of evidence.
cThese recommendations refer to stents that are supported by large-scale randomized trials with clinical endpoint evaluation leading to an unconditional CE mark.

































































































17.2 Non-ST-segment elevation acute
coronary syndrome
The activation of blood platelets and the coagulation cascade plays a
key role in the initial phase and evolution of an ACS. Hence, sufficient
platelet inhibition and anticoagulation is essential during ACS, and
especially in ACS patients undergoing PCI.
17.2.1 Choice of treatment and pre-treatment
For NSTE-ACS patients, DAPT including aspirin and a potent P2Y12
receptor inhibitor (prasugrel or ticagrelor) is recommended (see the
Supplementary Data).701,702 Clopidogrel should only be used when
prasugrel or ticagrelor are not available or are contraindicated. Based
on the results of the ACCOAST (Comparison of Prasugrel at the
Time of Percutaneous Coronary Intervention or as Pretreatment at
the Time of Diagnosis in Patients with Non-ST Elevation Myocardial
Infarction) trial,165 it is not recommended that prasugrel is adminis-
tered in patients in whom coronary anatomy is not known.
Nevertheless, pre-treatment with ticagrelor was part of the PLATO
trial (Study of Platelet Inhibition and Patient Outcomes) and was
associated with an early benefit over clopidogrel.702 For these rea-
sons, pre-treatment with ticagrelor can be used, although there is no
direct evidence from head-to-head comparisons between pre-
treatment strategies.
17.2.2 Peri-interventional treatment
Anticoagulation is recommended for all patients in addition to anti-
platelet therapy during PCI for NSTE-ACS.703 In general, a crossover
between anticoagulants should be avoided [especially between UFH
and low-molecular-weight heparin (LMWH)], with the exception of
adding UFH to fondaparinux when a patient proceeds to PCI.704,705
The respective agents should be discontinued after PCI except for
specific clinical settings, such as the presence of an LV aneurysm with
thrombus or AF requiring anticoagulation.
A number of trials have compared bivalirudin with UFH in ACS
patients undergoing PCI (see the Supplementary Data). Some of
these trials pursued a balanced use of adjunctive GP IIb/IIIa inhibitors
with both bivalirudin and heparin, whereas others, predominantly the
older ones, had selective use of GP IIb/IIIa inhibitors in the heparin
arm. These trials have been reviewed extensively in a number of
meta-analyses.706–708 A meta-analysis that included the MATRIX trial
but not VALIDATE-SWEDEHEART (Bivalirudin versus Heparin in
ST-Segment and Non-ST-Segment Elevation Myocardial Infarction in
Patients on Modern Antiplatelet Therapy on the Swedish Web-
system for Enhancement and Development of Evidence-based care
in Heart disease Evaluated According to Recommended Therapies)
showed no significant benefit of bivalirudin compared with UFH with
respect to death, MACE, and MI.708 Nevertheless, bivalirudin was
associated with a significant increase in the risk of stent thrombosis
and a significant decrease in the risk of bleeding. However, the reduc-
tion of bleeding risk was linked to unbalanced use of GP IIb/IIa inhibi-
tors predominantly with UFH. Recently, the VALIDATE-
SWEDEHEART study709 compared UFH vs. bivalirudin in a back-
ground of radial access and limited use of GP IIb/IIIa inhibitors. The
study demonstrated similar risk patterns for both ischaemia and
bleeding when comparing the two drugs. Of note, while prior studies
reported a reduced bleeding risk with bivalirudin vs. UFH, this was
not confirmed in VALIDATE-SWEDEHEART and in a contemporary
setting of preferred radial access and selective use of GP IIb/IIIa inhibi-
tors. More recently, a meta-analysis updated for the results of
VALIDATE-SWEDEHEART confirmed that bivalirudin compared
with heparin was associated with a similar incidence of all-cause death
and ischaemic events after PCI for ACS.710 A significant association of
bivalirudin with decreased risk of bleeding was only found with unbal-
anced use of GP IIb/IIIa inhibitors in conjunction with heparin. In sum-
mary and based on the above-mentioned trials, UFH is primarily
recommended as an anticoagulant for PCI. Due to its short half-life
and favourable results in some of the studies, bivalirudin may be con-
sidered as an alternative to UFH in selected cases.
Patients may undergo cardiac catheterization after a conservative
treatment phase and these patients are commonly treated with fon-
daparinux during the conservative treatment phase. This regimen is
based on the OASIS-5 (Optimal Antiplatelet Strategy for
Interventions 5) trial.711 Of note, catheter thrombus formation was
an issue with fondaparinux and therefore full-dose UFH must be
added to prevent thrombus formation when the patient proceeds to
PCI. Enoxaparin should be considered as anticoagulant for PCI in
patients pre-treated with subcutaneous enoxaparin. A benefit of
enoxaparin over UFH in reducing mortality and bleeding complica-
tions was recently reported in a meta-analysis including NSTE-ACS
patients.689 Yet, this meta-analysis did not include a dedicated
randomized study in NSTE-ACS and was largely based on non-
randomized comparisons.
Most of the trials evaluating GP IIb/IIIa inhibitors in PCI-treated
patients pre-date the era of routine oral DAPT treatment. These
early trials demonstrated a reduction in the incidence of ischaemic
events in favour of GP IIb/IIIa treatment in combination with UFH
compared with UFH alone, primarily through a reduction in MI.712
However, coronary angiography and PCI were delayed compared
with what is recommended now, and a consistent major bleeding risk
was observed. Overall, there is no compelling evidence for an addi-
tional benefit of routine upstream use of GP IIb/IIIa inhibitors in
NSTE-ACS patients scheduled for coronary angiography and receiv-
ing DAPT treatment.713,714 In a setting of potent platelet inhibition
with ticagrelor or prasugrel, where randomized data on GP IIb/IIIa
inhibitor use is limited, routine use of these agents cannot be recom-
mended. Nevertheless, it should be considered for bail-out situations
or thrombotic complications, and may be used for high-risk PCI in
patients without pre-treatment with P2Y12-inhibitors. The available
evidence on cangrelor suggests that the potential benefit is independ-
ent of the clinical presentation. Thus, similar to SCAD patients, can-
grelor may be considered in specific settings in P2Y12-naı̈ve patients
undergoing PCI.
17.2.3 Post-interventional and maintenance treatment
Following PCI for NSTE-ACS, DAPT consisting of a P2Y12 receptor
inhibitor in addition to aspirin is generally recommended for 12
months, irrespective of the stent type. Recently, the SMART-DATE
(Smart Angioplasty Research Team-safety of 6-month duration of
Dual Antiplatelet Therapy after percutaneous coronary intervention
in patients with acute coronary syndromes) prospective multicentre
randomized trial supported this notion in the setting of contempo-











































..patients undergoing PCI for NSTE-ACS or STEMI to either 6 month
DAPT or 12 month or longer DAPT. Although the primary
endpoint—a composite of all-cause death, MI, or stroke—did not
confirm the benefit of prolonged DAPT over 6 month DAPT (cumu-
lative event rate 4.7 vs. 4.2%; absolute risk difference 0.5%; upper limit
of one-sided 95% CI 1.8%; Pnon-inferiority = 0.03 with a predefined non-
inferiority margin of 2.0%), MI occurred more frequently in the 6
month DAPT group than in the prolonged DAPT group (1.8 vs. 0.8%;
P = 0.02). The rate of BARC type 2 - 5 bleeding was not significantly
affected by prolonged DAPT (HR 0.69, 95% CI 0.45–1.05, P = 0.09).
The authors stated that the increased risk of MI with 6 month DAPT
and the wide non-inferiority margin prevented them from concluding
that short-term DAPT was safe in this setting, and suggested that pro-
longed DAPT should remain the standard of care in patients with
ACS without excessive risk of bleeding.715
In specific clinical scenarios, this standard DAPT duration can be
shortened (<12 months) or extended (>12 months). Further on,
switching and especially a de-escalation of DAPT (switching from
potent P2Y12-inhibitors to clopidogrel) was subject to a number of
randomized clinical trials.716,717 Triggers for DAPT de-escalation
include clinical (bleeding events or presumed high bleeding risk) and
socio-economic factors.716 Based on recent results from the
randomized TROPICAL-ACS (Testing responsiveness to platelet
inhibition on chronic antiplatelet treatment for acute coronary syn-
dromes) trial717, an approach of DAPT de-escalation guided by plate-
let function testing may be considered in ACS patients (NSTE-ACS
and STEMI) as an alternative to 12 months potent platelet inhibition,
especially for patients deemed unsuitable for maintained potent pla-
telet inhibition. For a more detailed description of the pertinent clini-
cal trials in the field of DAPT duration and switching antiplatelet
drugs, we refer the reader to the International Expert Consensus
document on Switching Platelet P2Y12 Receptor-Inhibiting
Therapies718 and the 2017 ESC Focused Update on Dual Antiplatelet
Therapy in Coronary Artery Disease.410 Following DAPT, lifelong
single antiplatelet therapy (usually with aspirin) is recommended and
patients should be advised not to prematurely discontinue oral anti-
platelet therapy after stenting.677,719
Based on the results of the ATLAS-ACS 2–TIMI 51 (Anti-Xa
Therapy to Lower cardiovascular events in Addition to Standard
therapy in subjects with Acute Coronary Syndrome–Thrombolysis
In Myocardial Infarction 51) trial in NSTE-ACS and STEMI patients,720
low-dose rivaroxaban may be considered after discontinuation of
parenteral anticoagulation for patients with no prior stroke/TIA, and
at high ischaemic risk as well as low bleeding risk, receiving aspirin
and clopidogrel. Of note, rivaroxaban has not been investigated in a
background of potent P2Y12-inhibitors.
Recommendations for antithrombotic treatment in patients with non-ST-elevation acute coronary syndromes under-
going percutaneous coronary intervention
Recommendations Classa Levelb
Pre-treatment and antiplatelet therapy
Aspirin is recommended for all patients without contraindications at an initial oral loading dose of 150–300 mg (or
75–250 mg i.v.), and at a maintenance dose of 75–100 mg daily long-term.681,683,721
I A
A P2Y12 inhibitor is recommended in addition to aspirin, maintained over 12 months unless there are contraindica-
tions such as an excessive risk of bleeding.701,702,722,723 Options are:
I A
 Prasugrel in P2Y12-inhibitor naı̈ve patients who proceed to PCI (60 mg loading dose, 10 mg daily dose).701
 Ticagrelor irrespective of the preceding P2Y12 inhibitor regimen (180 mg loading dose, 90 mg b.i.d.).702





GP IIb/IIIa antagonists should be considered for bail-out if there is evidence of no-reflow or a thrombotic
complication.
IIa C
For pre-treatment in patients with NSTE-ACS undergoing invasive management, ticagrelor administration (180 mg
loading dose, 90 mg b.i.d.), or clopidogrel (600 mg loading dose, 75 mg daily dose) if ticagrelor is not an option,
should be considered as soon as the diagnosis is established.
IIa C
Cangrelor may be considered in P2Y12-inhibitor naı̈ve patients undergoing PCI.
673 IIb A
GP IIb/IIIa antagonists may be considered in P2Y12-inhibitor naı̈ve patients undergoing PCI. IIb C
Pre-treatment with GP IIb/IIIa antagonists in patients in whom coronary anatomy is not known is not
recommended.713,714,725
III A
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Peri-interventional therapy
Anticoagulation is recommended for all patients in addition to antiplatelet therapy.703,726 I A
It is recommended that anticoagulation is selected according to both ischaemic and bleeding risks, and according to
the efficacy–safety profile of the chosen agent.
I C
UFH is recommended. I C
In patients on fondaparinux, a single bolus UFH (85 IU/kg, or 60 IU in the case of concomitant use of GP IIb/IIIa
receptor inhibitors) is indicated.727
I B
Enoxaparin should be considered in patients pre-treated with subcutaneous enoxaparin.689 IIa B
Discontinuation of parenteral anticoagulation should be considered immediately after an invasive procedure. IIa C
Bivalirudin (0.75 mg/kg bolus, followed by 1.75 mg/kg/h for up to 4 h after the procedure) may be considered as an
alternative to UFH.163,708,710,714,728
IIb A
Crossover of UFH and LMWH is not recommended.705 III B
b.i.d. = twice daily; GP = glycoprotein; i.v. = intravenous; LMWH = low-molecular-weight heparin; NSTE-ACS = non-ST-segment elevation acute coronary syndromes; PCI =
percutaneous coronary intervention; UFH = unfractionated heparin.
aClass of recommendation.
bLevel of evidence.
Recommendations for post-interventional and maintenance treatment in patients with non-ST-elevation acute coro-
nary syndromes and ST-elevation myocardial infarction undergoing percutaneous coronary intervention
Recommendations Classa Levelb
In patients with ACS treated with coronary stent implantation, DAPT with a P2Y12 inhibitor on top of aspirin is rec-
ommended for 12 months unless there are contraindications such as an excessive risk of bleeding (e.g. PRECISE-
DAPT >_25).701,702,722,723
I A
In patients with ACS and stent implantation who are at high risk of bleeding (e.g. PRECISE-DAPT >_25), discontinua-
tion of P2Y12 inhibitor therapy after 6 months should be considered.
729,730 IIa B
In patients with ACS treated with BRS, DAPT should be considered for at least 12 months and up to the presumed
full absorption of the BRS, based on an individual assessment of bleeding and ischaemic risk.
IIa C
De-escalation of P2Y12 inhibitor treatment (e.g. with a switch from prasugrel or ticagrelor to clopidogrel) guided by
platelet function testing may be considered as an alternative DAPT strategy, especially for ACS patients deemed
unsuitable for 12-month potent platelet inhibition.717
IIb B
In patients with ACS who have tolerated DAPT without a bleeding complication, continuation of DAPT for longer
than 12 months may be considered.700,731
IIb A
In patients with MI and high ischaemic riskc who have tolerated DAPT without a bleeding complication, ticagrelor
60 mg b.i.d. for longer than 12 months on top of aspirin may be preferred over clopidogrel or prasugrel.732–734
IIb B
In ACS patients with no prior stroke/TIA, and at high ischaemic risk as well as low bleeding risk, receiving aspirin
and clopidogrel, low-dose rivaroxaban (2.5 mg b.i.d. for approximately 1 year) may be considered after discontinua-
tion of parenteral anticoagulation.720
IIb B
ACS = acute coronary syndrome; b.i.d. = twice daily; BRS = bioresorbable scaffold; DAPT = dual antiplatelet therapy; MI = myocardial infarction; PCI = percutaneous coronary




cDefined as >_50 years of age and having one of the following additional high-risk features: age >_65 years or older, diabetes mellitus requiring medication, a second prior sponta-





































..17.3 ST-segment elevation myocardial
infarction
17.3.1 Choice of treatment and pre-treatment
STEMI patients undergoing primary PCI should receive aspirin and a
P2Y12 receptor inhibitor as soon as the diagnosis of STEMI is estab-
lished. In line with the treatment recommendations for NSTE-ACS
patients, DAPT is the cornerstone of treatment for STEMI patients
and includes aspirin and a potent P2Y12 receptor inhibitor (prasugrel
or ticagrelor).701,702 For both antiplatelet drugs, published subgroup
analyses on STEMI patients are available (see the Supplementary
Data). Randomized data on a comparison of ticagrelor vs. prasugrel
in STEMI patients are limited, but the recently published randomized
PRAGUE-18 (Comparison of Prasugrel and Ticagrelor in the
Treatment of Acute Myocardial Infarction) trial735 with limited statis-
tical power found similar safety and efficacy profiles of ticagrelor and
prasugrel in a setting of primary PCI. When potent P2Y12 receptor
inhibitors are contraindicated or are not available, clopidogrel should
be given for primary PCI instead.724 The value of pre-treatment with
ticagrelor was addressed in the ATLANTIC (Administration of
Ticagrelor in the Cath Lab or in the Ambulance for New ST-
Elevation Myocardial Infarction to Open the Coronary Artery)
trial.736 No significant differences were observed in the levels of the
two co-primary surrogate endpoints measured before PCI (throm-
bolysis in Myocardial Infarction flow and ST-segment resolution).
Likewise, the incidence of a combined ischaemic endpoint (death, MI,
stroke, stent thrombosis, and urgent revascularization) did not differ
between the two treatment arms. Nevertheless, in both the
TRITON (TRial to Assess Improvement in Therapeutic Outcomes
by Optimizing Platelet InhibitioN with Prasugrel–Thrombolysis In
Myocardial Infarction) and PLATO trials, pre-treatment was part of
the therapeutic regimen in STEMI.
17.3.2 Peri-interventional treatment
Immediate and sufficient anticoagulation is mandatory in the setting
of primary PCI for STEMI and available options include UFH, bivaliru-
din, and enoxaparin. A number of RCTs compared bivalirudin vs.
UFH in different settings and with different utilization of GP IIb/IIIa
inhibitors (see the Supplementary Data). The primary recommenda-
tion of UFH, reserving bivalirudin for selected cases, is essentially the
same for primary PCI as for PCI in NSTE-ACS, and is mostly based
on the same clinical trials706,709 (see section 17.2.2).
Enoxaparin was compared with UFH in the randomized open-
label ATOLL (Acute STEMI Treated with primary PCI and intrave-
nous enoxaparin Or UFH to Lower ischaemic and bleeding events at
short- and Long-term follow-up) trial,737 and based on the trial
results, enoxaparin should be considered as an alternative to UFH
treatment in STEMI patients.
A number of clinical trials, performed at a time when pre-
treatment and potent platelet inhibition was not part of routine clini-
cal practice, have documented clinical benefits of GP IIb/IIIa inhibitors
as an adjunct to primary PCI performed with UFH.738,739 A meta-
analysis showed a significant survival benefit, especially in high-risk
STEMI patients, but also a higher risk of bleeding with GP IIb/IIIa
administration.740 Dedicated trials have investigated the value of
upstream treatment in the past.741,742 Based upon the available evi-
dence, the routine use of i.v. or intracoronary GP IIb/IIIa inhibitor
administration—regardless of whether treatment starts upstream or
in the catheterization laboratory—cannot be recommended.
Especially in a setting where potent P2Y12-inhibitors like prasugrel or
ticagrelor are used, the value of GP IIb/IIIa inhibitors remains uncer-
tain as these agents exhibit a fast onset of action (usually <1 h). GP
IIb/IIIa inhibitors remain an option as bail-out therapy or in high-risk
PCI without pre-treatment with P2Y12-inhibitors. Of note, the bail-
out scenarios have never been addressed in randomized controlled
trials. For reasons discussed above (see sections 17.1 and 17.2), can-
grelor may be considered in specific settings in P2Y12-naı̈ve patients
undergoing PCI.
17.3.3 Post-interventional and maintenance treatment
Following PCI for STEMI, DAPT consisting of a P2Y12 receptor inhibi-
tor in addition to aspirin is generally recommended for 12 months.
Recommendations for maintenance DAPT treatment are generally
consistent with those for NSTE-ACS patients and are detailed in sec-
tion 17.2.3.
Recommendations for antithrombotic treatment in ST-
elevation myocardial infarction patients undergoing per-
cutaneous coronary intervention
Recommendations Classa Levelb
Pre-treatment and antiplatelet therapy
Aspirin is recommended for all patients
without contraindications at an initial
oral loading dose of 150–300 mg (or
75–250 mg i.v.), and at a maintenance




A potent P2Y12 inhibitor (prasugrel or
ticagrelor), or clopidogrel if these are
not available or are contraindicated, is
recommended before (or at latest at the
time of) PCI and maintained over 12
months, unless there are contraindica-
tions such as excessive risk of
bleeding.701,702,724,743
I A
GP IIb/IIIa inhibitors should be consid-
ered for bail-out if there is evidence of
no-reflow or a thrombotic
complication.
IIa C
Cangrelor may be considered in P2Y12-
inhibitor naı̈ve patients undergoing
PCI.673
IIb A
GP IIb/IIIa antagonists may be consid-




























17.4 Coronary artery bypass grafting
Antithrombotic treatment before and after CABG is addressed in
the 2017 ESC Focused Update on Dual Antiplatelet Therapy in
Coronary Artery Disease.410 After reviewing the subsequent litera-
ture, the current Task Force endorses the recommendations of the
update on DAPT and does not identify a need for any major update.
Accordingly, the recommendation tables in this section are taken
from the Focused Update. For a detailed discussion, we refer the
reader to the Focused Update.
17.5 Special conditions
17.5.1 Antithrombotic therapy after percutaneous
coronary intervention in patients requiring oral
anticoagulation
Compared with OAC therapy alone, the addition of DAPT to OAC
therapy results in a two- to three-fold increase in bleeding complica-
tions, suggesting that every effort should be undertaken to avoid
bleeding (Table 8).753 Assessing the balance of ischaemic and bleeding
risks of relatively short (i.e. <_6 months) triple therapy duration com-
pared with double therapy consisting of clopidogrel and an OAC
Peri-interventional therapy
Anticoagulation is recommended for all
patients in addition to antiplatelet ther-
apy during PCI.703,726
I A
Routine use of UFH is recommended. I C
Routine use of enoxaparin should be
considered.737
IIa B
Routine use of bivalirudin may be
considered.708,710,728,744–746
IIb A
GP = glycoprotein; i.v. = intravenous; PCI = percutaneous coronary intervention;
UFH = unfractionated heparin.
aClass of recommendation.
bLevel of evidence.
Dual antiplatelet therapy in patients undergoing cardiac
surgery
Recommendations Classa Levelb
It is recommended that the Heart Team
estimates the individual bleeding and
ischaemic risks, and guides the timing of
CABG as well as the anti-thrombotic
management.
I C
In patients on aspirin who need to
undergo non-emergent cardiac surgery,
it is recommended to continue aspirin at
a low daily regimen throughout the peri-
operative period.
I C
In patients treated with DAPT after cor-
onary stent implantation who subse-
quently undergo cardiac surgery, it is
recommended to resume P2Y12 inhibi-
tor therapy post-operatively as soon as
it is deemed safe, so that DAPT contin-




In patients with ACS (NSTE-ACS or
STEMI) treated with DAPT who are
undergoing CABG and do not require
long-term OAC therapy, resumption of
P2Y12 inhibitor therapy as soon as
deemed safe after surgery and its contin-
uation up to 12 months is
recommended.
I C
In patients on P2Y12 inhibitors who
need to undergo non-emergent cardiac
surgery, postponing surgery for at least
3 days after discontinuation of ticagre-
lor, at least 5 days after clopidogrel, and
at least 7 days after prasugrel should be
considered.747–749
IIa B
In CABG patients with prior MI who are
at high risk of severe bleeding (e.g.
PRECISE-DAPT >_25), discontinuation of
P2Y12 inhibitor therapy after 6 months
should be considered.
IIa C
Platelet function testing may be consid-
ered to guide the decision on the timing




In patients perceived to be at high
ischaemic risk with prior MI and CABG,
who have tolerated DAPT without a
bleeding complication, treatment with
DAPT for longer than 12 months and up
to 36 months may be considered.
IIb C
ACS = acute coronary syndrome; CABG = coronary artery bypass grafting;
DAPT = dual antiplatelet therapy; MI = myocardial infarction; NSTE-ACS = non-
ST-elevation acute coronary syndrome; OAC = oral anticoagulant; STEMI = ST-
elevation myocardial infarction. PRECISE-DAPT = PREdicting bleeding
























































requires patient-by-patient decisions. Of note, previous randomized
studies evaluating the duration of triple therapy or the benefit of
NOACs vs. vitamin K antagonists (VKAs) were not adequately pow-
ered to assess ischaemic events, and data are lacking on the efficacy
of dual therapy in patients at high risk of stroke or recurrent
ACS.754–757 In the major trials, there was no interaction between the
duration of triple therapy and clinical presentation (ACS vs. no ACS).
The rate of bleeding events peaked within the first 30 days of initia-
tion of triple therapy, and was twice as high when compared with the
rate of acute coronary events including recurrent MI and stent
thrombosis. For these reasons, the duration of triple therapy should
be minimized depending on bleeding and ischaemic risks (see Tables 8
to 10 for guidance in decision-making). In stabilized event-free
patients, discontinuation of any antiplatelet agent at 1 year after stent-
ing is encouraged, while dual therapy may be continued beyond 1
year according to the stent-driven risk shown in Table 9.
Based on the favourable bleeding risk in the large phase 3 studies, a
NOAC should be preferred over a VKA. The PIONEER756
(Prevention of bleeding in patients with AF undergoing PCI) trial and
the more recent RE-DUAL (Randomised Evaluation of Dual
Antithrombotic Therapy with Dabigatran versus Triple Therapy with
Warfarin in Patients with Nonvalvular Atrial Fibrillation Undergoing
Percutaneous Coronary Intervention)757 trial compared a NOAC
plus single antiplatelet therapy with triple therapy with a VKA plus
DAPT and consistently showed significantly lower bleeding risks with
the dual antithrombotic regimen. In RE-DUAL, both dosing regimens
for dabigatran (150 mg and 110 mg b.i.d.) vs. warfarin triple therapy
were associated with a significant reduction of major or clinically
relevant bleeding events. However, as compared with triple therapy,
an increase in both MI (4.5 vs. 3.0%, P = 0.09) and stent thrombosis
risk (1.5 vs. 0.8%, P = 0.15) was reported for the lower dabigatran
dose (110 mg b.i.d.), but not for the higher dabigatran dose (150 mg
b.i.d.). Although statistical significance was missed, these findings raise
concern about the efficacy of the lower dabigatran dose in combina-
tion with single antiplatelet therapy in preventing coronary events.
Thus, the 150 mg b.i.d. dose of dabigatran is preferred. At present,
evidence for a dual treatment approach is available for VKA,755 rivar-
oxaban,756 and dabigatran,757 but none of these studies were pow-
ered to assess the efficacy of preventing stent thrombosis or
thrombo-embolic events and only RE-DUAL used a NOAC dose
that was previously shown to be effective in the prevention of
thrombo-embolic events. The ongoing AUGUSTUS trial
(ClinicalTrials.gov Identifier: NCT02415400) will address the value of
apixaban in a similar setting, and with and without aspirin. Edoxaban
is currently being investigated in a setting of triple treatment in the
ENTRUST-AF-PCI (Evaluation of the safety and efficacy of an edoxa-
ban-based antithrombotic regimen in patients with atrial fibrillation
following successful percutaneous coronary intervention) trial
(ClinicalTrials.gov Identifier: NCT02866175).
Figure 11 illustrates applicable DAPT algorithms in patients with an
indication for OAC undergoing PCI with the respective classes of
recommendations for the different treatment regimens. For more
details on the pertinent studies in the field of triple treatment (DAPT
plus OAC) and the associated issues, we refer the reader to the 2017
ESC Focused Update on Dual Antiplatelet Therapy in Coronary
Artery Disease.410
Table 8 Strategies to avoid bleeding complications in oral anticoagulation patients
Assess ischaemic and bleeding risks using validated risk predictors (e.g. CHA2DS2-VASc, ABC, and HAS-BLED) with a focus on modifiable risk
factors.
Keep triple therapy duration as short as possible; dual therapy after PCI (OAC and clopidogrel) to be considered instead of triple therapy.
One should consider the use of a NOAC instead of a VKA when NOACs are not contraindicated.
Consider a target INR in the lower part of the recommended target range and maximize time in the therapeutic range (i.e. >65%)
when a VKA is used.
Clopidogrel is the P2Y12 inhibitor of choice.
Use low-dose (<_100 mg daily) aspirin.
Routine use of PPIs.
Adapted from Valgimigli et al.410
ABC = Age, Biomarkers, Clinical history; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age >_75 years (doubled), Diabetes mellitus, prior Stroke or transient
ischaemic attack or thromboembolism (doubled), Vascular disease, Age 65–74 years, Sex category (female); HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke,
Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly; INR = international normalized ratio; NOAC = non-vitamin K antagonist OAC; OAC =
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Table 10 Unfavourable patient profile for a combina-







Prior major bleeding/prior haemorrhagic stroke
Chronic alcohol abuse
Anaemia
Clinically significant bleeding on dual antithrombotic therapy
Table 9 High-risk features for ischaemic events
Prior stent thrombosis on adequate antiplatelet therapy
Stenting of the last remaining patent coronary artery
Diffuse multivessel disease, especially in diabetic patients
Chronic kidney disease (i.e. creatinine clearance <60 mL/min)
At least three stents implanted
At least three lesions treated
Bifurcation with two stents implanted
Total stented length >60 mm
Treatment of a chronic total occlusion
History of STEMI
STEMI = ST-elevation myocardial infarction.
Dual antiplatelet therapy duration in patients with indi-
cation for oral anticoagulation
Recommendations Classa Levelb
It is recommended that periprocedural aspirin
and clopidogrel are administered to patients
undergoing coronary stent implantation.
I C
In patients treated with coronary stent implan-
tation, triple therapy with aspirin, clopidogrel,
and an OAC should be considered for 1 month,
irrespective of the type of stent used.755
IIa B
Triple therapy with aspirin, clopidogrel, and
an OAC for longer than 1 month and up to 6
months should be considered in patients
with high ischaemic risk due to ACS or other
anatomical/procedural characteristics, which
outweigh the bleeding risk.755
IIa B
Dual therapy with clopidogrel 75 mg/day and
an OAC should be considered as an alterna-
tive to 1-month triple antithrombotic ther-
apy in patients in whom the bleeding risk
outweighs the ischaemic risk.754,756,757
IIa A
In patients with non-valvular AF requiring anti-
coagulation and antiplatelet treatment, a
NOAC should be preferred over VKAs.758–760
IIa A
In patients with an indication for a VKA in com-
bination with aspirin and/or clopidogrel, the
dose intensity of the VKA should be carefully
regulated with a target INR in the lower part of
the recommended target range and time in the
therapeutic range >65%.754,755
IIa B
Discontinuation of antiplatelet treatment in
patients treated with OAC should be consid-
ered at 12 months.753
IIa B
When a NOAC is used in combination with
aspirin and/or clopidogrel, the lowest approved
dose effective for stroke prevention tested in
AF trials should be considered.c
IIa C
When rivaroxaban is used in combination with
aspirin and/or clopidogrel, rivaroxaban 15 mg q.d.
may be used instead of rivaroxaban 20 mg q.d.756
IIb B
When dabigatran is used in combination with
aspirin or clopidogrel, a dose of 150 mg b.i.d.
may be preferred over a dose of 110 mg b.i.d.757
IIb B
The use of ticagrelor or prasugrel is not rec-
ommended as part of triple antithrombotic
therapy with aspirin and an OAC.
III C
ACS = acute coronary syndrome; AF = atrial fibrillation; b.i.d. = twice daily; INR
= international normalized ratio; OAC = oral anticoagulant; NOAC = non-vita-
min K oral anticoagulant; q.d. = once daily; VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
cApixaban 5 mg b.i.d. or apixaban 2.5 mg b.i.d. if at least two of the following: age
>_80 years, body weight <_60 kg, or serum creatinine level >_1.5 mg/dL (133 mmol/
L); dabigatran 110 mg or 150 mg b.i.d.; and edoxaban 60 mg q.d. or edoxaban 30
mg q.d. if any of the following: creatinine clearance of 30–50 mL/min; body weight
<_60 kg; concomitant use of verapamil, quinidine, or dronedarone; and rivaroxa-




















17.5.2 Revascularization in patients with renal
failure
See the Supplementary Data.
17.5.3 Monitoring of antiplatelet drugs (platelet function
testing and genotyping)
See the Supplementary Data.
17.5.4 Surgery in patients on dual antiplatelet therapy
See 2017 ESC Focused Update on Dual Antiplatelet Therapy in
Coronary Artery Disease.410
17.6 Gaps in the evidence
The value of pre-hospital pre-treatment with prasugrel in STEMI
patients, as well as the safety and efficacy of ticagrelor given at












= Aspirin = Clopidogrel = Oral anticoagulation1
Beyond
12 months
Concerns about bleeding risk4  prevailing
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up to 12 months
Class IIa A
Dual Therapy
up to 12 months
Class IIa A 
Dual Therapy up to 12 months
Class IIa A
1 month Triple Therapy
Class IIa B
1 month Triple Therapy
Class IIa B
Triple Therapy




Colour-coding refers to the number of concomitant antithrombotic medication(s). Triple therapy denotes treatment with DAPT plus oral anticoagulant (OAC). Dual 
therapy denotes treatment with a single antiplatelet agent (aspirin or clopidogrel) plus OAC. 
ABC = Age, Biomarkers, Clinical history; AF = atrial fibrillation; HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, 
Labile INR, Elderly, Drugs/alcohol concomitantly; VKA = vitamin K antagonist. 
1Non-vitamin K antagonist oral anticoagulant (NOAC) preferred over VKA in patients with non-valvular AF. (Class IIaA).
2Periprocedural administration of aspirin and clopidogrel during PCI is recommended irrespective of the treatment strategy. 
3High ischaemic risk is considered as an acute clinical presentation or anatomical/procedural features which might increase the risk for myocardial infarction. 

























































































..hospital admission in NSTE-ACS patients, has not been addressed in
dedicated randomized studies.
The safety and efficacy of short-term potent antiplatelet treatment
with either prasugrel or ticagrelor in SCAD patients is unknown, and
is subject to ongoing clinical trials [the ALPHEUS (Assessment of
Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt
Ischemic Events in Patients Undergoing Elective Coronary Stenting)
trial: NCT02617290 and the SASSICAIA (Comparison of Loading
Strategies With Antiplatelet Drugs in Patients Undergoing Elective
Coronary Intervention) trial: NCT02548611].
The clinical benefit of a short-term DAPT duration followed by
long-term ticagrelor monotherapy (and stopping aspirin) remains
unknown. The ongoing GLOBAL LEADERS (Long-term ticagrelor
monotherapy versus standard dual antiplatelet therapy followed
by aspirin monotherapy in patients undergoing biolimus-eluting
stent implantation) and TWILIGHT (Ticagrelor With Aspirin or
Alone in High-Risk Patients After Coronary Intervention) trials aim
to close this gap in our current knowledge (NCT01813435 and
NCT02270242, respectively).
18 Volume outcome relationship
for revascularization procedures
Operator experience influences outcomes, particularly in critical,
complex situations. Greater total experience of an entire hospital
team—consisting of the supporting members in the operating room
or catheterization laboratory and those responsible for postopera-
tive care—results in more favourable outcomes.
18.1 Coronary artery bypass grafting
Studies have suggested that the volume of CABG surgery in a hos-
pital significantly impacts in-hospital mortality, although no consis-
tent cut-offs for volume were used in these studies.761–762 This
increase in mortality observed in lower volume centres seems to
be attributable to so-called ‘failure to rescue’: although patients
operated on at low-volume centres are not at particularly higher
risk of suffering a major complication, they are more likely to die
from such a complication should it occur.763 Therefore, consider-
ation should be given to the performance of CABG in centres
with an annual volume of at least 200 CABG cases. Apart from
hospital volume, higher surgeon volume also appears to be inver-
sely related to operative mortality. Birkmeyer et al. provided evi-
dence suggesting that both hospitals and surgeons have some
impact on outcomes.764
Several studies suggest that quality measures are more
important than volume per se.765,766 Missing quality indicators in
hospitals strongly predicted mortality, irrespective of surgeon or hos-
pital case volumes.767 Therefore, it is recommended that such quality
measures (as an example see Supplementary Table 9) are
adopted and reported to facilitate focused quality improvement.768
18.2 Percutaneous coronary
intervention
Numerous studies have investigated the relationship between the
volume of procedures and outcomes of PCI, suggesting a
volume–outcome relationship at the operator level, as well as at the
institutional level.761,769–773 A population-based study from the PCI
reporting system of New York indicated that hospital case volumes
<400 PCIs per year and operator case volumes <75 PCIs per year
were associated with impaired outcomes.769
Among patients with ACS, particularly STEMI, operator and hospi-
tal volumes play important roles. A large study in the USA reported
that, in a cohort of 36 535 patients undergoing primary PCI, in-
hospital mortality was significantly lower in institutions with higher
primary PCI volumes (5.7% in hospitals performing >33 primary
PCIs/year vs. 7.7% in hospitals performing <12 primary PCIs/year).774
Operator volume has also been shown to impact outcomes in LM
PCI. A single-centre study of 1948 patients who underwent unpro-
tected LM PCI, performed by 25 operators over a 7 year period,
showed reduced 30 day and 3 year mortality for patients who had
their PCI performed by a high-volume operator (defined as >_15 LM
PCI/year; mean 25/year) vs. a low-volume operator (<15 LM PCI/
year).775
An example of quality measures for PCI is provided in
Supplementary Table 10.
18.3 Training in cardiac surgery and
interventional cardiology for myocardial
revascularization
A European training programme in interventional cardiology has
been proposed by the EAPCI in order to ensure the high quality of
patient care and clinical excellence.776 The programme should last
1–2 years at high-volume institutions that handle >_800 PCIs per year
and that have an established 24 h/7 day service for the treatment of
patients with ACS.
For CABG, no standardized European programme exists at
this time. However, the pace at which proficiency reaches certain
acceptable standards differs from trainee to trainee. Therefore,
although it is recommended that trainees perform >_200 CABG pro-
cedures under supervision before becoming completely independ-
ent, a competency-driven residency programme with regular
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Recommendations for operator/institutional volume in myocardial revascularization
Recommendations Classa Levelb
CABG
It should be considered that CABG be performed at institutions with annual institutional volumes of >_200 CABG cases. IIa C
PCI
It should be considered that PCI for ACS be performed by trained operators with annual volumes of >_75 procedures
at institutions performing >_400 PCIs per year with an established 24 h/7 day service for the treatment of patients with
ACS.
IIa C
It should be considered that PCI for SCAD be performed by trained operators with annual volumes of >_75 procedures
at institutions performing >_200 PCIs per year.
IIa C
It should be considered that institutions with annual volumes of <400 PCIs collaborate in networks with higher-volume
institutions (>400 PCIs per year), with shared written protocols and exchange of operators and support staff.
IIa C
It should be considered that PCI for LM be performed by trained operators with an annual volume of >_25 LM PCI cases
per year.
IIa C
It should be considered that non-emergency high-risk PCI procedures—such as for LM disease, single remaining patent
coronary artery, and complex chronic total occlusions—are only performed by adequately experienced operators at
centres that have access to circulatory support and intensive care treatment.
IIa C




Recommendations for training in myocardial revascularization
Recommendations Classa Levelb
Training in CABG
It is recommended that trainees in cardiac surgery and interventional cardiology follow a competency-driven residency
programme with regular evaluation of progression.
I C




It should be considered that trainees in interventional cardiology perform >_200 PCI procedures as first operator, with
one-third of PCI procedures in emergency or ACS patients under supervision, before being independent.
IIa C
It should be considered that trainees in interventional cardiology complete formal training according to a 1–2 year cur-
riculum at institutions with >_800 PCIs per year and an established 24 h/7 day service for the treatment of patients with
ACS.
IIa C
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19 Medical therapy, secondary
prevention, and strategies for
follow-up
Myocardial revascularization must be accompanied by medical ther-
apy and other secondary prevention strategies for risk factor modifi-
cation and permanent lifestyle changes.42 Secondary prevention and
cardiac rehabilitation are an integral part of management after revas-
cularization because such measures reduce future morbidity and
mortality in a cost-effective way, and can further improve symptoms.
These measures are discussed in detail in the European Guidelines
on Cardiovascular Disease Prevention that were published in 2016.42
The need to detect restenosis has reduced in the DES era.
Likewise, the durability of CABG results have increased with the use
of arterial grafts, and ischaemia stems mainly from SVG attrition and/
or progression of CAD in native vessels. Nevertheless, the recur-
rence of symptoms or ischaemia due to disease progression or reste-
nosis deserves attention.
Recommendations for outcome registration, monitor-
ing, and benchmarking
Recommendations Classa Levelb
It is recommended that specific quality per-
formance measures for CABG are adopted
at a national level to allow outcome moni-
toring and benchmarking.
I C
It is recommended that national societies
establish national databases on CABG prac-
tice and outcomes.
I C
It is recommended that CABG outcome
data are reported by hospitals to national
databases.
I C
CABG = coronary artery bypass grafting.
aClass of recommendation.
bLevel of evidence.
Strategies for follow-up and management in patients
after myocardial revascularization
Recommendations Classa Levelb
After CABG or PCI for AMI, participation in
a cardiac rehabilitation programme is rec-
ommended to improve patient
outcomes.777
I A
It is recommended that secondary preven-
tion measures, including medical therapy




It is recommended that patients are re-eval-
uated after myocardial revascularization
(e.g. at 3 months and thereafter, at least on
an annual basis) in order to reassess symp-
toms and adherence to secondary preven-
tion measures, and reinforce medical




Coronary angiography is recommended in
patients with intermediate- to high-risk fin-
dingsc at stress testing.
I C
An imaging stress test should be considered




Surveillance by non-invasive imaging-based
stress testing may be considered in high-risk
patient subsets 6 months after
revascularization.
IIb C
After high-risk PCI (e.g. unprotected LM
stenosis), late (3–12 months) surveillance
angiography may be considered, irrespective
of symptoms.
IIb C
Routine non-invasive imaging-based stress
testing may be considered 1 year after PCI
and >5 years after CABG.
IIb C
AMI = acute myocardial infarction; CABG = coronary artery bypass grafting;




cIntermediate- and high-risk findings at stress imaging are ischaemia at low work-
load with exercise stress testing, early-onset ischaemia with pharmacological
stress testing, an inducible wall motion abnormality, or a reversible perfusion



















































..19.1 Gaps in the evidence
In all studies to date on the optimal follow-up after PCI, the gain from
discovering patients with restenosis is obscured by the high rate
of false positive exercise ECG tests indicating ischaemia. Therefore,
simple exercise ECG testing is not recommended for follow-up and
a non-invasive imaging approach is preferred. Specific studies to
clarify which subset of patients benefits more from a specific follow-
up approach are missing. More studies are needed to assess the role
of CT angiography in patient surveillance after myocardial
revascularization.
20 Key messages
(1) Myocardial revascularization is performed for the relief of symp-
toms of myocardial ischaemia and the improvement of prognosis.
In SCAD, the prognostic benefit is dependent on the extent of
myocardium subject to ischaemia.
(2) The prognostic and symptomatic benefits of myocardial revascula-
rization critically depend on the completeness of revascularization.
Therefore, the ability to achieve complete revascularization is a
key issue when choosing the appropriate treatment strategy.
(3) Apart from issues of individual operative risk and technical feasibil-
ity, diabetes mellitus and the anatomical complexity of CAD deter-
mine the relative benefits of PCI and CABG.
(4) The SYNTAX score is the recommended tool to gauge the ana-
tomical complexity of coronary disease.
(5) In some instances, both PCI and CABG are equally reasonable, or
sometimes even equally problematic, options. This calls for the
Heart Team to be consulted to develop individualized treatment
concepts, with respect for the preferences of the patient who has
been informed about early and late outcomes.
(6) Timely PCI of the culprit lesion remains the mainstay of treatment
of ACS.
(7) After PCI of the culprit lesion in ACS, the choice of further revas-
cularization modality should follow the criteria applied to patients
with SCAD.
(8) Radial access is preferred for any PCI irrespective of clinical pre-
sentation, unless there are overriding procedural considerations.
(9) DES are recommended for any PCI irrespective of clinical presen-
tation, lesion type, anticipated duration of DAPT, or concomitant
anticoagulant therapy.
(10) Even though 6 months of DAPT is generally recommended after
PCI in SCAD and 12 months of DAPT after ACS, the type and
duration of DAPT should be individualized according to the ischae-
mic and bleeding risks, and appropriately adapted during follow-
up. Based on this judgement, treatment durations for DAPT after
DES that are as short as 1 month or even as long as lifelong may be
reasonable.
(11) Off-pump surgery with no-touch aorta for high-risk patients
should be considered when expertise exists.
(12) Multiple arterial grafting should be considered using the radial
artery for high-grade stenosis and/or BIMA grafting for patients
who do not have an increased risk of sternal wound infection.
21 Evidence-based ‘to do’ and ‘not to do’ messages from the Guidelines
Risk models to assess short- and long-term outcomes after myocardial revascularization Classa Levelb
When evidence of ischaemia is not available, FFR or iwFR are recommended to assess the haemodynamic relevance
of intermediate-grade stenosis.
I A
It is recommended that the STS score is calculated to assess in-hospital or 30 day mortality, and in-hospital morbidity,
after CABG.
I B
In patients with LM or multivessel disease, it is recommended that the SYNTAX score is calculated to assess the
anatomical complexity of CAD and the long-term risk of mortality and morbidity after PCI.
I B
Indications for revascularization in patients with stable angina or silent ischaemia
For prognosis LM disease with stenosis >50%.c I A
Any proximal LAD stenosis >50%.c I A
Two- or three-vessel disease with stenosis >50%c with impaired LV function (LVEF <_35%).c I A
Large area of ischaemia detected by functional testing (>10% LV) or abnormal invasive FFR.d I B
For symptoms Any haemodynamically significant coronary stenosis in the presence of limiting angina or angina equivalent,
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Type of revascularization (CABG or PCI) in patients with SCAD with suitable coronary anatomy for both
procedures and low predicted surgical mortality
Recommendations according to the extent of CAD CABG PCI
Classa Levelb Classa Levelb
One-vessel CAD
With proximal LAD stenosis I A I A
Two-vessel CAD
With proximal LAD stenosis I B
LM CAD
LM with low SYNTAX score 0 - 22 I A I A
LM with intermediate SYNTAX score >22 and <_32 I A
LM with high SYNTAX score >32.e I A III B
Three-vessel CAD without diabetes mellitus
Three-vessel disease with low SYNTAX score 0 - 22 I A I A
Three-vessel disease with intermediate or high SYNTAX score >22e I A III A
Three-vessel CAD with diabetes mellitus
Three-vessel disease with low SYNTAX score 0 - 22 I A
Three-vessel disease with intermediate or high SYNTAX score >22e I A III A
Invasive evaluation and revascularization in NSTE-ACS
An early invasive strategy (<24 h) is recommended in patients with at least one high-risk criterion (Figure 4). I A
An invasive strategy (<72 h after first presentation) is indicated in patients with at least one intermediate-risk
criterion (Figure 4) or recurrent symptoms.
I A
It is recommended that the revascularization strategy (ad hoc culprit-lesion PCI/multivessel PCI/CABG) is based
on the patient’s clinical status and comorbidities, as well as the disease severity, i.e. distribution and
angiographic lesion characteristics (e.g. SYNTAX score), according to the principles for SCAD.
I B
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Primary PCI for myocardial reperfusion in STEMI
Indication
Reperfusion therapy is indicated in all patients with time from symptom onset <12 h duration and persistent ST-seg-
ment elevation.
I A
A primary PCI strategy is recommended over fibrinolysis within indicated timeframes. I A
Logistics
It is recommended that the pre-hospital management of STEMI patients be based on regional networks that are
designed to timely and effectively deliver reperfusion therapy, and to offer primary PCI to as many patients as possible.
I B
It is recommended that primary PCI-capable centres deliver a 24 h/7 day service and ensure that primary PCI is per-
formed as fast as possible.
I B
Patients transferred to a PCI-capable centre for primary PCI should bypass the emergency department and be trans-
ferred directly to the catheterization laboratory.
I B
Strategy/technique
In cardiogenic shock, routine revascularization of non-IRA lesions is not recommended during primary PCI. III B
Routine use of thrombus aspiration is not recommended. III A
Recommendations on revascularizations in patients with chronic heart failure and systolic LV dysfunction (EF 35%)
In patients with severe LV systolic dysfunction and coronary artery disease suitable for intervention, myocardial revas-
cularization is recommended.
I B
CABG is recommended as the first revascularization strategy choice in patients with multivessel disease and acceptable
surgical risk.
I B
Revascularizations in patients with cardiogenic shock
Emergency invasive evaluation is indicated in patients with acute heart failure or cardiogenic shock complicating ACS. I B
Emergency PCI is indicated for patients with cardiogenic shock due to STEMI or NSTE-ACS, independent of time delay
of symptom onset, if coronary anatomy is amenable.
I B
Emergency CABG is recommended for patients with cardiogenic shock if the coronary anatomy is not amenable to
PCI.
I B
Routine use of IABP in patients with cardiogenic shock due to ACS is not recommended. III B
Prevention of contrast-induced nephropathy
Patients with moderate-to-severe CKD
Use of low- or iso-osmolar contrast media is recommended. I A
It is recommended that the volume of contrast media is minimized. I B
Severe CKD
Haemodialysis therapy is not recommended as a preventative measure. III B
Pre-operative strategies to reduce the incidence of stroke in patients undergoing CABG
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Disease progression and late graft failure
Repeat revascularization is indicated in patients with extensive ischaemia or severe symptoms despite medical therapy. I B
IMA is the conduit of choice for redo CABG in patients in whom the IMA was not used previously. I B
DES are recommended for the treatment of in-stent restenosis within BMS or DES. I A
Drug-coated balloons are recommended for the treatment of in-stent restenosis within BMS or DES. I A
Prevention of ventricular arrhythmias by revascularization
A primary PCI strategy is recommended in patients with resuscitated cardiac arrest and an ECG consistent with STEMI. I B
Perioperative oral b-blocker therapy is recommended for the prevention of post-operative AF after CABG surgery. I B
Procedural aspects of CABG
Arterial grafting with an IMA to the LAD system is recommended. I B
Use of the radial artery is recommended over the saphenous vein in patients with high-degree stenosis. I A
Skeletonized IMA dissection is recommended in patients with high risk of sternal wound infection. I B
Minimization of aortic manipulation is recommended. I B
Procedural aspects of PCI
DESf are recommended over BMS for any PCI irrespective of:
• clinical presentation
• lesion type
• planned non-cardiac surgery
• anticipated duration of DAPT
• concomitant anticoagulant therapy.
I A
Radial access is recommended as the standard approach, unless there are overriding procedural considerations. I A
Stent implantation in the main vessel only, followed by provisional balloon angioplasty with or without stenting of the
side branch, is recommended for PCI of bifurcation lesions.
I A
Antithrombotic treatment in SCAD patients undergoing PCI
Treatment with 600 mg clopidogrel is recommended in elective PCI patients once anatomy is known and the decision
has been made to proceed with PCI.
I A
Aspirin is indicated before elective stenting. I A
Clopidogrel (600 mg loading dose and 75 mg daily maintenance dose) is recommended for elective stenting. I A
UFH is indicated as a standard anticoagulant (70–100 U/kg). I B
Life-long single antiplatelet therapy, usually aspirin, is recommended. I A
In patients with SCAD treated with coronary stent implantation, DAPT consisting of clopidogrel in addition to aspirin is
generally recommended for 6 months, irrespective of the stent type.
I A
Antithrombotic treatment in NSTE-ACS patients undergoing PCI
Aspirin is recommended for all patients without contraindications at an initial oral loading dose of 150–300 mg (or
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A P2Y12 inhibitor is recommended in addition to aspirin, maintained over 12 months unless there are contraindications
such as an excessive risk of bleeding. Options are:
I A
 Prasugrel in P2Y12-naı̈ve patients who proceed to PCI (60 mg loading dose and 10 mg daily dose) I B
 Ticagrelor irrespective of the pre-treatment and revascularization strategy (180 mg loading dose, 90 mg twice daily) I B
 Clopidogrel (600 mg loading dose and 75 mg daily dose), only when prasugrel or ticagrelor are not available or are
contraindicated.
I B
Pre-treatment with GP IIb/IIIa antagonists in patients in whom coronary anatomy is not known is not recommended. III A
Administration of prasugrel to patients in whom coronary anatomy is not known is not recommended. III B
Peri-interventional anticoagulation is recommended for all patients in addition to antiplatelet therapy. I A
In patients on fondaparinux (2.5 mg daily s.c.), a single bolus UFH (85 IU/kg, or 60 IU in the case of concomitant use of
GP IIb/IIIa receptor inhibitors) is indicated.
I B
Crossover of UFH and LMWH is not recommended. III B
In patients with ACS treated with coronary stent implantation, DAPT with a P2Y12 inhibitor on top of aspirin is recom-
mended for 12 months unless there are contraindications such as an excessive risk of bleeding (e.g. PRECISE-DAPT
>_25).
I A
Antithrombotic treatment in STEMI patients undergoing PCI
Aspirin is recommended for all patients without contraindications at an initial oral loading dose of 150–300 mg (or
75–250 mg i.v.), and at a maintenance dose of 75–100 mg daily long-term regardless of treatment strategy.
I A
A potent P2Y12 inhibitor (prasugrel or ticagrelor), or clopidogrel if these are not available or are contraindicated, is rec-
ommended before (or at the time of PCI at the latest) PCI and should be maintained over 12 months, unless there are
contraindications such as an excessive risk of bleeding.
I A
Strategies for follow-up and management
After CABG or PCI for AMI, participation in a cardiac rehabilitation programme is recommended to improve patient
outcomes.
I A
It is recommended that secondary prevention measures, including medical therapy and lifestyle changes, are started and
reinforced after myocardial revascularization.
I A
ACS = acute coronary syndrome; AF = atrial fibrillation; AMI = acute myocardial infarction; BMS = bare-metal stent; CABG = coronary artery bypass grafting; CAD = coronary
artery disease; CKD = chronic kidney disease; DAPT = dual antiplatelet therapy; DES = drug eluting stents; DUS = duplex ultrasound; ECG = electrocardiogram; EF = ejection
fraction; FFR = fractional flow reserve; GP = glycoprotein; IABP = intra-aortic balloon pump; iwFR = instantaneous wave-free radio; IMA = internal mammary artery; IRA =
infarct-related artery; i.v. = intravenous; LAD = left anterior descending; LM = left main; LMWH = low-molecular-weight heparin; LV = left ventricular; LVEF = left ventricular
ejection fraction; NSTE-ACS = non-ST-elevation acute coronary syndrome; PCI = percutaneous coronary intervention; PRECISE-DAPT = PREdicting bleeding Complications
In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy; s.c. = subcutaneous; SCAD = stable coronary artery disease; STEMI = ST-elevation myo-
cardial infarction; STS = Society of Thoracic Surgeons; SYNTAX = Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; TIA = transient
ischaemic attack; UFH = unfractionated heparin.
aClass of recommendation.
bLevel of evidence.
cWith documented ischaemia, a haemodynamically relevant lesion defined by FFR <_0.80 or iwFR <_0.89, or >90% stenosis in a major coronary vessel.
dBased on FFR <0.75 indicating a prognostically relevant lesion.
ePCI should be considered, if the Heart Team is concerned about the surgical risk or if the patient refuses CABG after adequate counselling by the Heart Team.
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